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Glossary
Community: In most contexts in this tool, “community” refers to populations of people who inject 
drugs, rather than the broader geographic, social or cultural groupings of which they may be a part. 
However, our definition of community takes into account the fact that people may move into or 
out of injecting drug use at various times in their lives, whether by their own choice or because 
of circumstances beyond their control, but may maintain community connectedness (see defini-
tion below). Thus, “community members” are people who inject drugs or people with community 
connectedness; “outreach to the community” means outreach to people who inject drugs; and 
“community-led interventions” are interventions led by people who inject drugs or people with 
community connectedness. 
Community connectedness: People who have previously injected drugs who continue to maintain 
associations, shared values and understandings with others who inject drugs may be considered 
community members by virtue of their “community connectedness”. Community connectedness 
also derives from the fact that people not currently using drugs, including people on opioid sub-
stitution therapy, are frequently subject to the same stigma and discrimination as people currently 
using drugs.
Drop-in centre is a place where people who inject drugs may gather to relax, meet other commu-
nity members, and hold social events, meetings or training. See Chapter 4, Section 4.6, for details.
Drug use refers to the use of psychoactive drugs for nonmedical reasons, including drugs that are 
illegal, controlled, prescription or non-prescription (“over-the-counter”).
Implementing organization is an organization delivering an intervention to people who inject 
drugs, with a client-centred approach. It may be a governmental, non-governmental, communi-
ty-based or community-led organization, and may work at a state, provincial, district or local level. 
Sometimes a non-governmental organization provides services through subunits at multiple loca-
tions within an urban area, and in this case, each of those subunits may also be considered an 
implementing organization. 
Peer outreach worker is used to mean a person who injects drugs, or a person with community 
connectedness, who conducts outreach to other people who inject drugs, and who is not gener-
ally full-time staff of an HIV prevention intervention (full-time staff might be called “staff outreach 
workers” or simply “outreach workers”). Peer outreach workers may also be known by other terms, 
including “peer educators”, “community outreach workers” or “outreach workers”. However, the 
terms “peer” or “community” should not be understood or used to imply that they are less qualified 
or less capable than staff outreach workers. 
Young people who use or inject drugs are those in the age range 10–24 years, in accordance with 
the Interagency Working Group on Key Populations’ HIV and young people who inject drugs: a 
technical brief (Geneva: World Health Organization; 2015). 
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Introduction
In all regions of the world, people who inject drugs are disproportionately affected by HIV.1 Globally, 
people who inject drugs are 28 times more likely to be living with HIV than the general population. 
The United Nations Office on Drugs and Crime (UNODC), the World Health Organization (WHO), 
the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Bank estimate that 
worldwide as of 2014, about 11.7 million2 people inject drugs, of whom an estimated 14% (1.6 mil-
lion) are living with HIV.3 Injecting drug use accounts for 30% of new HIV infections outside sub- 
Saharan Africa. People who inject drugs also have higher rates of hepatitis C (HCV) and tubercu-
losis than the general population. The global rate of HCV among people who inject drugs is 52%, 
greatly surpassing even the high prevalence of HIV among them. 
Among the immediate causes of these disparities is the lack of consistent access to sterile injecting 
equipment, opioid substitution therapy (OST), condoms and lubricant, HIV testing and antiretrovi-
ral therapy (ART) for those who are living with HIV. In 2014, out of 158 countries reporting injecting 
drug use, only 90 provided needle and syringe programmes in the community and eight in prisons, 
and only 80 provided OST (including 43 in prisons).4 UNAIDS estimated that USD$2.3 billion was 
needed in 2015 to fund comprehensive harm reduction programmes for people who inject drugs, 
but a recent study showed that international donors were investing only 7% of this sum.5
The Sustainable Development Goals (SDGs), adopted in 2015, include Goal 3, “Ensure healthy lives 
and promote well-being for all at all ages.”6 This goal includes a commitment to end the AIDS 
epidemic and to combat hepatitis (among other diseases). The UNAIDS Fast-Track strategy  is 
aligned with the SDGs and emphasizes a five-year window (2016–2021) for rapid acceleration of 
HIV treatment and prevention services, with the aim of ending the AIDS epidemic by 2030.7 
To achieve this, the strategy articulates the “90–90–90” treatment target8 and a prevention tar-
get of reducing the annual number of new HIV infections to 500,000. The Fast-Track strategy 
was adopted by the United Nations Political Declaration on AIDS 2016, in which member states 
committed to encouraging those member states with high HIV incidence to “tak[e] all appropriate 
steps to ensure that 90% of those at risk of HIV infection are reached by comprehensive preven-
tion services.”9
1 The terms “people who inject drugs” and “people who use drugs” are used throughout this publication, consistent with the International Network of 
People Who Use Drugs’ Statement and position paper on language, identity, inclusivity and discrimination (2011). These terms identify people who 
use drugs as people first and foremost, for whom drug use or injection drug use is just one facet of their lives.
2 Range: 8.4–19.0 million.
3 All statistics in this paragraph are from the World drug report 2016. Vienna: United Nations Office on Drugs and Crime; 2016. 
4 The global state of harm reduction 2014. London: Harm Reduction International; 2014. 
5 The funding crisis for harm reduction: donor retreat, government neglect and the way forward. London: International Harm Reduction Association; 
2014. 
6 Transforming our world: the 2030 Agenda for Sustainable Development. A/RES/70/1. New York (NY): United Nations; 2015.
7 UNAIDS Strategy 2016–2021: on the Fast-Track to end AIDS. Geneva: Joint United Nations Programme on HIV/AIDS; 2015.
8 90% of people living with HIV will get tested and know the result, 90% of people who know they are living with HIV will be on treatment, and 90% of 
those on treatment will have undetectable levels of HIV. 
9 Political declaration on HIV and AIDS: on the fast-track to accelerate the fight against HIV and to end the AIDS epidemic by 2030. A/70/L.52. New York 
(NY): United Nations; 2016.
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Harm reduction refers to policies, programmes and practices that aim primarily to reduce the 
adverse health, social and economic consequences of the use of licit and illicit drugs. The harm 
reduction approach is based on a strong commitment to public health and human rights. Harm 
reduction helps protect people from preventable diseases and death from overdose, and helps 
connect marginalized people with social and health services. All major United Nations bod-
ies have endorsed a comprehensive package of harm reduction interventions (Table 1), which 
forms an evidence-based approach to HIV prevention, treatment and care for people who inject 
drugs. The comprehensive package is also reflected in the Outcome Document of the 2016 
United Nations General Assembly Special Session (UNGASS) on the World Drug Problem, which 
calls for “effective measures aimed at minimizing the adverse public health and social conse-
quences of drug abuse, including appropriate medication-assisted therapy programmes, inject-
ing equipment programmes, as well as antiretroviral therapy and other relevant interventions 
that prevent the transmission of HIV, viral hepatitis and other bloodborne diseases associated 
with drug use”.10 
Table 1 Comprehensive package of harm reduction interventions 
1. Needle and syringe programmes
2. Opioid substitution therapy
3. HIV testing services
4. Antiretroviral therapy
5. Prevention and treatment of sexually transmitted infections
6. Condom programmes for people who inject drugs and their sexual partners
7. Targeted information, education and communication 
8. Prevention, vaccination, diagnosis and treatment of viral hepatitis B and C
9. Prevention, diagnosis and treatment of tuberculosis
10. Community distribution of naloxone
Source: WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to 
HIV prevention, treatment and care for injecting drug users–2012 revision. Geneva: World Health 
Organization; 2013. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for 
key populations–2016 update. Geneva: World Health Organization; 2016.
It is recognized that “criminalization of drug use, restrictive drug policies and aggressive law-enforce-
ment practices are key drivers of HIV and hepatitis C epidemics among people who inject drugs,”11 
a view that is shared by several United Nations agencies.12,13 These factors, together with discrimi-
10 Our joint commitment to effectively addressing and countering the world drug problem. Outcome document of the United Nations General Assembly 
Special Session on the World Drug Problem. A/RES/S-30/1. New York (NY): United Nations; 2016.
11 Science addressing drugs and HIV: state of the art of harm reduction. A scientific statement. Vienna: United Nations Office on Drugs and Crime; 2014. 
Science addressing drugs and HIV: state of the art. 2nd scientific statement. Vienna: United Nations Office on Drugs and Crime; 2016.
12 Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations–2016 update. Geneva: World Health Organization; 2016.
13 Do no harm: health, human rights and people who use drugs. Geneva: Joint United Nations Programme on HIV/AIDS; 2016.
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nation, marginalization, stigmatization and violence, drive people who inject drugs underground and 
exclude them from proper access to the harm reduction and health services they need to prevent 
overdose and protect themselves from HIV and hepatitis C.
Therefore, in addition to the availability of essential services for HIV, interventions are needed to 
enable access to these services for people who inject drugs. WHO’s Consolidated guidelines on HIV 
prevention, diagnosis, treatment and care for key populations–2016 update lists several “critical 
enablers”—strategies and approaches that can improve the accessibility, acceptability, availability 
and uptake of interventions for key populations most at risk of HIV, including people who inject 
drugs (Table 2).
Table 2 Critical enablers for key populations 
Laws, policies and practices should be reviewed and, where necessary, revised by policy-
makers and government leaders, with meaningful engagement of stakeholders from key 
population groups, to allow and support the implementation and scale-up of health-care 
services for key populations. For people who inject drugs: 
• Countries should work towards developing policies and laws that decriminalize the use of 
sterile needles and syringes (and that permit needle and syringe programmes) and that 
legalize OST for people who are opioid-dependent.
• Countries should work towards developing policies and laws that decriminalize injection 
and other use of drugs and, thereby, reduce incarceration.
• Countries should ban compulsory treatment for people who use or inject drugs.
Countries should work towards implementing and enforcing antidiscrimination and 
protective laws, derived from human-rights standards, to eliminate stigma, discrimination 
and violence against people from key populations. 
Health services should be made available, accessible and acceptable to key populations, 
based on the principles of medical ethics, avoidance of stigma, nondiscrimination and the 
right to health. Health-care workers should receive appropriate recurrent training and 
sensitization to ensure that they have the skills and understanding to provide services 
for adults and adolescents from key populations based on all persons’ rights to health, 
confidentiality and non-discrimination.
Programmes should work towards implementing a package of interventions to enhance 
community empowerment among key populations. 
Violence against people from key populations should be prevented and addressed 
in partnership with key population-led organizations. All violence against people from 
key populations should be monitored and reported, and redress mechanisms should be 
established to provide justice. 
Source: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key 
populations–2016 update. Geneva: World Health Organization; 2016.
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People who inject drugs share with everyone else a human right to the highest attainable stand-
ard of health, with health care provided without discrimination and regardless of the legal sta-
tus of drug use. Health-care workers, programme managers and national leaders should ensure 
that people who inject drugs have full access to harm reduction services, services for HIV and 
hepatitis C prevention, testing, treatment and care, guided by the principles of health for all and 
human rights.14 The 2016 UNGASS Outcome Document calls on governments to “consider ensur-
ing access to such interventions, including in treatment and outreach services, prisons and other 
custodial settings”.
The focus of this tool 
The primary focus of this tool is people who inject drugs because of the particular vulnerability 
to HIV and HCV associated with injecting practices. However, some people who do not 
inject but use stimulants and other psychoactive drugs can be at high risk of contracting HIV 
through unprotected sex, and they are subject to structural barriers similar to those faced 
by people who inject drugs. Therefore, much of the information in this tool—particularly the 
chapters related to structural barriers and some of the health-care interventions (Chapters 
1–3)—is relevant to people who use drugs in general.
As noted, people who inject drugs are vulnerable not only to HIV and HCV, but also to other 
bloodborne viruses such as hepatitis B, as well as to sexually transmitted infections and 
tuberculosis. For the sake of conciseness, this tool refers primarily to HIV and HCV prevention, 
but Chapter 3 in particular addresses the diagnosis, treatment and care of other infections 
to which people who inject drugs are disproportionately vulnerable.
The purpose of this tool
Previously published United Nations (UN) guidance documents describe the content of effective 
HIV and HCV prevention interventions for people who inject drugs, in the context of harm reduc-
tion15 and HIV prevention for key populations (Table 1).9 UN guidance is also grounded in an approach 
expressed in the critical enablers described in Table 2—strategies, activities and approaches to 
increase the accessibility, acceptability, coverage, quality and uptake of interventions and services 
for key populations.9 This tool offers practical advice on how to implement these programmes and 
these approaches for and with people who inject drugs, across the full continuum of HIV and HCV 
prevention, diagnosis, treatment and care, aligned with UN guidance. It contains examples of good 
practice from around the world that may support efforts in planning programmes and services, and 
describes issues that should be considered and how to overcome challenges. 
This tool does not seek to ignore the complex policy and legislative environment around drugs and 
injecting drug use in most countries, nor the need for advocacy to confront the stigma, discrim-
ination and human-rights violations faced by people who inject drugs. However, it aims primarily 
14 Consensus statement on drug use under prohibition: human rights, health and the law. International Network of People Who Use Drugs; 2015. 
15 WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug 
users–2012 revision. Geneva: World Health Organization; 2013. (Also referred to widely as the Target Setting Guide.)
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to address the question: what can we do now, with the resources we have, in the kinds of environ-
ments we face, to prevent the spread of HIV and hepatitis C among people who inject drugs? 
The tool describes how services can be designed and implemented to be accessible and accept-
able to people who inject drugs. This requires respectful and ongoing engagement, and this publi-
cation gives particular attention to programmes run in close partnership with, or by, organizations 
of people who use drugs. It is itself the product of a collaborative process including people who 
inject drugs, advocates, service-providers, researchers, government officials and nongovernmental 
organizations (NGOs) from around the world, as well as United Nations agencies and other devel-
opment partners. 
The intended users of this tool are public-health officials and managers of HIV and harm reduction 
programmes; nongovernmental, community and civil-society organizations, including networks of 
people who use drugs; and health workers. It will also be of interest to advocates and activists for 
the rights of people who use drugs, and to international funding agencies and health policy-makers. 
This tool is one of a series of publications that address HIV prevention with key populations. The 
others in this series are Implementing comprehensive HIV and STI programmes with sex work-
ers: practical guidance from collaborative interventions (WHO; 2013), informally known as the sex 
worker implementation tool or SWIT; Implementing comprehensive HIV and STI programmes with 
men who have sex with men: practical guidance for collaborative interventions (UNFPA; 2015) 
or MSMIT; and Implementing comprehensive HIV and STI programmes with transgender people: 
practical guidance for collaborative interventions (UNDP; 2016) or TRANSIT. In keeping with this 
style, users of this tool may wish to refer to it informally as the IDUIT.
How to use this tool
The tool’s five chapters fall broadly into three parts (Figure 1). The first two chapters describe 
approaches and principles for developing programmes and critical enablers (interventions that 
address structural factors underlying the HIV and HCV epidemics among people who inject drugs). 
Chapters 3 and 4 describe how to implement recommended interventions for HIV prevention, 
diagnosis, care and treatment. Finally, Chapter 5 describes how to manage programmes. 
Each chapter begins with an introduction that defines the topic and explains why it is important. 
Interventions are then broken down into stages or steps wherever possible, to make them easy 
to follow. Topics or points of particular interest are presented in text boxes. Case examples from 
programmes around the world are presented in shaded boxes. These examples do not describe 
an entire programme in detail but highlight specific aspects related to programming with people 
who inject drugs that have worked well in their contexts. They illustrate how an issue or challenge 
has been addressed and aim to inspire ideas about approaches that could work in the reader’s own 
context. The forms, charts etc. presented from various programmes have the same purpose. Each 
chapter ends with a list of further resources—tools, guidelines and other practical publications—
available online.
xx
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Figure 1 Structure of the tool
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Chapter ➊  Community Empowerment describes how empowerment of people who inject drugs 
is both an intervention in itself and also essential for ensuring community-led planning, implemen-
tation and monitoring of all aspects of prevention, treatment and care for HIV and other blood-
borne diseases. It also shows how groups and networks can be formed, and practical ways to 
strengthen their capacity for harm reduction and advocacy.
Chapter ➋ Legal Reform, Human Rights, Stigma and Discrimination focuses on the urgent need 
to counteract the impact of stigma, discrimination and criminalization upon people who inject 
drugs, for protection of their human rights and for effective HIV and HCV prevention.
Chapter ➌  Health and Support Services describes considerations for delivering the comprehen-
sive package of harm reduction services for people who inject drugs.
Chapter ➍ Service Delivery Approaches describes how to design services and how community 
members can be involved in varying aspects of service delivery, including (but not limited to) out-
reach to people who inject drugs, peer navigation and running drop-in centres.
Chapter ➎  Programme Management provides practical guidance on planning, starting, scaling 
up, managing and monitoring an effective programme. 
Although each chapter is subdivided to make it easier to find and use information, the reader is 
urged not to view them as separate or independent of one another. No single, stand-alone service 
modality or intervention will suffice when designing and implementing programmes tailored to 
the needs of people who inject drugs. Cross-referencing is provided to assist the reader in making 
connections between chapters.
Guiding principles for implementing comprehensive HIV  
and HCV programmes with people who inject drugs
Several principles underlie the implementation of HIV services for people who inject drugs 
and are articulated in this tool.
Human rights: Fundamental to the development of this tool is the respect, protection and 
fulfilment of human rights for people who inject drugs. Human rights underpins approaches 
to community empowerment (Chapter 1), prevention of stigma, discrimination and violence 
(Chapter 2), and access to services for the prevention, diagnosis, treatment and care of HIV 
and HCV (Chapters 3 and 4). 
Community empowerment is the process whereby people who inject drugs are supported 
to address for themselves the structural constraints to health, human rights and well-being 
that they face, and improve their access to services, including to reduce the risk of acquiring 
HIV and HCV, and to provide treatment and care for those living with HIV, HCV and other 
health problems. Community empowerment is an essential approach that underlies all the 
interventions and programme components described in this tool, and is inseparable from them. 
Community participation and leadership are essential in the design, implementation, 
monitoring and evaluation of programmes. Participation and leadership help to build 
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trust among those whom programmes are intended to serve, make programmes more 
comprehensive and more responsive to the needs of people who inject drugs, and create 
more enabling environments for HIV prevention. 
Acceptability of services: Interventions must be respectful, acceptable, appropriate and 
affordable to people who inject drugs in order to encourage their participation and ensure 
their retention in care. Services that are acceptable are more likely to be used in a regular 
and timely way. Consultation on service planning and design with people who inject drugs, 
and mechanisms for them to provide regular feedback, improve the acceptability of services.
Access to justice is a major priority for people who inject drugs, due to the illegality of 
injecting drug use in most countries. Access to justice includes freedom from arbitrary 
arrest and detention, the right to a fair trial, freedom from torture and cruel, inhuman and 
degrading treatment, and the right to the highest attainable standard of health, including in 
prisons and other closed settings. 
Access to quality health care: Evidence-based, high-quality health services should be 
accessible to people who inject drugs, and health-care providers and institutions must serve 
people based on the principles of medical ethics and the human right to health care. 
Health literacy: Health services should regularly and routinely provide accurate health and 
treatment information to people who inject drugs to help them make decisions about their 
health and about HIV risk behaviours. Health services should also strengthen providers’ ability 
to prevent and treat HIV and HCV in people who inject drugs.
Integrated service provision: Wherever possible, service delivery for people who inject 
drugs should be integrated. Integrated services provide opportunities for client-centred 
prevention, care and treatment of the multitude of illnesses, and to address various 
structural issues, that affect people who inject drugs. Integrated services also facilitate 
better communication among services. Where integrated services are not possible, strong 
links among health and other social services working with people who inject drugs should 
be established and maintained.
The principles that underlie this tool and the organizational approaches that it presents are 
universally relevant to all settings, and are as applicable to high-income countries as they are 
to low- and middle-income settings.
Community 
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What’s in this chapter?
Community empowerment is a key principle for all of the interventions and approaches described 
in this tool. This chapter:
•  defines community empowerment and explains why it is fundamental to addressing HIV and 
hepatitis C among people who inject drugs in an effective and sustainable way (Section 1.1)
• describes seven elements of community empowerment, with examples from a number of 
programmes (Section 1.2)
• gives examples of indicators to measure the empowerment of organizations of people who 
inject drugs (Section 1.3). 
The chapter also presents a list of further resources (Section 1.4).
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1.1 Introduction
Since well before the HIV epidemic, people who inject or otherwise use drugs have been proactive 
in protecting their health, fighting for their rights and supporting active, caring and committed 
communities. Organizations led by people who use drugs have played a central and creative role in 
the HIV response in many parts of the world, even in the most repressive environments. Commu-
nity empowerment has been key to this success.
Community empowerment refers to a process of enabling groups or communities of people to 
increase control over their lives. It means more than the involvement, participation or engagement 
of communities in pre-existing or new programmes: it implies community ownership, and action 
that explicitly aims at social and political change. Community empowerment addresses the social, 
cultural, political and economic determinants that affect health and seeks to build partnerships 
with other sectors in finding solutions. 
There have been many successful partnerships between communities of people who inject drugs 
and other actors—such as researchers, advocates, and service-providers who are not from com-
munities of people who inject drugs—that have led to the attainment of common goals. The most 
noteworthy and efficacious programmes are those that acknowledge and support community 
empowerment as a key principle and practice. 
In the field of HIV, hepatitis C (HCV) and drug use, community empowerment describes a pro-
cess whereby people who inject drugs take individual and collective ownership of activities, pro-
grammes and policies to achieve the most effective responses to HIV and HCV, and to address 
social and structural barriers to their health and their human rights. This may mean that people 
who inject drugs:
• come together for mutual assistance
• form a collective identity with common goals and address their collective needs in a supportive 
environment
• identify their own priorities and the appropriate strategies to address these
• advocate collectively for their rights as people who inject drugs and as human beings
• provide and facilitate access to HIV and HCV prevention, care and treatment, and support services
• participate meaningfully in all aspects of programme design, implementation, delivery, manage-
ment, monitoring and evaluation (M&E)
• build and strengthen partnerships with government, civil society, local allies and development 
partners.
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Defining community
In most contexts in this tool, “community” refers to populations of people who inject drugs, 
rather than the broader geographic, social or cultural groupings of which they may be a part. 
However, our definition of community takes into account the fact that people may move 
into or out of injecting drug use at various times in their life, whether by their own choice or 
because of circumstances beyond their control. 
People who have injected drugs who continue to maintain associations, shared values and 
understandings with others who inject drugs may be considered community members by 
virtue of their “community connectedness”. Community connectedness also derives from the 
fact that people not currently using drugs, including people on opioid substitution therapy 
(OST), are frequently subject to the same stigma and discrimination as people currently 
using drugs.
In this tool, “outreach to the community” therefore means outreach to people who inject 
drugs, “community-led interventions” are interventions led by people who inject drugs or 
people with community connectedness, and “community members” are people who inject 
drugs or people with community connectedness.
Investing time and resources in community empowerment not only is the right thing to do but also 
makes good sense. Strategies for HIV and HCV prevention are more relevant, effective and sus-
tainable when conducted within a community empowerment framework. People who inject drugs 
are experts in their own lives, and community-led organizations around the world have fostered 
improved access to quality and uptake of services, use of sterile needles and syringes, and engage-
ment by people who inject drugs in national policies and programmes. Scaling up comprehensive, 
community empowerment-based HIV interventions helps prevent significant numbers of new HIV 
infections, particularly in settings with high rates of HIV and highly concentrated populations of 
people who inject drugs. Meaningful partnerships with community-led organizations should be 
developed, nurtured and maintained throughout the life cycle of HIV and HCV responses. 
Community empowerment for people who inject drugs can be seriously hampered by repres-
sive drug control policies, laws, practices and regulations against people who inject drugs, as well 
as stigma and discrimination. Because of these structural barriers, in some contexts people who 
inject drugs may not be in a position to initiate programmes to prevent HIV and HCV. Most pro-
grammes are therefore started by other service-providers (e.g. governmental or nongovernmental 
organizations) with varying degrees of experience in working with communities of people who 
inject drugs. This chapter addresses such organizations in particular and shows how they can work 
in partnership with people who inject drugs in order to empower communities and create effective 
programming. Organizations that work in meaningful partnership with people who inject drugs 
understand community empowerment as more than a set of activities; it is an approach that can 
be integrated into all aspects of health and HIV programming. It is the cornerstone of an effective 
and human rights-based approach to HIV and, as such, underpins all the recommendations and 
components presented in this tool. 
Box 1.1
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Figure 1.1 A community-focused, rights-based framework for HIV and HCV prevention
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This chapter explains the principles and practices of community empowerment, so that they can 
be better integrated into HIV programme design and implementation for people who inject drugs. 
The chapter also gives guidance on how to strengthen organizational and programme manage-
ment of community-led organizations. 
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Box 1.2
Community empowerment  
and the Vancouver Declaration (2006)
Global international activists who use drugs issued the Vancouver Declaration in 2006 to 
articulate principles for members of the drug-using community to collaborate in claiming 
their human rights and reforming oppressive laws. A number of these principles, excerpted 
below, are principles of community empowerment:
It is time to raise our voices as citizens, establish our rights and reclaim the right to be our 
own spokespersons striving for self-representation and self-empowerment:
• to enable and empower people who use drugs legal or deemed illegal worldwide to sur-
vive, thrive and exert our voices as human beings to have meaningful input into all deci-
sions that affect our own lives
• to use our own skills and knowledge to train and educate others, particularly our peers and 
any other fellow-citizens concerned with drugs in our communities. 
We strive to:
• value and respect diversity and recognize each other’s different backgrounds, knowledge, 
skills and capabilities, and cultivate a safe and supportive environment within the network 
regardless of which drugs we use or how we use them 
• spread information about our work in order to support and encourage development of 
user organizations in communities/countries where there are no such organizations 
• promote tolerance, cooperation and collaboration, fostering a culture of inclusion and 
active participation 
• [enact] democratic principles and create a structure that promotes maximum participa-
tion in decision-making 
• [promote] maximum inclusion with special focus to those who are disproportionately vul-
nerable to oppression on the basis of their gender identity, sexual orientation, socioeco-
nomic status, religion etc. 
1.2 Key elements of community empowerment 
Community empowerment should take a flexible approach, adapted to the needs of each commu-
nity. There is no fixed order in which the elements depicted in Figure 1.2 should be addressed; the 
process may flow from working with communities of people who inject drugs to community-led 
outreach, the development and strengthening of organizations and networks led by people who 
inject drugs and, consistent with local needs and contexts, shaping human rights-based policies 
and creating an enabling environment for a sustainable movement. 
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Figure 1.2 Key elements of community empowerment among people who inject drugs
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This process represents a paradigm shift, from people who inject drugs being recipients of ser-
vices to the self-determination of communities of people who inject drugs. Even when initiated 
by organizations that are not community-led, community empowerment builds a social movement 
where community members collectively exercise their rights, are recognized as an authority and 
as an equal partner in the planning, implementation, provision and monitoring of health and social 
services. Organizations that aim to work effectively and meaningfully with people who inject drugs 
should support and advocate for community empowerment where possible. 
Community systems strengthening is an approach that promotes the development of informed, 
capable and coordinated community-led organizations, groups or other structures, to enable 
them to contribute as partners alongside other actors to the long-term sustainability of communi-
ty-based health and other interventions. Community systems strengthening also includes creation 
of an enabling environment within which this community development can occur (see Box 1.3).
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Box 1.3
Core components of community systems strengthening
• Enabling environments and advocacy—includes community engagement and advocacy 
to improve policy, laws, governance and the social determinants of health. 
• Community networks, linkages and partnerships—to enable effective activities, ser-
vice delivery and advocacy, and to maximize resources and impact.
• Resource- and capacity-building—human resources (with appropriate personal, techni-
cal and organizational capacities), financing (operational and core funding) and material 
resources (infrastructure, information and essential commodities).
• Community activities and service delivery—accessible to all who need them, evidence-in-
formed and based on community members’ assessments of their resources and needs.
• Organizational and leadership strengthening—including management, accountability 
and leadership. 
• Monitoring and evaluation and planning—including M&E systems, situation assessment, 
evidence-building and research, learning, planning and knowledge management.
Source: Community Systems Strengthening framework: revised edition February 2014. 
Geneva: Global Fund to Fight AIDS, Tuberculosis and Malaria; 2014.
At the local level, this means that organizations and networks of people who inject drugs are 
members of planning, funding and implementation committees and other relevant bodies. It also 
means strengthening the capacity of community-led organizations to deliver services, manage 
programmes, develop leadership and handle human and financial resources on a sustained basis, 
especially in the face of changes in donor funding or the leadership of government or NGOs. Con-
nections with national, subregional, regional and global networks of people who inject drugs are 
useful to exchange knowledge, experience and support. 
1.2.1 Working with communities of people who inject drugs
Community empowerment takes significant time and effort. Trust, empathy and respect are 
important for all partners. Building trust involves treating people who inject drugs with dignity and 
respect, listening to and addressing their concerns, and working with them throughout the pro-
cess of developing and implementing an intervention. The goal is to ensure that organizations of 
people who inject drugs are respected as partners by officials and service-providers in health, law 
enforcement and social services. Where informal groups or more formal organizations of people 
who inject drugs already exist in a chosen service area, programme managers should work with 
them, as these are likely to be community-led rather than simply community-based (see Box 1.6). 
In the initial stages of community empowerment, people who inject drugs may have limited experi-
ence in organizing as a group, and service-providers may not be accustomed to working with com-
munity members as equals. National, regional and global networks of people who inject drugs are 
able to provide essential technical assistance and support (see Section 1.2.4). Allies, whether individ-
uals or organizations, also have an important role in facilitating meaningful participation of people 
who inject drugs (see Section 1.2.5). Meaningful participation means that people who inject drugs:
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Box 1.4
• choose whether to participate
• choose how they are represented, and by whom
• choose how they are engaged in the process
• have an equal voice in how partnerships are managed.
Case example: Community involvement  
in policy advocacy in Nepal
Recognizing the lack of specific laws or policies in Nepal to support people who inject drugs 
and the lack of services at the community level, Naya Goreto, a local nongovernmental 
organization (NGO), created Bridging the Gap: Health and Human Rights Programme for the 
Key Population. The programme aims to engage partners ranging from parliamentarians to 
local councillors, public-health officials to health volunteers in advocacy on issues of concern 
to the community of people who inject drugs. 
Naya Goreto emphasizes the meaningful participation of people who inject drugs at all levels 
of the programme. More than 200 people from the community have been trained to lead 
activities ranging from situation analysis to advocacy campaigning and programme monitoring. 
The programme has brought together key stakeholders to establish a committee that lobbies 
for the health and human rights of people who inject drugs. Empowerment activities have 
included advocacy in small-group environments; forming advocacy networks for broader 
reach; linking people who inject drugs with experts and other concerned stakeholders for 
information on programmes and budgets; mobilization of community representatives to 
participate in consultation meetings with key government officials; lobbying duty-bearers 
for the health and human rights of the injecting community. 
Naya Goreto has built strong partnerships between people who inject drugs, creating a sense 
of solidarity to collectively address the issues that directly affect them. Such issues are now 
included in the yearly action plans of local government and civil-society organizations, and a 
member of the injecting community now sits on the District AIDS Coordination Committee.
www.nayagoreto.org.np
Source: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key 
populations–2016 update. Geneva: World Health Organization; 2016.
Because of the widespread and punitive laws used against people who inject drugs, safeguards must 
be built into partnerships to ensure that people who inject drugs do not face criminal sanctions 
for organizing, do not fear that identifying themselves will lead to exclusion from social services or 
employment and other forms of harassment, and do not experience further stigmatization or denial 
of service from health-care providers. Among other things, this means that partners in community 
empowerment should be prepared to advocate for the replacement of punitive environments 
and processes with ones that are supportive and inclusive of people who inject drugs. For more 
information on community-led drug policy advocacy, see the Australian Injecting & Illicit Drug Users 
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League (AIVL) research report, The involvement of drug user organisations in Australian drugs 
policy (2014). 
Ten principles for meaningful engagement in drug policy
1. Human rights should underpin all drug policy and the meaningful engagement of people 
who inject drugs in the drug policy process.
2. Processes of meaningful engagement between organizations of people who inject drugs 
and policy agencies should commence from the beginning of the policy process rather 
than part way through it.
3. Acknowledge the expertise of people who inject drugs and their organizations: this 
expertise should be given equal respect, recognition and priority within the policy process 
as other forms of expertise or experience.
4. Engage with a broad range of communities affected by drug policies, including a 
recognition of the diversity of people who use illicit drugs, and acknowledge and respond 
to changing drug use patterns.
5. People who inject drugs and their organizations must be properly supported to participate 
in a meaningful way in drug policy. This includes proper resourcing and funding, training, 
support and mentoring for drug-user representatives engaged in the process, sufficient 
timelines to support meaningful engagement, and guidelines on patterns of engagement.
6. Open communication among all stakeholders is important, including genuine willingness 
to compromise, and transparency in the policy process. 
7. There is a need for a commitment to genuine engagement rather than tokenistic 
representation of people who inject drugs and their organizations in drug policy.
8. Recognize that organizations of people who inject drugs are under-resourced for policy 
and advocacy roles, and therefore need adequate time to respond properly to new and 
revised policies that affect the lives of those they represent.
9. Understand and accept that organizations of people who inject drugs have a responsibility 
to act as powerful advocates on behalf of their constituents without being characterized 
as “difficult”, unwilling to compromise or unrealistic about political imperatives.
10. Representatives of organizations of people who inject drugs should commit to acting 
in a respectful, open and professional manner when representing their community 
in policy forums. At the same time, it must be recognized that representatives often 
expose themselves to personal risk by publicly identifying as persons who injects drugs 
and engaging in policy activity.
Adapted from: 10 principles of meaningful engagement in drug policy. Canberra: Australian 
Injecting & Illicit Drug Users League (AIVL); 2012. 
Box 1.5
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1.2.2 Fostering outreach and service provision led by people who inject drugs
There is a difference between outreach programmes that are done for people who inject drugs and 
those done with or led by people who inject drugs (Table 1.1). Initiatives done with or led by people 
who inject drugs operate under the principle that people who inject drugs are best equipped to 
help each other learn not only to protect themselves from risks to their health and safety, but also 
to promote and protect their human rights, and to seek redress when their rights are violated. Peo-
ple who inject drugs should therefore be a strong force in programmes addressing HIV and HCV. 
It is not enough to “consult” with people who inject drugs before creating a programme. Rather, 
programmes should be based on the needs, perceptions and experiences of people who inject 
drugs, who should be meaningfully involved in the design of programmes from the outset, and 
their implementation and evaluation.
Table 1.1 Comparison of programme approaches from a community empowerment perspective
PROGRAMMES DONE FOR PEOPLE WHO INJECT DRUGS PROGRAMMES DONE WITH/LED BY PEOPLE WHO INJECT DRUGS
Often assume that knowledge and power reside with the 
programme staff and managers.
Programmes focus on the collectively identified needs of people who inject drugs and 
develop appropriate solutions.
People who inject drugs are engaged in all stages of planning and implementation. 
Involve people who inject drugs in programme implementation 
often as volunteers, or in low-paid positions, not as equal partners.
Involve people who inject drugs as equal partners in programme implementation, more 
commonly as paid employees or as peer outreach workers working with the community.
Monitoring focuses primarily on goods and services 
delivered and targets to be achieved.
Monitoring focuses primarily on quality of services and programmes; their 
accessibility and acceptability to people who inject drugs; community 
engagement; adequacy of service coverage; and responsiveness to the changing 
locations and needs of people who inject drugs. 
Focus on building relationships within the health system 
with health-care providers. Less emphasis is placed on build-
ing relationships among groups of people who inject drugs. 
Focus on building relationships within communities of people who inject drugs 
as well as between people who inject drugs and other organizations, service-
providers, human-rights institutions and similar groups.
Fostering outreach led by people who inject drugs requires that non-community service-provid-
ers support organizations of people who inject drugs in becoming partners in service provision. It 
is important to employ educators and outreach workers who are themselves current or former 
injecting drug users in order to ensure the trust and confidence of service recipients (see Chapter 
4, Section 4.4). However, people who inject drugs should not be limited to these roles in commu-
nity-based programmes, but should have the opportunity to participate at all other levels of the 
programme, including decision-making on programme implementation, management and govern-
ance. Capacity-building and mentoring should be a priority to enable people who inject drugs to 
take up these leadership positions (see Section 1.2.5).
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Community-led and community-based organizations
It is crucial to note that community-led organizations (i.e. those led by and for people 
who inject drugs) are not the same as generic community-based organizations (CBOs). In 
community-led organizations, power and decision-making lie in the hands of community 
members—i.e. people who inject drugs—whereas in a CBO (which may be a local affiliate 
of a national or international NGO), power may reside only with some members of the 
community, or, more commonly, with administrators who are not community members. 
It is the self-determining and self-governing nature of an organization, and its commitment 
to pursue the goals that its own members have agreed upon, that makes it a genuinely 
community-led organization. 
1.2.3 Adapting to local needs and contexts
HIV and HCV programmes must be sensitive to the diversity of cultures of people who inject drugs 
and respond to different drug use patterns and the needs and priorities of the local drug-using 
community. What it means to be a part of this community varies considerably according to social 
class, ethnicity, language, gender and race. Drug laws disproportionately affect the most margin-
alized and oppressed sectors of the drug-using community: in different settings these may be 
women, ethnic minorities, migrants and mobile workers, men who have sex with men, sex workers, 
prisoners, transgender people, the young or the poor. 
Flexibility, responsiveness and adaptability are essential in implementing community empower-
ment initiatives. Intervention goals need to remain aligned with the needs of people who inject 
drugs, even if these change over time. 
1.2.4 Developing organizations of people who inject drugs
Community-led organizations and networks have an important role in institutionalizing support for 
people who inject drugs and empowering communities to lead their own responses. Forming any 
type of group of people who inject drugs will be more successful if the process is initiated and led 
by the community, which gives communities a sense of ownership. A common first step in develop-
ing community cohesion is providing or identifying a space (such as a drop-in centre) where people 
who inject drugs can come together to socialize and discuss common issues (see Box 1.7). This 
helps them break down the internalized stigma and isolation common among people who inject 
drugs, and creates shared community norms and values. 
People who inject drugs may also come together over issues that affect them individually but 
that require a group response, such as addressing violence, extortion and harassment; overdose 
and overdose deaths; responding to contaminated batches of street drugs or unscrupulous sell-
ers; needs for child care; or seeking information as new (and frequently undocumented) migrants. 
Groups are likely to function most effectively when communities decide collectively on priorities 
for the whole group, agree on a process for making decisions, and on a common set of rules for 
being together as a group. 
Box 1.6
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Bringing people who inject drugs together
• Organize group activities at safe spaces (which may be drop-in centres, but might also be 
members’ homes, community centres, church rooms or other public facilities) based on 
the interests of the group members. 
• Plan activities for special occasions, such as festivals, holidays or commemorative days.
• Invite recognized community activists or peer outreach workers from neighbouring areas 
to speak at a gathering of local people who inject drugs. 
A strong community-led organization is characterized by vibrant membership, increasing financial 
independence and political power, and broadening social engagement. However, not all groups of 
people who inject drugs will become independent organizations. Some groups deliberately choose 
the independence that comes with not being funded, and this can foster a dynamism and flexibility 
lacking in groups tied to funded work plans and donor objectives or imperatives. 
If a community-led group decides to establish itself as a formal organization, it is important to 
develop a clear plan for its size, geographic reach, types of activities etc. Mission and vision state-
ments,1 together with a strategy statement or strategic plan, help an organization to: 
• Create a clear understanding of what it wants to accomplish: for example, if the community 
wants to be involved in advocacy for legal reform or policy issues, forming or joining a net-
work of like-minded groups may be the most effective approach. If it wants to provide services 
directly to other community members, forming an organization (which may eventually become 
legally registered) may be more appropriate. 
• Establish a framework for how it will achieve its vision: this requires understanding the steps 
needed and resources available for forming the kind of group that best fits the community’s 
vision.
• Describe clearly the mechanisms (roles/responsibilities) to reach its goals: although these 
may only go into effect once the network or group has been formed, it is important to have 
some idea of what will be needed so that the members can assess whether they are prepared 
to take on the responsibilities.
Forming a registered organization 
Depending on a group’s size and goals, as well as the country in which it is forming, it may decide 
to become a legally registered entity. The process to do this varies from country to country. Group 
members may need to: 
• understand the legal requirements (e.g. becoming a legal entity) so that funding opportunities 
and tax requirements/exemptions can be addressed
• establish full-time, part-time and volunteer positions for management and operations or ser-
vice delivery
1 Organizations summarize their goals and objectives in mission and vision statements. A mission statement describes what an organization wants to 
do now—its focus, critical processes and desired level of performance. A vision statement outlines what an organization wants to be in the future. It is 
a source of inspiration and motivation, sometimes looking at broader society and describing the change that the organization wants to effect.
Box 1.7
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• establish clinical oversight, if a clinic is part of the service offered
• establish advisory bodies and connect with relevant existing organizations to maximize oppor-
tunities for networking, support and mentoring 
• identify and manage funders and associated contractual obligations. Funding may come from 
one source or a mix of government, development partners, private institutions, corporate bod-
ies, philanthropic organizations etc.
The necessary registration materials must be obtained from the relevant government office. Pre-
cise requirements for documentation are set out by each government. Examples of the types of 
documentation required are: 
• memorandum of association, by-laws, constitution and charter
• report of annual activities
• financial reports/audit reports
• summary of organizational resources
• organizational chart/staffing plan (and human resources manual, if available)
• board of directors and rules and regulations governing the board (board endorsement of reg-
istration is also needed)
• board of trustees with registered charitable status, deed and rules of governance including the 
beneficiaries of the Trust
• letters of support from key partners.
Some of these documents may not be available for organizations just starting up and may need to 
be developed. 
Most countries have NGO coordinating bodies that offer advice or guidance on forming an organ-
ization. Organizations of people who inject drugs in neighbouring countries, or regional networks 
of such organizations, can also often provide advice and support on dealing with registration and 
overcoming the barriers that face people who inject drugs registering their own organizations. 
Networks
If the organization finds the requirements too complex or difficult to meet, it may be possible to 
register as a member of a network. This may be an appropriate intermediate step for a nascent 
organization on its way to registration, giving it the protection and support of the network as it 
grows and develops the materials needed for individual registration. 
National networks of people who use drugs have been established in many countries, including in 
challenging environments such as Afghanistan. In the absence of national networks, groups can affil-
iate with regional or global networks such as the International Network of People Who Use Drugs 
(INPUD). There are networks of people who use drugs in each region. Similarly, there are regional 
networks of AIDS service organizations with which groups or national networks could affiliate. 
1.2.5 Strengthening organizations and building capacity
Organizational capacity-building is a comprehensive approach to strengthening an organization’s 
ability to plan, manage and finance itself so that it can implement its own vision and strategy. Capac-
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ity-building can help organizations led by people who inject drugs to become resilient, self-suffi-
cient and respected as equal partners at the policy table. Capacity-building is also important to cre-
ate an organizational structure that provides consistency over time and establishes processes for 
succession planning, ensuring that community-led programmes continue. Lastly, capacity-building 
also helps the organization deliver on indicators and targets required by funders. Whether organ-
izations of people who inject drugs are already established, or whether they come into being as a 
result of HIV and HCV prevention programming, it is important for them to understand the goals 
and needs of funders, while developing the ability to shape those goals where necessary to ensure 
that they do not conflict with the organization’s own vision. 
Like other organizations, organizations of people who inject drugs face varying challenges to becom-
ing stronger and more sustainable, and they benefit from different approaches. An established organ-
ization may have a good understanding of its community’s needs and be able to lead the process of 
capacity-building without outside facilitators. A recently formed organization may need more guid-
ance, but certain principles apply to capacity-building in general. Support should be: 
• Comprehensive: Acknowledging all the capacity-building needs of an organization makes 
it possible to design a systematic approach to address all the essential needs, e.g. service 
provision, procurement, advocacy, programme management, M&E, governance, and resource 
mobilization.
• Contextualized and customized: Support should take account of the organization’s particular 
cultural, political and social environment.
• Locally owned: Persons providing capacity-building support may understand the processes and 
can help identify needs. However, if the organization is not making its own decisions, capacity-
building efforts will not be as successful.
• Based on the organization’s current abilities: The type, level and amount of capacity-building 
should be based on the organization’s ability to absorb and use the resources (financial and 
nonfinancial) being offered.
• Oriented both inward and outward: While it is essential for an organization to ensure the 
health of its staff and internal structures, it is also important to remember that any organization 
is part of a larger community and needs to understand opportunities for partnership and the 
potential benefits of external links.
• Sustainability-based: Capacity-building should strengthen an organization’s ability to maintain 
a base of financial resources so that it may continue to function well.
• Learning-focused: An organization that does not continue to learn about its functions, its com-
munity, the wider community and technical areas will become stagnant and cease to be relevant.
Whether an organization of people who inject drugs is a legally registered NGO or not, capacity- 
building can present specific challenges:
• Stigma, discrimination and the illegality of drug use can make it hard to engage people who 
inject drugs in roles that demand time and a certain level of publicly visible activities.
• Organizations staffed by people solely on the basis that they use drugs may initially lack the full 
range of managerial and technical skills needed to function optimally.
• Aspects of the lifestyle of people who inject drugs (including drug dependence) may make it 
difficult to retain staff and maintain optimal consistency within the organization. 
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Box 1.8
To deal with missing skills, some organizations outsource certain functions, such as financial man-
agement, to organizations that provide this service. One way to mitigate the loss of staff is to have 
more people involved in organizational activities, so that there is a larger number with institutional 
memory. This is especially important to facilitate smooth transitions. 
Organizations can build their capacities in specific areas. A best practice in preparation for this 
is for an organization to undergo a capacity assessment. There are many tools for this, including 
self-assessments, although a good, externally facilitated assessment helps an organization bring 
out issues it might not identify itself. The assessment provides the organization with a capaci-
ty-building plan to address areas identified for improvement. Box 1.8 summarizes areas of organi-
zational capacity-building, and these are explored in more detail below.
Strengthening organizational capacity 
Governance
• Develop a strategic plan to guide programming that reflects the organization’s vision and 
mission. Reassess goals and objectives regularly.
• Create a fair and transparent method for making decisions that includes staff (if the organ-
ization has them) and other members of the organization. 
• Establish processes to manage change and seek new opportunities for action. 
Project management
• Ensure that the process for carrying out and managing activities is participatory, transparent 
and has accountability, and that information is shared promptly across the organization.
• Identify skills needed and organize training to build capacity of members in programming, 
human resources, financial management, advocacy etc.
• Introduce mentoring and support systems to enable sustainability, and leadership succes-
sion planning and to safeguard against burnout.
Resource mobilization
• Build knowledge of funding sources and develop grant-writing skills.
Networking
• Encourage cooperation and learning from other organizations and networks of people 
who inject drugs, nationally and internationally.
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Governance 
Good governance means the responsible management of an organization’s strategic vision and 
resources. Transparency, accountability and effective management are essential components of 
good governance and of an organization’s ability to meet its mandate. 
A board gives strategic direction, provides support in legal affairs and accounting, and protects 
the organization. The board should combine expertise and appropriate representation. In the case 
of organizations of people who inject drugs, a board may include allies with the connections and 
influence to advocate to reduce the stigmatization faced by people who inject drugs, and to help 
with fundraising. The size of a board is less important than their demonstrated commitment to the 
organization’s cause and to helping establish and grow the organization. 
Project management
Well-managed, technically sound programmes and projects not only ensure that organizational 
objectives are achieved, but also instil confidence in donors and key stakeholders about the com-
petence of the organization. An organization is on the right track if it:
• develops and follows realistic work plans and budgets that are in line with its vision and mission
• defines technical interventions that are in line with local and international good practices
• ensures that its programmes and projects are responsive to the needs of its members. 
Resource mobilization 
Organizations should always be engaged in resource mobilization to fund efforts on a long-term 
basis. It is important to be strategic and look beyond the short term, especially if the organization 
is currently benefitting from a grant that will end after several years. While there is no guarantee 
that an organization will be able to raise money, there are good practices that may help. Important 
issues to consider with respect to resource mobilization include:
• Is the resource mobilization strategy in line with the organization’s vision and mission?
• Can resources be raised from members of the organization, i.e. through a small monthly or 
annual membership fee? This increases a sense of ownership, but the sum should not be so 
high as to exclude people from joining. A scaled membership fee may be considered.
• Are there government schemes that may be able to fund specific activities or programmes 
(without imposing an agenda that conflicts with that of the programme)? 
Developing partnerships
Developing a strong, successful organization of people who inject drugs is as much about relation-
ships as it is about systems. Networking involves donors, communities, and national- and local-lev-
els government, service-providers and NGOs. The organization must learn to engage and influence, 
focusing on the principles of justice and empowerment. Some of the functions of networking are 
ensuring human rights, securing comprehensive services for clients and developing relationships 
with donors (see Section 1.2.7). 
Two areas of networking that are especially important for organizations of people who inject drugs 
are engagement with state institutions and structures, such as policy-makers, law enforcement, 
health and social services and entitlement programmes; and engagement with non-state organ-
izations and institutions. Examples of issues that can be addressed through networking include 
institutional discrimination against people who inject drugs and biased media portrayals of them. 
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Engagement with governmental organizations: This is particularly important to enable pro-
grammes for people who inject drugs to advocate for access to health services, freedom from 
discrimination and harassment, protection from and redress for violence, and securing rights and 
entitlements as citizens. A partner organization working with the organization of people who 
inject drugs may have connections to enable members of community-led groups to join commit-
tees that oversee health programmes, or provide access to politicians and other officials. Capac-
ity-building may help guide people who inject drugs who are unfamiliar with formal meeting 
processes, or with protocol for dealing with officials, enabling them to learn how to participate 
and engage effectively. 
Engagement with nongovernmental organizations and institutions: Fostering partnerships with 
allies is an important aspect of capacity-building. It helps to establish an organization of people 
who inject drugs as a legitimate community with valid aims and objectives. Building links with other 
organization also helps identify a network of service-providers that can meet the needs of people 
who inject drugs more holistically. Such networking includes:
• other community-led and community-based organizations and NGOs
• community-led networks and organizations of sex workers, men who have sex with men, trans-
gender people, young key populations, and people living with HIV
• local women’s organizations, faith-based organizations and other community groups or relevant 
organizations with a focus on gender-based violence, human rights, access to health, access to 
justice, adult education and skills-building, and a range of other social issues and entitlements.
In each case, organizations of people who inject drugs should seek allies that value their input and 
see them as a partner, rather than a beneficiary. This means that the organizational allies should be 
respectful, supportive, and serious about meaningful engagement. 
1.2.6 Shaping policy and creating enabling environments
Community empowerment processes can reach beyond the community to influence policy and 
create enabling environments through advocacy. This involves community organizing, educat-
ing policy-makers, raising public awareness, documenting the lived experiences of community 
members, training, demonstrations, litigation and lobbying, as well relationship-building and 
forming networks. Advocacy can use communications strategies including mainstream media 
and Internet-based communication technologies such as social media to issue public state-
ments or raise awareness. 
Advocacy designed to influence law and policy must consider the safety and security of com-
munity members. This includes protecting the confidentiality of individuals and data collected 
for advocacy purposes. Programmes serving people who inject drugs should have safety and 
security protocols in place to respond quickly to violence, blackmail, arbitrary arrest or other 
harassment. 
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Box 1.9
Case example: Organizing to shape government  
policy in Indonesia
Persaudaraan Korban Napza Indonesia (PKNI) is a national network of organizations of 
people who use drugs. Established in 2006, PKNI has grown from a loose arrangement 
of support groups scattered across 11 provinces to an independent, leading national 
network representing the common priorities of 25 self-organized drug user groups 
across 19 provinces. 
PKNI empowers Indonesia’s drug-using community to adopt safer injecting practices 
that reduce HIV and other bloodborne virus transmission, to understand the country’s 
drug laws and their rights, and to articulate their needs and experiences to policy-
makers, service-providers and donors through reports, presentations, policy reviews and 
community-based research. 
PKNI has provided an important platform for the voice of the drug user community within 
the national response to HIV. In 2014, PKNI partnered with Indonesia’s Ministry of Health 
to develop its national harm reduction guidelines to ensure that the needs and rights of 
people who use drugs were accommodated. This was the result of a two-year process 
of sustained advocacy. Based on the findings of a 2013 quality monitoring and control 
survey, PKNI advocated for the inclusion of people who use drugs in the pre-consultations 
and negotiations around the harm reduction guidelines. PKNI built relationships with 
government officials and ministries, eventually obtaining a seat on the National Harm 
Reduction Taskforce. 
Community members now have the opportunity to shape policy processes, monitor and 
evaluate the effectiveness of the national HIV programme for people who inject drugs 
from the community’s perspective, and engage in strategy for reducing HIV among people 
who use drugs. 
http://korbannapza.org/en
1.2.7 Sustaining the movement
Funding community-led organizations of people who inject drugs is now widely recognized as cen-
tral to an effective HIV response and is specifically recommended by the Global Fund in its Key pop-
ulations action plan 2014–2017 and by the World Health Organization in the 2016 Consolidated 
guidelines on HIV prevention, diagnosis, treatment and care for key populations. It is unreasonable 
to expect any group to grow from a small collection of individuals to a movement whose members 
actively contribute to the national HIV response unless it receives sustained support and its partic-
ipation is welcomed. It is therefore essential that governments, national partners and development 
partners actively support the establishment and sustainability of organizations and networks led by 
people who inject drugs. Social contracting is key not only to sustaining movements of communi-
ties of people who inject drugs, but also to an effective and sustained HIV response, and thus it is 
an essential part of a government’s efficient allocation of its resources. 
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Box 1.10
Case example: Community advocacy  
for improved OST in Australia
A number of consumer representatives sit on the Opioid Treatments Advisory Committee 
of the Australian Capital Territory (ACT). Staff from the Canberra Alliance for Harm 
Minimisation and Advocacy (CAHMA) and from The Connection, an organization of people 
who use drugs, participate in the advisory committee, along with two consumers from the 
community chosen by CAHMA’s peer-support group PHAAT (Pharmacotherapy Advocacy 
Action Team). 
In 2009–2010 the ACT undertook a review of its pharmacotherapy guidelines. The consumer 
representatives argued for greater flexibility, more respect to be shown for consumers 
within treatment settings and better mechanisms for dispute resolution. The methods used 
to influence change in this policy area included consumer consultations to identify priority 
issues; regular PHAAT meetings to strategize; research into national guidelines and other 
policy documents; and representation of the issues at the Advisory Committee meetings. 
The ACT guidelines were improved as a result.
Source: The involvement of drug user organisations in Australian drugs policy: a research 
report from AIVL’s ‘Trackmarks’ project. Canberra: Australian Injecting & Illicit Drug Users 
League (AIVL); 2012. 
Funding support should not, however, be tied to donor-driven approaches that may conflict with 
the needs and priorities determined by the community. Flexible approaches that are based on gen-
uine and open communication, and therefore more responsive to community needs, are more likely 
to lead to more effective outcomes. Furthermore, heavy and restrictive reporting requirements 
often place a high burden on organizations that are understaffed and inadequately resourced. 
Quantitative targets may not capture the nuance and complexity of the work of community-led 
organizations, and what counts as success on the ground in the eyes of the organization may differ 
from the viewpoint of the donor. This risk can be mitigated—and more productive funding strat-
egies negotiated—if the community empowerment process has progressed to the stage where 
decision-making power is vested within the community-led organization. 
The extreme marginalization of people who inject drugs makes it particularly challenging to sus-
tain community-led organizations and networks, and unless this marginalization is recognized and 
addressed, no community empowerment approach will be successful or even conceivable. Organi-
zations of people who inject drugs should try to operate in solidarity with other social movements, 
particularly those that also advocate for human rights. This may include movements of other key 
populations with similar experiences of heightened HIV risk and social exclusion—such as sex work-
ers, men who have sex with men, transgender people, and prisoners or former prisoners (many of 
whom are also people who inject drugs)—as well as organizations and networks of people living 
with HIV and HCV. Collaboration between movements can be difficult while the stigma attached 
to drug use continues to be very strong, but ultimately it can strengthen the collective response to 
HIV and ensure that communities are at the centre of that response. 
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Box 1.11
Case example: Supporting communities through  
a regional harm reduction network in Eastern Europe and Central Asia
Low-threshold grants programmes that make funding available to small, new or not even 
formalized organizations of people who use drugs who want to make positive change in 
their communities have repeatedly shown significant impact. The Eurasian Harm Reduction 
Network, with support from the Robert Carr Civil Society Networks Fund, initiated a small-
grants programme in 2013, through which it disbursed 25,750 Euros (approx. USD $33,000) 
to seven organizations in Armenia, Georgia, Latvia, Moldova, the Russian Federation, 
Tajikistan and Ukraine. Projects were implemented by groups of people who use drugs to 
mobilize, document and respond to human-rights violations, and to evaluate and improve the 
quality of harm reduction programming, applying their particular motivation and knowledge 
to improving the communities they live in. Each project received technical support from 
EHRN and benefited from its capacity as a regional network uniting professionals, activists 
and representatives of the community of people who use drugs.
Apart from the particular gains achieved by each project in their individual countries, EHRN 
found there were benefits common to all of them: 
• The particular expertise and knowledge of people who use drugs was applied to improve 
health and human-rights outcomes. 
• People who use drugs showed they can be a driving force behind policy reforms that bring 
their countries into line with international standards.
• EHRN made space for groups from different countries to learn from and inspire each 
other.
• People who use drugs felt the impact of their work, and all groups supported by the pro-
gramme continued with sustained advocacy work.
• The project showed people who use drugs concrete examples of positive change that 
they can bring to their communities.
Source: People who use drugs making meaningful change. Vilnius: Eurasian Harm Reduction 
Network (EHRN), 2014.
Despite political, legal and financial challenges, it remains essential to mobilize resources and build 
political commitment for community-led organizations, and this approach has had positive results. 
Community advocates must be respected partners in policy-making, irrespective of the legal sta-
tus of drug use. A strong, healthy and vibrant civil society working in genuine partnership has been 
the backbone of the HIV response for 30 years. As we move forward, organizations and networks 
of people who inject drugs should be core members of this partnership. 
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Box 1.12
Case example: Broadening the range of allies  
and partners in a campaign in Eastern Europe and Central Asia
The Eurasian Harm Reduction Network’s (EHRN) regional advocacy campaign “Women 
Against Violence” aims to stop police violence against women who use drugs. The campaign is 
being implemented with partners from 16 cities in Belarus, Georgia, Kazakhstan, Kyrgyzstan, 
Moldova, the Russian Federation and Ukraine. EHRN enlisted 18 partner organizations in the 
campaign, which began in March 2014. Most of these were organizations providing harm 
reduction services with which EHRN had already cooperated on issues of gender and drug 
use. EHRN signed a memorandum of cooperation with each of the organizations so that 
they would have a sense of ownership of the campaign. This was important to keep partners 
motivated to pursue activities at the local level (especially since the campaign had no central 
budget). The memorandum gave clear details of responsibilities, of the support that EHRN 
would provide, and of the expectations of what the organization would do. 
During the first year of the campaign, the partner organizations collected details of more than 
805 cases of police violence through a specially designed online platform. They then organized 
roundtable discussions with law-enforcement representatives and other stakeholders, including 
a human-rights advocacy organization, health-ministry representatives, a lawyers’ association, 
and a private law firm that offered pro bono services. Partners signed memorandums of 
cooperation with police departments and organized trainings on harm reduction and the 
rights of women who use drugs. This led to the formation of a network of cooperative law-
enforcement representatives, and EHRN has since participated in international conferences on 
law enforcement and public health, and on criminal justice. 
At the same time as expanding its network of allied organizations and institutions and advocating 
for an end to violence against women who use drugs, EHRN and its partners have learned more 
about how police officers think and work, and how the criminal justice system is organized, 
enabling them to strategize better to help women manage legal systems within their countries. 
Source: Women against violence. Vilnius: Eurasian Harm Reduction Network (EHRN); 2014.
1.3 Monitoring progress
The progress of community empowerment can be documented, to inform and improve upon com-
munity-led or community-based programming. Short- and long-term objectives and goals should 
be established to guide community empowerment, and related indicators should be used to meas-
ure outcomes and impact. As an example, monitoring community empowerment in relation to HIV 
and HCV prevention, treatment, care and support and health services would measure the involve-
ment of people who inject drugs in each of the following: how services are run, quality assur-
ance, funding allocations, training of health personnel to address stigma, and advocacy to address 
discrimination—rather than simply whether a target percentage of people who inject drugs has 
accessed a particular service.
Communities can also monitor the progress of their success towards improving and shaping the 
services that they receive. Organizations of people who inject drugs should set the measurement 
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parameters in partnership with national policy-makers and programmers to monitor and evaluate 
programmes at all stages. 
Special attention must be paid to ensuring that doubly marginalized sectors of the drug-using 
community (see Section 1.2.3) are included. The use of qualitative research and narratives to tell 
complex stories of community empowerment are particularly valuable. Table 1.2 describes sample 
outcomes and indicators for monitoring community empowerment.
Table 1.2 Monitoring indicators for empowerment of people who inject drugs
LEVEL EMPOWERMENT OUTCOMES EXAMPLES OF EMPOWERMENT INDICATORS
Central  Inclusion of people who 
inject drugs in policy, 
programming and funding 
decisions 
 Prioritization and investment 
in community-led HIV 
prevention approaches
 Number of representatives from organizations of people who inject drugs who 
are members of national multisectoral HIV coordinating bodies
 Increase in contracts and amount of funding allocated to groups led by people 
who inject drugs
State/provincial 
level
 Increased participation of 
people who inject drugs in 
formation of state/district-
level policies and programmes
 Increased involvement of 
people who inject drugs in 
planning and implementation 
of health, legal and social 
services
 Increased knowledge of 
health-care providers, police 
and social-service agencies 
on rights and needs of people 
who inject drugs
 Number of organizations of people who inject drugs included in state/district 
policy and programming bodies
 Number of people who inject drugs actively involved in planning and 
implementing health, legal and social services
 Number (and proportion) of health-care providers, police and social-service agents 
who have received training and sensitization about people who inject drugs
 Attitudes and practices of health-care providers, police and social-service agents 
towards people who inject drugs (measured by surveys of these groups and of 
people who inject drugs) 
District/county 
level
Municipality/
Submunicipality
 Increased awareness of the 
wider community about the 
rights of people who inject 
drugs 
 Expanded partnership 
between organizations led by 
people who inject drugs and 
other community groups
 Percentage of sample of people who inject drugs reporting stigma and 
discrimination from service-providers and from the wider community
 Number of outside organizations that have partnered with organizations led by 
people who inject drugs
Organizations of 
people who inject 
drugs
 Increased capacity of people 
who inject drugs to operate in 
groups/organizations 
 Increased capacity of people 
who inject drugs as legal 
advocates to document and 
challenge human-rights 
violations 
 Number of available drop-in centres for people who inject drugs
 Number of organizations led by people who inject drugs
 Number of public meetings, marches or rallies held to promote rights of people 
who inject drugs
 Percentage of people who inject drugs who report participation in a group/
collective of people who inject drugs
 Number of people who inject drugs trained as legal advocates
 Documentation of human-rights violations
Note: Some of these indicators are based on those given in the Tool to set and monitor targets for HIV 
prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2015.
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What’s in this chapter?
This chapter offers practical advice on the human-right issues faced by people who inject drugs, 
especially recognizing and responding to stigma, discrimination and criminalization. It suggests 
approaches for legal and policy reform, and ways to monitor interventions for promoting and pro-
tecting the human rights of people who inject drugs. 
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2.1 Introduction
People who use drugs1 face high levels of stigma, discrimination, violence and other human-rights 
violations. These include denial of health services and social services, restrictions on employment 
or access to education, the removal of children from parental custody, incarceration or detention 
without trial, coerced drug treatment (often against their will in “treatment centres”), denial or 
cessation of opioid substitution therapy (OST), and physical violence. Stigma, discrimination and 
violence are reinforced by the criminalization of drug use in most countries, and together these 
factors drive the HIV and hepatitis C (HCV) epidemic among people who inject drugs by prevent-
ing them from accessing lifesaving services for harm reduction as well as HIV and HCV diagnosis, 
treatment and care. 
Principles for a human-rights based approach are listed in the introduction to this tool, since such 
an approach is essential to all aspects of harm reduction and HIV and hepatitis C prevention. This 
chapter addresses several priorities for legal reform, and some practical aspects of securing and 
monitoring human rights, before turning to strategies to address violence, stigma and discrimina-
tion against people who use drugs, and monitoring of programmes. 
Because stigma and discrimination operate at both institutional and individual levels, the experi-
ences and suggested practices presented in this chapter are directed at national programme-plan-
ners and policy-makers, and also at implementing organizations2 working at the local level, includ-
ing organizations led by people who use drugs.
2.2 Reviewing and reforming laws and policies 
Laws and policies, when essentially punitive, can be major barriers to accessing services for people 
who use drugs. Advocacy is important for the reform of laws and policies to incorporate access 
to human-rights based, evidence-informed programmes, in particular needle and syringe pro-
grammes (NSPs) and OST services. 
2.2.1 Frameworks for reform 
Advocacy for human-rights based reform of drug laws should emphasize that international conven-
tions on drugs do not mandate the criminalization of drug use, and that they contain flexibility that 
permits countries to refrain from criminalizing the possession of drugs for personal consumption. 
Reference can be made to rights enshrined in the International Covenant on Economic, Social and 
Cultural Rights (ICESCR), and the International Covenant on Civil and Political Rights (ICCPR), and 
other relevant core human-rights treaties, especially to specific clauses such as:
• the right to the highest attainable standard of physical and mental health (ICESCR, Article 12)
• the right not to be subjected to torture or other cruel, inhuman or degrading treatment or pun-
ishment (ICCPR, Article 7; Convention Against Torture, Articles 2 and 16)
• the right to nondiscrimination (ICCPR, Article 2; ICESCR, Article 2).
1 Drug use refers to the nonmedically sanctioned use of psychoactive drugs, including drugs that are illegal, controlled, or prescription.
2 An implementing organization is an organization delivering an intervention to people who inject drugs, with a client-centred approach. It may be 
a governmental, nongovernmental, community-based or community-led organization, and may work at a state, provincial, district or local level. 
Sometimes a nongovernmental organization provides services through subunits at multiple locations within an urban area, and in this case, each of 
those subunits may also be considered an implementing organization.
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Box 2.1
The United Nations (UN) 2016 General Assembly Special Session on the World Drug Problem Out-
come Document3 has a specific emphasis on human-rights, gender- and health-focused responses, 
including to: 
• encourage the voluntary participation of individuals with drug use disorders in treatment pro-
grammes, with informed consent (paragraph 1(j))
• ensure nondiscriminatory access to health, care and social services in prevention, primary care 
and treatment programmes, including those offered to persons in prison or pre-trial detention 
(paragraph 4(b))
• encourage the development, adoption and implementation … of alternative or additional mea-
sures with regard to conviction or punishment (paragraph 4(j))
• promote and implement effective criminal-justice responses to drug-related crimes to ensure 
legal guarantees and safeguard due process, including practical measures to uphold the prohi-
bition of arbitrary arrest and detention and of torture and other cruel, inhuman or degrading 
treatment or punishment and to eliminate impunity, in accordance with relevant and applicable 
international law and taking into account UN standards and norms on crime prevention and 
criminal justice, and ensure timely access to legal aid and the right to a fair trial (paragraph 4(o)).
For further information on the relationship between criminalization of drug use and human-rights 
violations, see the INPUD consensus statement on drug use under prohibition: human rights, 
health, and the law (2015).
A framework for legal review
The Canadian HIV/AIDS Legal Network published a series of eight modules in 2006 for 
review of laws on drug use in the context of HIV prevention. These model laws are useful 
tools to propose and advocate for reforms. Each module starts with a rationale and proposes 
models that are in line with human rights, addressing: 
• Criminal law reform
• Treatment for drug dependence
• Sterile syringe programmes
• Supervised drug consumption facilities
• Prisons
• Outreach and information
• Stigma and discrimination
• Heroin prescription programmes
The modules provided a framework for a legal review conducted in six Central Asian 
countries in 2010. For more information, see Accessibility of HIV prevention, treatment and 
care services for people who use drugs and incarcerated people in Azerbaijan, Kazakhstan, 
Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan: legislative and policy analysis and 
recommendations for reform. Toronto (ON): Canadian HIV/AIDS Legal Network; 2010.
3 Our joint commitment to effectively addressing and countering the world drug problem. Outcome document of the United Nations General Assembly 
Special Session on the World Drug Problem. A/RES/S-30/1. New York (NY): United Nations; 2016.
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Box 2.2
Case example: Reforming drug law through  
a consultative process in Myanmar
As part of a comprehensive effort to respond to drug use in Myanmar, in 2015 the United 
Nations Office on Drugs and Crime (UNODC) and the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) supported a consultation on amending Myanmar’s Narcotic Drugs and 
Psychotropic Substances Law. The objectives of this workshop were to present proposed 
amendments to the drug law and receive technical guidance and input from participants.
The workshop, held by the Central Committee for Drug Abuse Control, involved a broad 
range of stakeholders, including senior representatives of government, parliamentarians, 
international health and legal experts, international and local nongovernmental organizations 
(NGOs), drug-user networks, development partners and UN agencies. Participants suggested 
crucial changes, such as removing compulsory registration for drug users, switching from 
imprisonment to drug treatment, reducing penalties for minor offences and including the 
harm reduction approach in the law. Recommendations were also made by the UN to remove 
the death penalty for drug-related criminal offences.
UNODC is now supporting three rounds of consultations organized by the government 
and including civil-society groups to draft a National Drug Control Strategy. The technical 
inputs provided by UNODC for the strategy are aligned with the suggestions made during 
the consultation on the drug law. Once the strategy is finalized (probably in March 2017), the 
draft law will be submitted to parliament for ratification.
2.2.2 Removing criminal sanctions for drug use and drug possession for personal   
 consumption
In recent years, a few countries have experimented with drug policy reforms, including regulations, 
largely focused on cannabis. While these policy changes are yet to be evaluated, Portugal’s expe-
rience confirms that alternatives to criminalization of drug use lead to positive outcomes in terms 
of health and public safety (see Box 2.3).
2.2.3 Abolition of the death penalty
Many countries have reformed their penal codes to eliminate the death penalty, but of the 58 
that retain capital punishment as of 2016, some 32 countries or subnational jurisdictions allow it 
to be applied to drug-related crimes. In 2007, the UN General Assembly adopted a resolution (A/
RES/62/149) calling upon all states that still maintain the death penalty to establish a moratorium 
on executions with a view to abolishing the death penalty. 
There is no evidence that the imposition of the death penalty for drug-related offences has con-
tributed to reductions in drug use or the drug trade. As a UN entity, UNODC also advocates for 
the abolition of the death penalty, as does the International Narcotics Control Board. At the 2014 
and 2015 high-level sessions of the UN Commission on Narcotic Drugs, numerous member states, 
including a number of countries from the global south, expressed their support for elimination of 
capital punishment for drug-related offenses. 
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Box 2.3
For states that are not party to the Second Optional Protocol to the ICCPR, the imposition of the 
death penalty per se is not prohibited by international law. The ICCPR itself, however, limits it to 
use only for the “most serious crimes”. These are widely interpreted as intentional crimes with 
lethal or other extremely grave consequences for humanity as a whole.
Case example: Portugal’s experience 
Since 2001 Portugal does not criminalize any drug use. People who use drugs remain subject 
to administrative charges that usually result in a referral to a regional Commission for the 
Dissuasion of Drug Addiction (CDT in Portuguese). CDT members are health, legal and 
social-work professionals whose chief goal is to assess health risks and provide people who 
use drugs with access to as wide a spectrum of services as they need or choose to access. 
CDTs suspend most cases referred to them, effectively leaving most “offenders” without 
penalty, and offer harm reduction interventions, various drug-treatment options, and social 
integration and job placement programmes. 
Portugal’s drug use is below the European average and has declined among 15–24-year-olds—
the population most at risk for drug use initiation. The incidence of HIV and viral hepatitis 
have demonstrated downward trends in the last decade, due to the combined effects of a 
supportive drug policy and significant investments in harm reduction.
2.2.4 Young people: advocating for removal of age-related barriers 
Despite the sometimes young age of initiation into injecting drug use in many countries, young 
people who use drugs4 find it difficult to obtain information, sterile injecting equipment, drug-de-
pendence treatment, including methadone treatment for opioid dependence, and HIV testing, 
counselling and treatment. Age restrictions or requirements for parental consent make needle and 
syringe services, opioid substitution treatment and HIV testing less accessible to young people, 
increasing their vulnerability to HIV.
Considerations for legal and policy reform include:
• Examine current consent policies to consider removing age-related barriers and parent/guard-
ian consent requirements that impede young people’s access to HIV and sexually transmitted 
infection (STI) testing, treatment and care.
• Include relevant programming specific to the needs and rights of young people who use drugs 
in national health plans and policies, with linkages to other relevant plans and policies, such as 
those pertaining to the child-protection and education sectors.
4  Young people who use or inject drugs are those in the age range 10–24 years, in accordance with the Interagency Working Group on Key Populations 
HIV and young people who inject drugs: a technical brief (Geneva: World Health Organization; 2015).
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For further information on young people who inject drugs, including programmatic considerations 
for ensuring their human rights and access to appropriate services, see the World Health Organi-
zation (WHO) technical brief HIV and young people who inject drugs (2015).
2.3 Advancing human rights
2.3.1 Access to justice: organizing legal aid programmes and legal empowerment  
 of people who use drugs
Legal literacy and legal aid are essential elements to ensure that the right of people—including 
people who inject drugs—to access justice are respected. For people who inject drugs, poor 
awareness of one’s rights, and the inability to access legal aid in a timely manner, can result in 
police abuse, prolonged detention, denial of access to adequate health and social services, dis-
putes related to child custody, breach of confidentiality, coerced abortion (see Section 2.3.6) and 
workplace discrimination.
Even where the right to legal aid is supported by a country’s legal system, access to high-qual-
ity counsel for people who use drugs and are accused of crimes may be severely restricted due 
to their marginalization and economic disadvantage. People who use drugs are also frequently 
unaware of their rights; many cannot afford counsel or do not know how to access free legal aid. 
Ensuring legal literacy and adequate and timely provision of legal aid should be a high priority for 
government and for civil-society organizations to ensure access both to justice and to a range of 
other services for people who use drugs. 
The responsibility of states to provide legal aid to people in the criminal justice system, including 
people who use drugs and people living with HIV, has been recognized in the United Nations prin-
ciples and guidelines on access to legal aid in criminal justice systems (2012). The right to legal 
aid is also established by a range of international treaties, including the ICCPR. 
Legal aid services can provide a variety of support to people who use drugs, including infor-
mation on their rights; advice to individuals who have been detained, arrested or searched; or 
advice on matters related to housing, health care, child custody, education, or work-related 
issues. Legal aid services can include representation (oral or written) in court proceedings, and 
mediation of disputes. Services can be provided by lawyers (including pro bono), paralegals (Box 
2.4), law students under supervision at legal clinics, or health/harm reduction workers who have 
been trained to deliver one or more of these services. Legal aid services may also be needed 
by staff working in harm reduction services, for example in cases of police harassment. Legal 
aid services can be integrated within harm reduction and other health services to ensure best 
access (Box 2.5). 
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Box 2.5
Box 2.4
Case example: Paralegal services in Indonesia 
In Indonesia, Persaudaraan Korban Napza Indonesia (PKNI), a network of organizations of 
people who use drugs, provides paralegal assistance through trained and qualified peers. 
Around 120 people who use drugs have been trained across eight provinces to provide 
paralegal assistance to their peers whose drug-related cases are presently before the courts. 
Paralegals give detained people who use drugs information about their rights and refer cases 
to lawyers. During 2013–2016, 160 cases in five provinces were supported by peer paralegals. 
http://korbannapza.org/en
Case example: Integrating legal aid and  
HIV services into harm reduction programmes in Ukraine
Five harm reduction organizations in Ukraine have integrated legal services into their pro-
grammes in Kyiv, Kherson, Lviv, Mykolaiv and Poltava by placing staff lawyers at locations 
where people who inject drugs go to pick up needles and syringes, or for counselling and 
referrals. The organization also provides legal services through an individual lawyer or law firm 
contracted by the organization. The programme has increased access to harm reduction by 
drawing in new clients who come for the legal services and stay for the HIV prevention services. 
For more information, see Tipping the balance: why legal services are essential to health 
care for drug users in Ukraine. New York (NY): Open Society Foundations; 2008.
Where hiring a lawyer is not feasible for an organization, alternatives may include establishing 
relationships with law firms who can make legal aid services available pro bono and forming part-
nerships with civil-society organizations that work for access to justice. 
Legal aid should be low-threshold and easily accessible to people who use drugs (Box 2.6). 
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Box 2.7
Box 2.6
Case example:  
Online legal resources in Eastern Europe and Central Asia
Navigating legal aid can be challenging for people who use drugs and for their friends and 
families seeking assistance and advice. hand-help.ru is an online resource that provides 
easy-to-understand explanations of laws and regulations on drug use in the Russian 
Federation. With support from the United Nations Development Programme (UNDP) and 
co-financing from the European Union, a Regional HIV Legal Network was established 
in 2012. The Network works in nine countries in Eastern Europe and Central Asia and has 
a system for submitting complaints online. In 2015, the Network and UNDP released a 
handbook in English and Russian on addressing legal issues and accessing free legal aid: 
Know your rights, use your laws.
In addition to providing legal aid to people who use drugs, giving the community5 the education and 
resources that allows them to know and understand their rights is both an empowering and trans-
formative process that can have a significant impact on stigma and violence reduction (Box 2.7). 
Case example: Legal empowerment of  
people who use drugs in Tanzania and the USA
The Tanzanian Network of People Who Use Drugs (TaNPUD) works with Médecins du Monde 
to train members on their rights and support them to advocate on their own behalf and on 
behalf of their peers. Members of the network and other participants in harm reduction 
programmes carry information cards to use in case of arrest, explaining their rights and 
responsibilities as well as the responsibilities of the police (see Figure 2.1). Anecdotal reports 
suggest that the police are less likely to harass people who use drugs who have the card 
with them. A TaNPUD crisis response team with 13 members works in different areas of Dar 
es Salaam and has negotiated the release from police custody of people who use drugs or 
helped to arrange bail from courts to prevent their pre-trial imprisonment.
VOCAL NY, a New York City-based organization, makes human rights and legal rights a 
regular topic of “teach-ins” for people who use drugs at harm reduction and other service 
or community gathering points. The teach-ins allow people who use drugs to discuss their 
rights with peers and have their questions and concerns addressed. 
5 In most contexts in this tool, “community” refers to populations of people who inject drugs, rather than the broader geographic, social or cultural 
groupings of which they may be a part. People may move into or out of injecting drug use at various times in their lives but may maintain community 
connectedness. Thus, “community members” are people who inject drugs or people with community connectedness, “outreach to the community” 
means outreach to people who inject drugs, and “community-led interventions” are interventions led by people who inject drugs or people with 
community connectedness. For a closer definition, see Chapter 1, Box 1.1.
40
➋ Legal Reform, Human Rights, Stigma and Discrimination
Figure 2.1 Know your rights card
Rights of beneficiary
• Every human being is equal
• No one is above the law
• Every human being has a right to life
• Right not to be judged for his or her appearance
• Right not to be discriminated or stigmatized
• Right to privacy and confidentiality
• Right to work
Responsibilities of police
• To tell beneficiary the reason they are being 
apprehended 
• To inform beneficiary of their rights
• To inform beneficiary of their right to communicate 
with a lawyer, guardian or relative
• To record a statement correctly within four hours, and 
the statement to be read out to the beneficiary before 
he or she signs it
• To be taken to court within 24 hours
Responsibilities of beneficiary
• To respect authority
• To have their ID with them for easy identification 
• To take care of themselves and their personal hygiene
• Not to argue with the police
• To communicate immediately with the project whenever 
there is a problem with the police
Source: Médecins du Monde, TanPUD
2.3.2 Documenting human-rights violations 
Documenting human-rights violations can be an important tool to advocate for the rights of peo-
ple who use drugs, to address violations more broadly or to build a court case to affect policy at 
national levels. 
Ideally, organizations of people who use drugs should lead any documentation efforts. Where this 
is not possible or where doing so would endanger them, it may be appropriate for local or interna-
tional human-rights organizations—or international organizations of people who use drugs, if they 
are more protected—to assist. 
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Box 2.8
No single approach to documenting human-rights violations will suit all situations. In some cases, 
accounts of a few extreme violations may be sufficient to sound the alarm. In others, it may be nec-
essary to demonstrate many incidents. Different objectives may dictate different levels of human-
rights analysis. Box 2.8 summarizes preparatory steps for organizations of people who use drugs 
seeking to record abuses.
     Tips and strategies for documenting human-rights violations
√ Clarify the objectives of the documentation: is it meant to be a detailed record of 
many kinds of violations or to highlight a few key problems? What will be done with the 
documentation, and what will be needed to enable it to be used most effectively?
√ Identify the key issues or violations that you want to document: make a preliminary 
list of violations known to the community and highlight the most important topics for 
documentation and advocacy. 
√ Take account of what is known already: based on the preliminary list, prepare a list of 
activists or groups knowledgeable about these violations and the actions they may have 
already taken, and subgroups of the population of people who use drugs who are likely 
to have encountered these violations.
√ Think about the information you need to collect: compile a preliminary list of 
information that it will be necessary to collect (see Box 2.9). This may include medical 
records, photographs, videos, oral testimonies or written reports.
√ Identify all potential sources of information: people, documents and organizations; 
where these are difficult to reach, consider alternate ways of getting information.
√ Develop a method based on what is needed: the number of persons who use drugs to be 
interviewed, the number and identity of other experts, alleged perpetrators of violations 
and others, the degree of detail needed, the level of analysis of existing evidence etc. 
√ Get informed consent: it is important to have a mechanism for obtaining informed 
consent of those to be interviewed. Train interviewers to minimize re-traumatization of 
interviewees.
√ Develop resources to undertake an ethical and good-practice approach: ensure 
also that the financial and human resources, and equipment (e.g. secure file storage) 
necessary for the investigation are in place.
Source: Kaplan K. Human rights documentation and advocacy: a field guide for organiza-
tions of people who use drugs. New York (NY): Open Society Institute; 2009.
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The “6 W” guide for documenting human-rights violations
WHAT – What violation occurred? What was the accusation made, the law cited or the 
weapon used?
WHERE – The street, building or facility, and the address
WHEN – The time, day, date and year of the incident
WHO – Who was the direct victim? Who were the perpetrators? Are there witnesses or 
other people with direct knowledge of the violation (e.g. medical staff, police, outreach 
workers)?
WHY – Gather assessments or documentation from those most closely involved as to the 
circumstances, motivations, actions or words that led up to the violation. 
HOW – How did the violation occur, and how did the victim’s status as a person who uses 
drugs contribute to the violation?
Adapted from: Know your rights, use your laws: handbook for legal empowerment of 
people who live with or are at risk of HIV, their close ones, and service providers. New 
York (NY): United Nations Development Programme; 2014 and Kaplan K. Human rights 
documentation and advocacy: a field guide for organizations of people who use drugs. 
New York (NY): Open Society Institute; 2009. 
2.3.3 Addressing violence and other barriers by law-enforcement officers
People suspected of using drugs may be subjected to forced drug testing, searches and the destruc-
tion or confiscation of harm reduction equipment (sterile needles and syringes etc.) by police or 
other law-enforcement agents. They may also suffer beatings, torture or other cruel, inhuman or 
degrading practices during interrogation or detention, sometimes leading to death. 
Documenting punitive practices
Many organizations of people who use drugs and those that provide services to them have 
either documented police violence or harassment on an ad-hoc basis, or made it a systematic 
practice to monitor police stopping individuals near service points. Documenting punitive 
practices allows for advocacy either on an individual basis (addressing problems with a single 
police officer) or when addressing system-wide issues.
Documenting issues on an ad-hoc basis can include asking for police officers’ names and 
badge numbers to see whether harassment is an issue of one particular police officer. 
For systematic documentation, communities of people who use drugs share information 
regularly with needle and syringe distribution points so that these issues can be resolved 
on a district- or citywide basis. Other approaches include mapping locations where police 
harassment is occurring and sharing information on harassment instantly via text messages. 
Box 2.10
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Some countries or agencies that conduct regular surveillance of HIV and HCV prevalence 
among key populations have added questions about police harassment and violence to 
yearly epidemiological assessment questionnaires. Advocating for such measures could be 
beneficial to countries, as it allows interested parties to monitor and track progress towards 
reducing police violence and human-rights violations. 
Experiences from various parts of the world show that police attitudes and practices can change 
to be more respectful of human rights (Box 2.12). An important development has been the estab-
lishment of international groups such as the Law Enforcement and HIV Network (LEAHN), an 
organization of active and retired police officers and other former criminal-justice system workers 
who believe that the police have an important role to play in supporting the access of people who 
use drugs to harm reduction services. These groups are important resources for educating other 
police officers and the general public. 
Excerpt from the LEAHN Statement of Support  
for Harm Reduction Policing
1. Historically, law-enforcement agencies have always played an essential role in the 
protection and maintenance of public health. Currently, preventing the spread of HIV 
is a major public-health challenge in which law enforcement plays a crucial role. As part 
of the response, harm reduction policies and practices are pragmatic, comprehensive, 
evidence-based approaches which have proven successful in reducing the spread of HIV 
throughout the world.
2. The prevention and reduction of crime and enhanced community safety are important 
goals and benefits of harm reduction programmes. Even where behaviours are unlawful, 
law-enforcement agencies can have a significant impact in creating an environment 
enabling key populations to protect both themselves and the community from harm, 
including HIV.
3. Law-enforcement agencies, as key partners in implementation of these programmes, are in 
a position to facilitate access to HIV prevention and treatment services. Law-enforcement 
agencies (particularly the police and prison services) can make a significant contribution to 
improving public health by actively participating in and supporting these programmes.
4. Law-enforcement and health sectors should work in partnership to develop and support 
legislation, policy and practice that facilitate the common goals of HIV prevention 
through enhancing community safety and crime reduction. Directly and through more 
appropriate allocation of law-enforcement and health resources they enhance the ability 
of law-enforcement agencies to achieve their goals of crime prevention, crime reduction 
and community safety.
Source: LEAHN statement of support for harm reduction policing 
Website: www.leahn.org
Box 2.11
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At the local level, finding police champions and educating officers about HIV and harm reduction can 
have significant benefits. Police officers might be familiar with and sympathetic to such issues as 
drug use or HIV in their local community, but might need guidance in order to participate effectively 
in prevention programming. Organizing dialogues between civil-society organizations and law-en-
forcement officers helps increase mutual understanding of needs. Since police forces are hierarchi-
cal, it is often necessary for senior officers to provide leadership for such change to happen. 
It is important that training and sensitization take place on a regular basis. The inclusion of training 
on harm reduction or HIV and key populations within the curriculum of a police academy allows for 
a large number of police to be trained in a sustainable manner. It should be presented in a way to 
appeal to the interests of the police, e.g. as a more rational use of their resources (pursuing major 
drug traffickers rather than people who have committed minor, nonviolent drug-related offences), 
and protecting themselves from needle-stick injuries. Organizations of people who use drugs can 
play crucial roles as advocates and trainers with the police (Box 2.12). 
Case example: Changing police attitudes and practices
In 2013–2014, UNODC conducted joint sensitization workshops for law-enforcement 
authorities and civil-society organizations in 18 countries. For two days, 40 participants, half 
from civil-society organizations and half from the police, were trained on harm reduction 
and on how to advocate with the police. In each city where the workshop was conducted, all 
participants agreed that they learned a lot from each other; it was the first time they had a 
place for joint dialogue. One result was that in 2016, CSOs and police developed joint plans 
of action in Armenia, Kazakhstan, Moldova and Ukraine.
UNODC has also developed a Training manual for law enforcement officials on HIV service 
provision for people who inject drugs, to be used in police academies or for in-service 
training, and a Practical guide for civil society HIV service providers among people who 
use drugs: improving cooperation and interaction with law enforcement officials. 
The 2014 Open Society Foundations (OSF) publication To protect and serve highlights 
examples of improved attitudes of the police towards people who use drugs:
• In Kolkata, India, the deputy commissioner of police was persuaded of the wastefulness 
of pursuing people committing petty drug crimes, and worked with community groups 
to set up drop-in centres6 where people could get support and nonjudgemental health 
services. The success of those efforts depended on training a wary police force of the 
value of these services. The effort eventually helped transform police attitudes, enabled 
thousands of people who use drugs to get social services, and helped the drug police to 
target their resources more effectively against major criminals.
• In Kyrgyzstan, a high-ranking drug enforcement police officer saw the devastating impact 
of HIV in the country and became aware of the importance of harm reduction. With his 
6 A drop-in centre is a place where people who inject drugs may gather to relax, meet other community members, and hold social events, meetings or 
training. See Chapter 4, Section 4.6, for details.
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support, and working with human-rights and HIV prevention organizations as well as com-
munities of people who use drugs, national guidelines on police involvement in the national 
HIV strategy were revised. Police were ordered not to interfere with harm reduction ser-
vices, but attitudes did not change until countrywide training involving health workers 
and people who use drugs enabled rank and file officers to understand that they had an 
important role to play in ensuring access to life-saving services, and that people who use 
drugs were worth saving. The police academy has since developed an HIV curriculum and 
instituted regular training on harm reduction, and increasing numbers of police officers 
see ensuring access to HIV services as part of their job.
• In Baltimore, USA, where police officers were noted to approach individuals near needle 
distribution sites, the Police Department’s Office of Occupational Health and Safety and 
the city’s Health Department, which operated NSPs, offered training on HIV and harm 
reduction basics and described the benefits of harm reduction in terms of limiting police 
exposure to needles during searches. Police officers’ fears of needle-stick injuries were 
addressed and prevention strategies were discussed. People who use drugs provided per-
sonal perspectives on their experience with the police. In addressing police concerns, the 
training took on a protective angle, explaining how harm reduction programming benefits 
all, including the police.
2.3.4 Forced or compulsory treatment
In many countries people who use drugs are sent by the courts to mandatory drug-dependence 
treatment or coerced treatment, either in the community as an alternative to incarceration, or in 
addition to incarceration. Drug-dependence treatment is a health service with the same ethical 
standards as any other. No treatment should be initiated without the informed consent of the cli-
ent. The person who uses drugs must have the choice to accept or refuse this alternative. 
In some countries, people charged with drug offenses—including minor, nonviolent offenses, and 
in many cases simply consumption and without a conviction—may be detained against their will 
in facilities that claim to provide treatment or rehabilitation and offer no freedom to leave the 
treatment facility. There they are often subjected to physical abuse, deprivation and forced, unpaid 
labour. A 2012 joint statement by 12 UN entities condemned these practices and called for states 
to “close [these centres] without delay and to release the individuals detained,” and to replace 
compulsory detention with voluntary community-based care for those who need it.7 
7 Joint statement: compulsory drug detention and rehabilitation centres. International Labour Organisation; Office of the High Commissioner 
for Human Rights; United Nations Development Programme; United Nations Educational, Scientific and Cultural Organisation; United Nations 
Population Fund; United Nations High Commissioner for Refugees; United Nations Children’s Fund; United Nations Office on Drugs and Crime; United 
Nations Entity for Gender Equality and the Empowerment of Women; World Food Programme; World Health Organisation; and Joint United Nations 
Programme on HIV/AIDS; 2012.
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Strategies to advocate for the closure of detention  
centres with compulsory or coercive treatment 
Documenting abuses can be difficult or impossible where governments restrict access to 
these facilities and where “patients” or even former patients may fear to tell their stories. 
International human-rights organizations may be able to help, as in the case of Human 
Rights Watch’s revelation of abuses in compulsory drug detention centres in Cambodia, 
China, Laos and Viet Nam, and similar reporting on Thailand by the Canadian HIV/AIDS 
Legal Network. Human-rights organizations can help local civil-society organizations to 
make appeals to human-rights bodies, as Human Rights Watch has done in the Universal 
Periodic Review process of the UN Human Rights Council, based on the results of its 
investigations of these centres. Backed up by the clear UN position on this subject, UN 
staff should also be called upon to assist in advocacy to close these institutions.
2.3.5 Access to health services in detention
Prisoners shall have access to the health services available in the country without discrimi-
nation on the grounds of their legal situation.
Principle 9 of the Basic principles for the treatment of prisoners, UN General Assembly
According to Harm Reduction International, in 2015 only eight countries offered NSP in prisons, 
and only 52 offered OST for people who were incarcerated. Treatment for HIV and tuberculosis is 
more widely accessible in prisons, but is still complicated by the competing priorities of health and 
prison authorities. In many countries, the provision of harm reduction and drug-dependence treat-
ment services in detention settings is limited by legal or financial restrictions, or by official denial 
of the real situation in prisons. Resolving these legal barriers requires significant advocacy efforts 
and political will.
The UN Rules for the treatment of women prisoners and non-custodial measures for women 
offenders (the Bangkok Rules, 2013) and the UN Standard minimum rules for the treatment of 
prisoners (the Nelson Mandela Rules, 2015) provide clear guidance on the need to provide services 
in prisons equivalent to those available in the wider community, and to provide drug-dependence 
and HIV treatment and ensure their continuity. 
Denying access to OST during interrogation, detention or in health-care settings may occur 
because systems have not been established to provide OST; to elicit a confession; from a misin-
formed desire to “treat” or “cure” drug use (despite the lack of any evidence for the basis or effi-
cacy of this approach); or simply to punish. The UN Special Rapporteur on Torture and Other Cruel, 
Inhuman or Degrading Treatment or Punishment has stated that “denial of medical treatment and/
or absence of access to medical care [including OST] in custodial situations may constitute cruel, 
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inhuman or degrading treatment or punishment and is therefore prohibited under international 
human rights law.”8
Case example: Advocacy for prison needle  
and syringe programmes in Australia
In 2011, the Australian NGO Anex investigated the legislative and regulatory considerations 
underlying the introduction of prison NSPs in the state of Victoria. Anex found that 
legislation relating to workplace health and safety and the provision of reasonable medical 
treatment and care to prisoners establishes the duty of care underlying the provision of 
such programmes. This duty of care is reinforced by the state’s Charter of Human Rights 
and Responsibilities Act 2006. To establish NSP in prisons, compliance with the state’s 
Corrections Regulations 2009 is required and consent must be obtained from the prison 
governor.
Source: A handbook for starting and managing needle and syringe programmes in prisons and 
other closed settings. Vienna: United Nations Office on Drugs and Crime; 2014.
www.anex.org.au
The following points can be used to advocate for health care and harm reduction services in prisons: 
• Show the need: conduct a review of the epidemiologic situation in prisons in the country, 
including data on infectious disease incidence, injection and risk behaviours inside prisons.
• Show the obligations under international and national law dealing with human rights, health 
or the standards of prison facilities and legal obligations. People in prisons are entitled to 
health care equivalent to that received by the non-incarcerated population. 
• Show the scientific evidence on the effectiveness of interventions in prisons, e.g. the World 
Health Organization (WHO), UNODC and UNAIDS publication Interventions to address HIV in 
prisons: drug dependence treatments.
• Show international guidance, e.g. the UNODC, International Labour Organization and WHO 
publication HIV prevention, treatment and care in prisons and other closed settings: a com-
prehensive package of interventions (2013).
• Show the benefits for prison staff, i.e. workplace safety—where needles and syringes are 
allowed, prisoners will either exchange them, dispose of them instantly or do not feel the 
need to hide them where staff might be injured during searches. Providing access to OST to 
people in need in prisons reduces drug trafficking and facilitates prison management. 
• Show the benefits for the entire population: prison health is public health—where needles 
and syringes are allowed, prisoners do not share injection equipment, reducing the risk of 
transmitting HIV and HCV among prisoners and their partners, in prisons or after release. 
8 Promotion and protection of all human rights, civil, political, economic, social and cultural rights, including the right to development. Report of the 
Special Rapporteur on torture and other cruel, inhuman or degrading treatment or punishment, Manfred Nowak. United Nations General Assembly A/
HRC/10/44, para. 71. New York (NY): United Nations; 2009. 
48
➋ Legal Reform, Human Rights, Stigma and Discrimination
• Show the benefits of involving prisoners in support services: people who use drugs can be 
involved in prison NSPs, assisting with provision of information and education, HIV testing 
services, overdose management, and helping prison and medical staff make programming 
more effective.
For an example of advocacy material, see: Harm Reduction International’s Advocating for needle 
and syringe exchange programmes in prisons. Evidence and advocacy briefings series. 
2.3.6 Advocating for gender-responsive harm reduction services 
Women who inject drugs often experience greater stigma and discrimination than men who inject, 
and this is often heightened by gender-based violence. They face a range of gender-specific barriers 
to accessing HIV-related services, and in many contexts they remain a particularly hard-to-reach pop-
ulation, even where harm reduction programmes are in place. 
Other laws and policies that affect women and their access to HIV services include those where 
indicating drug use is criterion for loss of child custody, for forced or coerced sterilization or 
abortion.9 However, research indicates that with access to adequate medical and social support, 
women who inject drugs can have healthy babies and provide their children with appropriate care 
and a loving and supportive developmental environment. Organizing women who use drugs—par-
ticularly through community-led women’s groups and networks—coupled with targeted efforts to 
stop violent practices against them, can contribute to improvements in drug policy and access to 
reproductive health services. 
The UNODC policy brief Women who inject drugs and HIV: addressing specific needs (2014) lists 
interventions that respond to the needs of women who inject drugs:
• sexual and reproductive health services, including for STIs and prevention of mother-to-child 
transmission of HIV
• maternal and child health services
• gender-specific peer education and support
• services related to gender-based violence
• services tailored for sex workers who inject drugs 
• provision of male and female condoms
• parenting support
• child care
• couples counselling (aimed at ensuring that the responsibility for reducing HIV and health risks
• is equally shared between partners)
• information, education and communication that is specifically relevant to women who inject 
drugs (including safer injecting and safer-sex techniques)
• legal aid that is accessible and relevant to the needs of women who inject drugs
9 Coerced abortions include the overt use of physical force or emotional or psychological pressure to make a woman have an abortion against her will, 
as well as cases where a woman is manipulated by misinformation (for example about the effects of using drugs during pregnancy) or financial 
incentive into consenting to an abortion that she might not otherwise have freely chosen to undergo.
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• provision of psychosocial and ancillary services and commodities
• income-generation interventions for women who inject drugs.
For more information, see also the UNODC Addressing the specific needs of women who inject 
drugs: practical guide for service-providers on gender-responsive HIV services (2016).
Case example: The International Network of  
Women Who Use Drugs (INWUD)
INWUD is a subsidiary group of INPUD (the International Network of People Who Use 
Drugs). The organization provides a women-only online safe space (via a listserve) where 
ideas, challenges and support can be shared. INWUD promotes equity for women on all 
INPUD boards and working groups, and reviews and has input into all INPUD documents to 
ensure they are sensitive to women prior to their publication. 
INWUD engages and promotes women who use drugs as equal partners and contributors 
in all aspects of drugs theory and practice, including policy, legal reform and harm reduction 
development. The group actively seeks to collaborate with relevant UN and other international 
groups and bodies to give greater voice to issues affecting women who use drugs. INWUD 
prepared a position statement for the 2016 UN General Assembly Special Session on the 
World Drug Problem. 
In 2014 INWUD worked in collaboration with the National Advocates for Pregnant Women 
in the USA to make a submission to the UN Human Rights Council on the rights of pregnant 
women who use drugs; and in 2015 it partnered with the International Community of Women 
Living with HIV (ICW) to produce a joint position statement on women who use drugs and 
HIV. These are examples of a women drug users’ network working with more mainstream 
women’s networks to improve the human rights of women who use drugs and reduce stigma 
and discrimination. 
2.4 Addressing stigma and discrimination
The extreme level of stigma routinely experienced by people who inject drugs is a form of struc-
tural violence. The language, policies and practices of legal, health and educational institutions 
and the media often create, reinforce and perpetuate this stigma. This makes it more difficult to 
reform harsh drug laws or properly resource HIV and HCV prevention, diagnosis, treatment and 
care programmes for people who use drugs. Stigma can lead to toleration of human-rights viola-
tions against people who use drugs and is also used to legitimize discriminatory practices. 
Examples of legal, social and institutional discrimination include restrictions on funding of health 
services such as injection equipment for distribution through NSPs; legal prohibitions on OST; 
impeded access to harm reduction services through zoning rules or the opposition of the wider 
community to having services in their neighbourhood; and age restrictions or requirements for 
parental consent for treatment, which limit young people’s access to services.
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Forms of stigma related to people who use drugs
Stigma from individuals: the negative views and stereotypes held by individual members of 
society towards people who use drugs. These may be based on personal observations and 
direct experiences, or on media reporting, government laws and policies. 
Stigma from services/programmes: policies and practices that create barriers to service 
access, e.g. judgemental attitudes of service-providers, lack of confidentiality or privacy for the 
client, lack of informed consent for treatment, or coercive, compulsory or abusive treatment. 
Systemic, structural or institutional stigma: punitive and harsh drug-control laws and 
coercive and corrupt law-enforcement practices, including violence and extortion; and policies 
that officially restrict or prohibit access to public services for people who inject or otherwise 
use drugs. 
Self-stigma: the internalization of stigmatizing views and attitudes by people who use drugs. 
Stigma by association: stigma directed against family and friends of people who use drugs, 
or against those who express empathy or support for people who use drugs, or who support 
more progressive drug laws, or against providers of harm reduction services or researchers.
Adapted from: Understanding drug-related stigma: tools for better practice and social 
change. New York (NY): Harm Reduction Coalition.
2.4.1 Local-level programming to reduce stigma and discrimination 
Use participatory methods. People who use drugs should be invited to engage in processes to 
identify their problems, analyse causes, identify priorities and develop solutions. Such methods 
strengthen programme relevance, build life and relationship skills and help ensure the long-term 
success of programmes.
Understand local patterns of stigma and discrimination against people who use drugs and the 
relationship between these and vulnerability to HIV and HCV. Use this understanding as the basis 
for designing programmes. 
Use an integrated approach in designing interventions. A greater impact on stigmatization and 
discrimination against people who use drugs can be achieved via broad-based programmes that 
provide information and holistic health services, work with the legal and justice sectors and are 
community-based.
Build capacity of programme staff to understand and address the links between stigma and dis-
crimination against people who use drugs and HIV. Programme staff should be able to respond 
sensitively to people who use drugs who experience discrimination or violence, without further 
stigmatizing or blaming them. 
Recognize that programmes may have unintended harmful impacts for people who use drugs, 
such as retaliatory or “backlash” violence. Prepare for this possibility and monitor programmes for 
such unintended consequences.
Evaluate programmes to identify strategies that reduce risk factors and levels of discrimination 
faced by people who use drugs, in order to build the evidence base and ensure that resources are 
directed to the most beneficial strategies. Evaluation should always take place with the participa-
tion of people who use drugs themselves. 
51
➋ Legal Reform, Human Rights, Stigma and Discrimination
Box 2.17
Checklist for a code of good practice to combat  
stigma and discrimination within a service or organization
This checklist can help an organization providing services to people who use drugs to develop 
or evaluate a code of good practice to eliminate stigma and discrimination. Completing the 
checklist is best done as a team exercise, which can be repeated on a regular basis (at least 
once a year). The questions and statements are suggestions and should be tailored to the 
type, size and scope of the organization. They can be assessed against a scoring framework 
such as: Y—yes, we currently do this well, NI— we currently do some work in this area but it 
needs improvement, NC—not currently undertaken/we currently do not work in this area, 
NA—not applicable to our work/organization. An action plan should be developed to address 
any areas that are identified as NI or NC. 
Language: Do written policies and practices use language that is nonjudgemental, neutral 
and empowering (e.g. “person who injects drugs” or “drug-dependent person” rather than 
“drug addict”, “drug abuser” etc.)?
Confidentiality and privacy: Are all services provided in a manner that is confidential and 
protects people’s privacy? Does the organization ensure people are not asked about their 
drug use, HIV or HCV status in front of other clients? Can female and young service-users 
access programmes (such as OST) without being required to have a “guardian” (partner or 
family member) with them?
Assumptions: Are policies and practices free of assumptions about people accessing 
services, e.g. assuming that drug users who present for treatment for illness or relief of 
pain are simply “seeking drugs”; treating people known to use drugs differently from other 
clients; or refusing services because they are viewed as “trouble” or “difficult”?
Data protection: Are all personal records and data about service-users managed through a 
system that is safe and confidential? What information are people required to provide, and 
could it make them vulnerable to police action, child protection intervention or violence in 
the community? Is it absolutely necessary to gather all information that is recorded? What 
local laws assist or obstruct the protection of data?
Informed consent: Is full and informed consent gained before any medical tests or procedures 
are undertaken? How do you know that consent has really been given freely?
Voluntary: Are all services and programmes provided on a voluntary basis, i.e. clients can 
enter and leave when they choose and are not forced to enter or remain, either by the 
organization, the police, the courts or family members? 
Nonpunitive: Can service-users be removed from the service or denied access for certain 
reasons? Are these reasons fair and do they put the person’s health first and include a process 
of appeal? Have service-users been fully involved in the drafting of these rules, and are new 
service-users informed of these rules upon arrival?
Safety: Are there policies and procedures to ensure that every service-user feels safe access-
ing programmes? 
Evidence-based: Are all services and programmes based on the best available and scientifi-
cally sound evidence of good practice? 
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Meaningful involvement: Are service-users involved in the planning, development and 
implementation of services? Does the organization work with and involve a local or national 
organization of people who use drugs? Is there an accessible way for service-users to provide 
feedback and tell you what services they want or need? 
Complaint mechanism: Is there a complaints mechanism that people are comfortable 
accessing and are able to use easily? How is this publicized?
Staff training and support: Are adequate training and support provided to all staff working 
with people who use drugs for the roles they undertake?
Employment of people who use drugs: Are people who use drugs also employed as full 
staff members, and are they given the same training and remuneration as staff who do not 
use drugs?
2.4.2 Changing attitudes towards people who use drugs
Influencing the media 
Many people gain their information and opinions about injecting drug use from the mainstream 
media. Several strategies have been used to challenge stigmatizing and discriminatory media por-
trayals of people who use drugs (Box 2.18).
Case example: Strategies for challenging stigmatizing  
and discriminatory attitudes in the media
• Since 2011, the Latin America regional conferences on drug policy, convened by a con-
sortium of NGOs led by Intercambios in Argentina, have offered awards for the best Latin 
American journalism on drugs and drug policy. Many journalists have entered the compe-
tition, and Intercambios believes that the competition has improved news coverage. 
• The West African Commission on Drugs conducted a workshop for journalists in that 
region to encourage better coverage of drug policy issues. Participating journalists exam-
ined the results of the war on drugs and the impact of media discrimination against people 
who use drugs. 
Communities of people who use drugs have also organized collective campaigns to address dis-
crimination in the media (Box 2.19).
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Box 2.19
Case example: Challenging discriminatory views  
in the press in Ukraine
Despite national efforts to establish well-run OST and support programmes, communities 
of people who inject drugs in Ukraine have been heavily stigmatized. In 2006–2008, as 
Ukraine began scaling up methadone and buprenorphine programming, an anti-drug national 
billboard campaign was launched by a local nonprofit agency using stigmatizing language 
about people who use drugs. In response, the All-Ukrainian Charitable Foundation “Drop-In 
Centre” (an NGO of people who use drugs) and the Association of Substitution Therapy 
Advocates of Ukraine (ASTAU) launched a campaign to highlight the opportunities presented 
to people who inject drugs by OST. Billboards in five cities ran the message: “Return ticket: 
what can help an individual who uses drugs to return to work/family/society? ASK!” The 
Ukrainian acronym for OST is ZPT, which is similar to the Ukrainian verb “ask”—zapitay. 
Viewers were encouraged to visit the campaign’s website, zapitay.in.ua, which discusses 
the benefits of OST. In addition to the billboards, press releases and press conferences 
conducted by people who use drugs and OST clients and their parents contributed to an 
improved societal understanding of people who use drugs and their communities. 
Creating a voice for people who use drugs
Some organizations of people who use drugs have created magazines, newsletters, Internet blogs, 
videos and other online resources to counter stigmatizing and discriminatory media reporting. 
These provide an alternative, humanizing perspective about people who use drugs, as well as 
essential, nonjudgmental peer education and harm reduction information. Peer-based publica-
tions, online resources and advocacy statements have been produced even in environments where 
drug use is criminalized and people who use drugs are vulnerable to arrest. 
Community-led publications, resources and advocacy tools
For ideas on how to create or further develop a “drug users’ voice” in your local context, refer 
to these drug user-led publications, resources and advocacy tools from a range of settings:
We are drug users: voices from the international movement of people who use drugs. 
(YouTube video; 2014.)
INPUD consensus statement on drug use under prohibition: human rights, health, and 
the law. London: International Network of People Who Use Drugs; 2015. 
Paper planes (Canberra: Australian Injecting & Illicit Drug Users League; 2014) is a book that 
uses a simple narrative to encourage people to examine their own prejudice towards women 
who use drugs and to challenge stigma and discrimination.
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Box 2.21
Advocating with stakeholders
Another strategy for influencing the public and the media is to mobilize statements by celebrities 
or other high-profile persons whose stature draws media attention. The Global Commission on 
Drug Policy, a group convened in 2010 including former heads of state, activists and intellectuals, 
has drawn considerable attention to drug policy issues. The 2014 report of the West Africa Com-
mission on Drugs received wide coverage in the media and has helped to open debates on the 
negative impact of discrimination and human-rights violations against people who inject drugs 
across Africa. Efforts to advocate with government and NGOs may also be successful (Box 2.21).
Case example: Advocacy to increase acceptance of  
Roma people who use drugs
In 2012 the Romanian NGO Carusel developed an advocacy project to sensitize Romania’s 
National Agency for Roma (NAR) and other major Roma NGOs to the drug use situation in 
the community, especially regarding the vulnerability, stigma and discrimination faced by 
Roma drug users. In order to build political will and commitment on these issues, Carusel 
recognized that wider community acceptance was the first step.
Carusel’s advocacy strategy includes dissemination of key human-rights and public-health 
messages, sensitization and capacity-building trainings, and field visits for data collection, 
outreach to community leaders and supervision of activities. People who use drugs are 
themselves involved in all project activities. A scholarship programme supports young 
people to attend the Roma Harm Reduction Summer School to develop outreach and harm 
reduction advocacy skills. 
As a result of this work, NAR and other Roma NGOs are becoming more understanding of 
drug use in the Roma community, and there is greater acceptance of the users themselves. 
Roma NGOs provide financial assistance for Carusel to purchase harm reduction supplies 
and to provide technical expertise for reporting cases of human-rights violations against 
all drug users. The needs of Roma drug users—including culturally appropriate harm 
reduction activities—are now addressed in the strategy and action plans of the National 
Anti-drug Agency. 
www.carusel.org
2.5 Monitoring programmes
Monitoring and evaluation of stigma, discrimination and violence prevention and response efforts 
is important because:
• These strategies are a key component of HIV prevention and treatment programming globally, 
informed by the evidence that HIV can only be defeated by ensuring enabling environments for 
key populations.
• Data on the experience of stigma, discrimination and violence by people who use drugs can 
provide a basis for planning and designing appropriate strategies.
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• Routine monitoring allows programmes to identify whether there are any unintended conse-
quences of programmes and interventions (e.g. “backlash”).
• Evidence of the stigma, discrimination and violence faced by people who use drugs is a power-
ful tool for advocacy to change laws and policies and create an enabling environment for pro-
moting the rights of people who use drugs. 
The 2015 WHO Tool to set and monitor targets for HIV prevention diagnosis, treatment and care 
for key populations provides indicators that can apply to people who use drugs in the context of 
human rights and enabling environments. Suggested indicators are given below: 
To monitor stigma and discrimination:
• percentage of drug users reporting stigma and discrimination 
• percentage of service-providers surveyed responding that they “agree” or “strongly agree” to a 
collection of discriminatory statements. 
To assess work in the area of providing an enabling environment:
• involvement of people who use drugs in policy and strategy formulation
• number of services providing legal support to drug users
• support services for people who use drugs who experience violence
• sensitization trainings on people who use drugs for health-care providers/law-enforcement 
officers.
The development of indicators should be done in consultation with, or by, communities of people 
who use drugs. 
2.6 Further resources
1. Policy brief – HIV prevention, treatment and care in prisons and other closed settings: a 
comprehensive package of interventions. Vienna: United Nations Office on Drugs and Crime, 
International Labour Organization, World Health Organization; 2013.  
http://www.who.int/hiv/pub/prisons/interventions_package/en
2. UNODC and the promotion and protection of human rights: a position paper. Vienna: United 
Nations Office on Drugs and Crime; 2012.  
http://www.unodc.org/documents/justice-and-prison-reform/UNODC_Human_rights_
position_paper_2012.pdf
3. From coercion to cohesion: treating drug dependence through health care, not punishment. 
Vienna: United Nations Office on Drugs and Crime; 2010. 
http://www.unodc.org/docs/treatment/Coercion/From_coercion_to_cohesion.pdf
4. Training manual for law enforcement officials on HIV service provision for people who inject 
drugs. Vienna: United Nations Office on Drugs and Crime; 2014.  
http://www.unodc.org/documents/hiv-aids/LE_MANUAL_02.10.14.pdf 
5. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key 
populations–2016 update. Geneva: World Health Organization; 2014.  
http://www.who.int/hiv/pub/guidelines/keypopulations-2016/en
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6. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV 
prevention, treatment and care for injecting drug users–2012 revision. Geneva: World Health 
Organization; 2013.  
http://www.who.int/hiv/pub/idu/targetsetting/en
7. “Nothing about us without us”: greater, meaningful involvement of people who use illegal 
drugs: a public health, ethical, and human rights imperative. Toronto (ON): Canadian HIV/AIDS 
Legal Network, International HIV/AIDS Alliance, Open Society Institute; 2008. 
https://www.opensocietyfoundations.org/reports/nothing-about-us-without-us
8. Legislating for health and human rights: model law on drug use and HIV/AIDS—Module 7: 
stigma and discrimination. Toronto (ON): Canadian HIV/AIDS Legal Network; 2006. 
http://www.aidslaw.ca/site/legislating-for-health-and-human-rights-model-law-on-drug-
use-and-hivaids-module-7-stigma-and-discrimination
9. Human rights documentation and advocacy: a guide for organizations of people who use 
drugs. New York (NY): Open Society Institute; 2009. 
http://www.opensocietyfoundations.org/sites/default/files/hrdoc_20090218.pdf 
10. Know it, prove it, change it: a rights curriculum for grassroots groups. Bangkok: Thai AIDS 
Treatment Action Group, Dongjen Center for Human Rights Education and Action, Asia 
Catalyst; 2010.  
http://asiacatalyst.org/resources/cbo-resources
11. Handbook of basic principles and promising practices on alternatives to imprisonment. 
Vienna: United Nations Office on Drugs and Crime; 2007.  
http://www.unodc.org/pdf/criminal_justice/07-80478_ebook.pdf 
12. Toolkit: scaling up HIV-related legal services. Rome: International Development Law 
Organization (IDLO) and United Nations Joint Programme on HIV/AIDS; 2009. 
http://data.unaids.org/pub/Manual/2010/20100308revisedhivrelatedlegalservicetool 
kitwebversion_en.pdf
13. Practical guide for civil-society HIV providers among people who use drugs: improving 
cooperation and interaction with law-enforcement officials. Vienna: United Nations Office on 
Drugs and Crime, International Network of People Who Use Drugs, Law Enforcement and HIV 
Network. 
http://www.unodc.org/documents/hiv-aids/2016/Practical_Guide_for_Civil_Society_HIV_
Service_Providers.pdf
14. Addressing the specific needs of women who inject drugs: practical guide for service-
providers on gender-responsive HIV services. Vienna: United Nations Office on Drugs and 
Crime; 2016. 
http://www.unodc.org/documents/hiv-aids/2016/Addressing_the_specific_needs_of_
women_who_inject_drugs_Practical_guide_for_service_providers_on_gender-responsive_
HIV_services.pdf
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What’s in this chapter?
This chapter discusses how to implement the recommended package of health services for 
people who inject drugs. The services covered in this chapter are:
• Needle and syringe programmes (Section 3.2)   
• Opioid substitution therapy and other evidence-based drug-dependence programmes  
(Section 3.3)       
• HIV testing services (Section 3.4)     
• Antiretroviral therapy (Section 3.5)       
• Sexually transmitted infection services (Section 3.6)
• Sexual and reproductive health (Section 3.7)   
• Condom and lubricant programmes (Section 3.8)
• Information, education and communication (Section 3.9)    
• Prevention, vaccination, diagnosis and treatment of viral hepatitis (Section 3.10)
• Prevention, detection and treatment of tuberculosis (Section 3.11)
• Prevention and management of overdose (Section 3.12)
• Psychosocial services (Section 3.13).
The chapter also provides a list of further resources (Section 3.14).
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3.1 Introduction
The World Health Organization (WHO), the United Nations Office on Drugs and Crime (UNODC) 
and the Joint United Nations Programme on HIV/AIDS (UNAIDS) defined an evidence-based public-
health response for people who inject drugs with a comprehensive package of nine interventions 
in a technical guide published in 2009 and revised in 2012.1 This harm reduction package has since 
been expanded2 to include the following interventions:
1. Needle and syringe programmes (NSPs) 
2. Opioid substitution therapy (OST) and other evidence-based drug-dependence treatment
3. HIV testing services (HTS) 
4. Antiretroviral therapy (ART) for people living with HIV
5. Prevention and treatment of sexually transmitted infections (STIs) (and sexual and reproduc-
tive health services)
6. Condom programmes for people who inject drugs and their sexual partners
7. Targeted information, education and communication (IEC) 
8. Prevention, vaccination, diagnosis and treatment of viral hepatitis B and C 
9. Prevention, diagnosis and treatment of tuberculosis (TB)
10. Community distribution of naloxone for prevention and treatment of opioid overdose. 
In mapping communities of people who inject drugs before establishing services, data on the avail-
ability and quality of harm reduction services, current use of services, their acceptability and acces-
sibility should also be collected. This information may be used to determine the need to make 
services available and develop a plan to improve existing services or establish new ones for people 
who inject drugs. For more information on mapping, see Chapter 5, Section 5.2.1.
3.2 Needle and syringe programmes
The provision of sterile injecting equipment through NSPs is highly effective in reducing transmission of 
HIV and hepatitis B and C. NSPs facilitate the use of sterile needles and syringes and reduce the number 
of injections with unsterile or used equipment. NSPs have proven to be effective and cost-effective 
and have not been shown to increase drug use3 or injecting. NSPs should not operate in isolation: a 
multidisciplinary approach is essential. NSPs also serve as an important point of entry for people who 
inject drugs to other health and social services, which they might otherwise be reluctant to use. 
People who inject drugs play a crucial role in the design, delivery and implementation of NSPs. As 
peers they are able to attract people who would otherwise be reluctant to attend services. Fur-
thermore, they are able to distribute needles and syringes to hard-to-reach groups. Staffing NSPs 
with peers is recommended.
Needle and syringe needs will differ according to the drug injected. People who inject cocaine may 
inject up to 20 times a day for a few days and then stop for one or two days. By contrast, people 
who inject heroin tend to do so one to three times a day. 
1 WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. 2012 
revision. Geneva: World Health Organization; 2013.
2 Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations–2016 update. Geneva: World Health Organization; 2016.
3 Drug use refers to the nonmedically sanctioned use of psychoactive drugs, including drugs that are illegal, controlled, or prescription.
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The best-practice characteristics of NSPs are that they:
• are low-threshold, easy to enrol in, harm reduction-oriented, and actively attract clients into 
services
• offer a range of commodities, all free of charge (see Box 3.1)
• engage community members4 in the selection and distribution of commodities 
• do not impose the strict exchange of needles and syringes, i.e. that clients are required to bring 
in used equipment before receiving new injecting equipment; this model increases the risk of 
needle and syringe sharing and is not recommended
• do not restrict the number of needles and syringes provided and do not prevent secondary 
distribution
• offer a range of other support and care services by qualified staff, such as on-site medical care 
and information about health maintenance (e.g. vein care and abscess management) 
• are accompanied by a safe disposal plan to prevent accidental hazards (including to people 
from the wider community) from discarded used injecting equipment
• offer overdose management, both by ensuring all staff are trained in overdose revival tech-
niques and by providing naloxone to people who inject opioids and their families and members 
of the wider community (see Section 3.12)
• use all available opportunities to discuss individual risks with people who inject drugs, opportu-
nities to reduce risk and available risk reduction services
• are integrated with other services where possible and offer referrals to drug treatment, legal 
aid, family and housing advice and safer injection sites, where available, as well as testing for 
HIV, TB and viral hepatitis (see also Chapter 4, Section 4.2.2)
• continually assess results to understand the changing needs of their clients. 
The WHO Guide to starting and managing needle and syringe programmes (2007) describes in 
detail how to begin and manage an NSP. 
4 In most contexts in this tool, “community” refers to populations of people who inject drugs, rather than the broader geographic, social or cultural 
groupings of which they may be a part. People may move into or out of injecting drug use at various times in their lives but may maintain community 
connectedness. Thus, “community members” are people who inject drugs or people with community connectedness, “outreach to the community” 
means outreach to people who inject drugs, and “community-led interventions” are interventions led by people who inject drugs or people with 
community connectedness. For a closer definition, see Chapter 1, Box 1.1.
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What commodities should an NSP provide?
At its most basic, an NSP provides sterile needles and syringes to people who inject drugs. 
The types (gauge and volume) should be those preferred by local people who inject drugs. 
Whenever feasible, possible and acceptable to the injecting community, NSPs should also 
provide low-dead-space syringes (LDSS—see Box 3.3). It is not recommended to use self-
retracting syringes for NSPs. NSPs should also provide a range of related commodities that 
are also essential for hepatitis C (HCV) prevention: 
• condoms and lubricant
• filters
• sterile water
• alcohol swabs
• cotton swabs
• spoons
• puncture-proof containers
• acidifiers
• tourniquets.
Programmes should also distribute IEC material and the addresses of relevant health and 
social services, and should have naloxone available for overdose treatment. 
3.2.1 Modes of service delivery 
There are two basic modes of delivering NSP services: fixed sites and mobile services. Many of the 
most effective NSPs provide both. 
A fixed site is a place where people who inject drugs can collect new injecting equipment, dis-
pose of used needles or syringes, and possibly make use of other services. Examples of fixed sites 
include:
• Drop-in centre: Here people who inject drugs can access a range of harm reduction services 
alongside NSP (see Chapter 4, Section 4.6). 
• Needle and syringe programme centre: Where a drop-in centre is not available, a distribution 
centre allows an NSP to begin or expand with limited cost and resources. 
• Pharmacies: In many settings pharmacies are an important resource for NSPs and can link cli-
ents to broader harm reduction services (see Box 3.2).
• Other secondary outlets such as shops and cafes can be used as distribution points for NSP in 
areas with high rates of drug use. 
• Vending machines are a practical solution for public or semi-public places where people inject 
drugs, such as underground passages or public toilets.
• Drug treatment sites should provide access to sterile needles through dedicated staff.
Box 3.1
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Box 3.2
 Case example: Using pharmacies to expand an NSP in Ukraine
In Ukraine, the Alliance for Public Health (formerly the International HIV/AIDS Alliance) 
involved a number of pharmacies as secondary outlets for distributing injecting instruments, 
other prevention commodities and information to people who were reluctant to contact 
specialized harm reduction services. In certain parts of Ukraine the involvement of pharmacies 
allowed the programme to increase overall coverage by as much as 10% within a year of 
introduction. In 2015 there were 97 pharmacies involved in service delivery across Ukraine, 
reaching some 22,000 people who use drugs with NSP during the year. 
Mobile services are provided from a van, bus, motorbike or other vehicle, or by individuals on foot. 
Usually a regular route with regular hours is followed, stopping to distribute commodities at several 
locations frequented by people who inject drugs.
• Mobile clinics: Mobile NSP can be expanded to include clinical services as well as medical inves-
tigation, including HTS and further referral to treatment programmes. Alternatively, existing 
mobile clinics can start dispensing needles and syringes.
• Outreach/backpack: Workers travel through streets or visit other settings to distribute sterile 
needles and syringes and other commodities, and collect used injecting equipment for safe 
disposal.
• Secondary syringe distribution: Using networks of people who inject drugs is effective for 
recruiting new clients into NSP, for example by providing an active client with a large quantity of 
syringes to distribute to their peers. It also enables people who wish to remain hidden or cannot 
come to the service, to get sterile injecting equipment. 
Every NSP must establish a protocol for transporting and disposing of used injecting equipment. 
This equipment can be a serious hazard for staff and the general public, and the NSP should con-
sider itself responsible for all steps in the disposal process, from the collection of used equipment 
from clients to its ultimate destruction, where possible in a medical-waste facility. It is important 
that NSPs take measures to make it simple for people to return or deposit used syringes. These 
may include installing safe collection boxes in hotspot areas. Not only is this vital for public health, 
i.e. to avoid accidental punctures, but it will also improve the acceptability of harm reduction by the 
wider community. 
Although NSP clients should always be encouraged to return used injecting equipment to the NSP 
or mobile service, the return of used injecting equipment should not be a condition for provision of 
new equipment. Some NSP clients may not be able to carry used equipment safely, or there may 
be risk of police search and arrest. The primary aim of the NSP is to provide sterile equipment to 
reduce re-use of injecting equipment and to ensure its safe disposal. It is essential to minimize any 
barriers or pre-conditions for this distribution.
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Box 3.4
Box 3.3
Case example: Improving LDSS coverage in Viet Nam
Low-dead-space syringes (LDSS) are designed to reduce the amount of blood remaining in 
the syringe after completely pushing down the syringe plunger. Studies have shown that this 
difference in dead space reduces the survival of HCV and HIV in blood remaining in syringes, 
leading to a reduction in the transmission of these viruses. WHO suggests that NSPs provide 
LDSS for distribution to people who inject drugs (Guidance on prevention of viral hepatitis 
B and C among people who inject drugs [2012]).
In Viet Nam, LDSS are preferred by the majority of people who inject drugs in Ho Chi Minh 
City and a few other localities, but they are not widely available in the central and northern 
areas of the country. Healthy Markets, an initiative of the US Agency for International 
Development and PATH, is working with local and international manufacturers to make LDSS 
more widely available, particularly in areas where there are increases in new HIV infections 
due to sharing. Part of this effort will involve bringing down the price of LDSS, which are 
currently four to five times the price of high-dead-space syringes. The initiative will also help 
local manufacturers secure ISO standards so that they are able to make LDSS available to 
the government and outside Viet Nam.
3.2.2 Providing NSP to people who are incarcerated
Models for distribution of needles and syringes in prison include installing vending machines, out-
reach to prisons by nongovernmental organization (NGO) workers or prison inmates, or distribu-
tion by prison medical staff. For more information, see the UNODC Handbook for starting and 
managing needle and syringe programmes in prisons and other closed settings (2014). 
Case example: Prison NSP and OST in Moldova
NSPs have been operating in prisons in Moldova since 1999 through regulations that allow 
syringes into prison as medical equipment as part of the national HIV programme, and 
OST was introduced in 2005. The NSPs are run by peer volunteer inmates in collaboration 
with medical staff. The NSPs also serve as sites for condom distribution, IEC and overdose 
management. All volunteers have been trained in providing first aid, and naloxone is available 
at every NSP site. As a result of the programme, HIV and HCV prevalence among prisoners 
decreased by more than 50% over a period of five years. 
3.3 Opioid substitution therapy and other evidence-based drug-dependence  
        treatment
Treatment of drug dependence typically blends different treatment modalities, but approaches 
may be simply categorized as psychosocial or pharmacological. Pharmacological approaches can 
be further categorized as detoxification, relapse prevention and treatments to reduce drug craving 
and use. At present, no approved medications are available for the treatment of dependence on 
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cocaine, crack, or amphetamine-type substances (ATS). As a general principle, psychosocial inter-
ventions should be part of comprehensive treatment for drug dependence. 
Opioid substitution therapy (OST) has been proven to be the most effective drug-dependence 
treatment for preventing HIV among people who inject and are dependent on opioids. OST is an 
effective, safe and cost-effective medical treatment that is also proven to reduce the frequency of 
injecting heroin or other opioids and the associated risks of overdose, infection and transmission 
of bloodborne viruses, as well as reducing criminal activity. In addition, OST is effective for encour-
aging adherence to ART for people who are HIV positive, and adherence to TB treatment.
Where OST is not available, or in cases of dependency on non-opioid drugs such as cocaine or 
ATS, the only treatment options are psychosocial interventions and withdrawal management (see 
Section 3.3.5). However, these are less effective in the prevention of HIV among people who inject 
drugs. For more information, see the WHO 2016 mhGAP intervention guide for mental, neuro-
logical and substance use disorders in nonspecialized health settings–version 2.0 (2016) and the 
WHO Western Pacific Regional Office’s Technical briefs on amphetamine-type stimulants (ATS).
3.3.1 OST programme-level guidelines
To achieve optimal coverage and treatment outcomes, OST should be accessible to anybody in 
need of treatment who meets the criteria for inclusion, whether or not they inject, and be provided 
free of charge or be affordable or covered by public health insurance. OST can be delivered in pri-
mary health-care settings or in specialized outpatient clinics. An induction period where dosage 
is slowly increased, coupled with medical monitoring over a two-week period, is recommended. 
Research has shown that longer-term OST at higher dosages is more effective than shorter-term 
programmes aimed at detoxification, and treatment plans should take a long-term perspective. For 
more detailed clinical guidance, see the WHO Guidelines for the psychosocially assisted pharma-
cological treatment of opioid dependence (2009).
Staff requirements and teamwork
Programmes should develop a clinical protocol based on national or WHO guidelines. While pre-
scriptions must usually be written by a physician, OST may be dispensed by pharmacists or medical 
and nursing staff, or in community-based clinics, depending on national laws. Community-based 
outreach and support should also be provided (see Chapter 4). 
Creating a welcoming environment
Treating clients with respect and dignity and making the clinic as pleasant and relaxing as possi-
ble will make the process of repeated clinic visits more tolerable for clients, and afford the staff 
safety. Putting up bars or screens to separate clients and service-providers inevitably creates 
mistrust. Similar attention must be paid to the external amenities of the clinic. Signage on the 
outside of the building should be discreet in order not to attract unwanted attention and to allow 
clients anonymity.
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Box 3.5
OST as a holistic treatment
Offer help with social integration: Individual or group counselling and self-help groups can 
help OST clients develop communication and socialization skills. Peer support groups have 
also been an important emotional resource for people who inject drugs in many settings. 
Work with peer advocates so that client feedback informs services: Local organizations 
led by people who inject drugs can help OST providers by providing information to people 
who inject drugs, OST clients, parents and relatives, as well as to doctors and the general 
public. They can also train local clients to become peer advocates for OST or to staff 
information hotlines. 
Work with family and relatives for a supportive environment: To ensure the effectiveness 
of OST and the quality of clients’ lives, programmes should offer psychological and social 
services to families and friends of programme participants (and especially to children, 
ensuring that they are kept with the parents and family wherever possible). However, it is 
essential that clients retain their right to confidentiality. 
Advocate for OST and clients’ rights: It is important to engage in advocacy for clients’ 
rights to access high-quality and sustained OST, and expanded programmes. Advocacy by 
programme providers can be done alongside peer advocacy networks and family groups, 
who can also help mobilize national campaigns for access to treatment.
3.3.2 Providing treatment 
Inclusion criteria
The criteria for entering OST differ widely between programmes and countries, and may include: 
minimum age, length of opioid dependence, physical and mental health, and personal motivation. 
OST is indicated for people who are opioid-dependent (non-injectors as well); who are able to 
give informed consent, and for whom there are no specific contraindications. Most successful pro-
grammes are low-threshold, i.e. easy to enrol in, harm-reduction oriented, offer a range of treat-
ment options, and actively attract people who inject drugs into services.
Choice of treatment approach
WHO recommends OST primarily for longer-term maintenance therapy. Both methadone and 
buprenorphine are on the WHO List of Essential Medicines for the treatment of substance 
dependence. To cover different clients’ needs, it is recommended to have both medications 
available for OST. 
Some opioid users repeatedly fail to respond to methadone and buprenorphine. In a few countries, 
prescription morphine and/or supervised injectable diacetylmorphine (medical heroin) is availa-
ble for difficult-to-treat clients. Treatment is delivered under direct medical supervision to ensure 
safety and prevent diversion. Research shows that this treatment can lead to improved health and 
well-being of this group, including improvements in social functioning. 
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Box 3.6
Key principles for OST
Retention in therapy: The use of illegal drugs while in OST should never be a reason for 
excluding a client from the programme. This could indicate the need for a clinical adjustment 
of the treatment. However, the medication dosage must never be adjusted as a reward or 
punishment for behaviour. 
Safety: The OST programme should ensure the safety of clients, staff and medication. Clear 
information should be given to clients on the rules and regulations within the centre. 
Openness and flexibility: Rules and regulations surrounding entry and retention in OST 
should not be overly burdensome on the client. Long waiting times, limited dispensing hours 
and compulsory urine testing are not recommended. Offering same-day treatment upon 
registration is a good practice.
Respect: High-quality care that is nonstigmatizing and nondiscriminatory is a cornerstone of 
effective and principled treatment. 
For opioid-dependent people with TB, viral hepatitis B (HBV), HCV or HIV, it is recommended that 
opioid agonists be administered in conjunction with medical treatment. There is no need to wait 
for abstinence from opioids to start treatment for these conditions. Treatment services should 
offer hepatitis B vaccination to all opioid-dependent clients (whether or not they are participat-
ing in OST programmes). Care settings that provide OST should initiate HIV testing and start and 
maintain ART for all people living with HIV, according to national guidelines.
For more detailed information on treatment approaches, refer to the WHO Guidelines for the psy-
chosocially assisted pharmacological treatment of opioid dependence (2009).
Takeaway doses
While a period of supervised consumption with incremental dosing is essential to safe induction, 
there are important arguments for starting takeaway doses for clients who are stable and for 
whom daily supervision would impede work, study or child-care obligations. Takeaway doses may 
be provided for clients when the benefits of reduced frequency of attendance are considered to 
outweigh the risk of diversion. Clients should be responsible for using their medications according 
to medical recommendations. 
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Box 3.7
Steps in methadone treatment
Welcome by member of staff
Administrative intake of personal details
Check if individual meets intake criteria (if applicable)
Medical intake by doctor
Assessment of opioid dependence through:
• personal interview
• medical assessment
• assessment of level of dependence 
Treatment plan 
• Induction and calculation of starting dose (if withdrawal symptoms recur, an additional 
dose will be given)
• Patient kept under supervision for a few hours to check if initial dose is correct
• Patient given detailed information on the treatment and on the risks of using other drugs
• In case of co-morbidity, liaison with relevant medical services
• Stabilization period to establish the right dose 
Source: Verster A, Buning E. Methadone guidelines. Amsterdam: Euro-Methwork; 2000.
Case example: Advocating for OST programmes in Ukraine
In Ukraine, advocacy efforts to improve access to OST were led from 2008 by the NGO Hope 
and Trust (Nadiya ta Dovira), an organization of parents of OST patients and people who 
inject drugs, working with the Association of Substitution Therapy Advocates of Ukraine 
(ASTAU). In the face of substantial opposition to the development of OST, and stigmatization 
of activists from the drug-using community, Hope and Trust started a national OST hotline 
and led an advocacy campaign involving informational booklets, videos, trainings and 
television appearances, eventually contributing to the revision of the law on OST access, and 
advocating successfully for the opening of 12 new OST sites.
Hope and Trust’s success was helped by the social status accorded to parents in a country 
with traditionally strong family values, and by the influence of some members who were 
well known and respected in their communities. Due in part to its work, between 2008 and 
2015 the number of OST patients in Ukraine almost quadrupled, to 8,300, and the number 
of OST sites trebled, to 167.
ASTAU and Hope and Trust collaborated to persuade authorities to permit take-home dosages 
of OST. These services have proven lifesaving for many individuals with complicated diagnoses. 
A proxy (representative of the individual), approved by the client’s treating doctor, can collect 
the medication. In the case of intra-institutional delivery, staff communicate with drug-
treatment facilities to obtain doses necessary to support those receiving in-patient treatment. 
Box 3.8
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3.3.3 OST for pregnant women 
Pregnant women who enter or are already on maintenance OST should be encouraged to con-
tinue treatment during their pregnancy. Long-term OST is considered the best option clinically, 
and women need to be informed of possible risks in opting for detoxification while pregnant. It is 
not uncommon to need to increase medication dosage during pregnancy due to weight gain and 
other physiological changes. Links to other medical and social services should be established for 
pregnant clients. For further information, see the WHO Guidelines for identification and manage-
ment of substance use and substance use disorders in pregnancy (2014).
3.3.4 OST in prison
Prisoners enrolled in OST prior to imprisonment should be able to continue while in prison and 
after being released. The time of arrest and entry in prison for people who are on OST is particu-
larly crucial for the continuity of treatment. To avoid interruption of treatment, a good communica-
tion system must be established between the medical services in detention and the services in the 
community that prescribe or dispense the OST. For example, on leaving prison, people under OST 
could be given a card signed by the prescriber indicating the treatment, dosage and contact details 
of an OST service-provider in the community to which they are returning. For more information, 
see also Chapter 4, Section 4.2.1. 
For more information on the provision of OST in prisons, see the WHO Clinical guidelines for with-
drawal management and treatment of drug dependence in closed settings (2009).
3.3.5 Psychosocial interventions and other evidence-based drug-dependence treatment
Brief interventions: information and counselling
The primary goal of brief interventions is to provide information about substance use, health risks, 
and how to reduce these risks, including by use of condoms and avoiding sharing injection equip-
ment. Information and counselling can be conducted by trained counsellors or psychologists, by 
trained peer counsellors in drop-in centres or through outreach (see Chapter 4). 
Cognitive behavioural therapy (CBT)
Behavioural interventions support the adoption of a health-protective attitude and lifestyle through 
the adoption of less risky behaviours, and enhance skills for coping with factors that could trigger 
risky behaviours, or relapse in the case of abstinence. CBT includes provision of psychotherapy 
and psychosocial support by a trained clinician. CBT can be delivered in addition to OST or in the 
context of abstinence-based treatment.
Withdrawal management 
Withdrawal management refers to the provision of medical and psychological care to people expe-
riencing withdrawal symptoms due to cessation or reduction of drug use. In settings where OST is 
not available, or in cases of non-opioid dependence, symptomatic medications should be provided 
to reduce the pain and discomfort of withdrawal. For clinical guidance, see the WHO Clinical guide-
lines for withdrawal management and treatment of drug dependence in closed settings (2009).
It is important that people be informed that withdrawal results in lower tolerance levels, and if the 
person resumes drug consumption at their usual dose after withdrawal, there is an increased risk 
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of overdose. For this reason, withdrawal management should be undertaken with other psychoso-
cial support programmes. 
For more information on all psychosocial interventions, please refer to WHO mhGAP intervention 
guide–version 2.0 (2016). 
 
3.4 HIV testing services 
HIV testing services (HTS) are an entry point to HIV prevention services and are essential to care 
and life-sustaining treatment for people living with HIV. By combining counselling with knowledge 
of one’s HIV status, HTS can help link people to harm reduction services to prevent HIV trans-
mission, while persons living with HIV can access supportive counselling, ART, and treatment for 
opportunistic infections. 
HTS should be part of an integrated programme of HIV prevention, care and treatment. Services 
should adhere to the “5 C” principles—consent, confidentiality, counselling, correct test results 
and connection to follow-up services. See also the WHO Consolidated guidelines on HIV testing 
services (2015). Since research and practices on different aspects of HTS are evolving rapidly, it is 
recommended that programme developers consult WHO for the most recent guidelines. 
Rapid HIV tests can be used in community and clinical settings, either with finger-prick (whole 
blood) or mouth swab (oral-fluid based) samples. This may be more acceptable to people who 
inject drugs, who may have difficulty with venous blood access. Rapid HIV tests can be performed 
outside medical settings by, or with the assistance of, a trained lay volunteer or peer outreach 
worker.5 (See also Section 3.4.4.) 
3.4.1 Preparation for delivering HTS
Community awareness and building demand 
• Community members should be informed about the benefits of knowing one’s HIV status and 
about the availability of effective treatment if they are diagnosed with HIV. 
• Information about places where people who inject drugs can receive HTS can be distributed 
through harm reduction programmes, medical facilities, rehabilitation centres, telephone hot-
lines and Internet forums of people who inject drugs. 
• People who inject drugs should be informed of their right to confidentiality and consent and 
their right to refuse HIV testing if they choose.
Delivery and location of services
HTS may be provided in a variety of settings, including along outreach routes, in mobile units or 
temporary testing sites, at drop-in centres, NSP sites, dedicated HTS and health facilities, as well 
5 A peer outreach worker is a person who injects drugs, or a person with community connectedness, who conducts outreach to other people who 
inject drugs, and who is not generally full-time staff of an HIV prevention intervention (full-time staff might be called “staff outreach workers” or 
simply “outreach workers”). Peer outreach workers may also be known by other terms, including “peer educators”, “community outreach workers” or 
“outreach workers”. However, the terms “peer” or “community” should not be understood or used to imply that they are less qualified or less capable 
than staff outreach workers.
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as in home-based settings. Community settings may be more attractive and accessible than health-
care institutions. Both the location and the timing of HTS should be responsive to the needs and 
requests of people who inject drugs. In some settings, this might mean providing services during 
evening hours or weekends, or at home through self-testing (see Section 3.4.4).
3.4.2 Delivering HTS
Pre-test information
Pre-test information can be given individually or in groups and should: 
• provide basic HIV information and information about the HIV testing process
• ensure that testing is voluntary; forced or coercive testing is never warranted
• ensure that the client understands that the test result is confidential and will not be shared 
without their explicit consent
• provide information on follow-up prevention, ART and counselling and support services.
Note that individualized risk assessments and intensive counselling during the pre-test information 
session are no longer recommended by WHO, since most people receive their test results on the 
day of the test itself, and the prospect of intensive counselling may be a barrier to uptake of HTS.
Ensuring correct results
For specific information on how to correctly perform HIV rapid diagnostic tests and interpret test 
results, as well as how to use the correct HIV testing strategy and algorithm according to the 
setting and national guidelines, refer to the WHO Consolidated guidelines on HIV testing ser-
vices (2015). It is important that programmes use the correct testing strategy for low-prevalence 
(<5%) or high-prevalence (>5%) settings with appropriate rapid diagnostic tests, in accordance 
with national testing algorithms. 
Training, support and supervision for people carrying out HTS are essential to ensuring correct 
test results. 
Post-test counselling
This counselling is provided when the test results are ready to be given to the client. 
• Information about what is needed in the post-test counselling session may be found in the WHO 
publication Delivering HIV test results and messages for re-testing and counselling in adults (2010).
• All people, including people who inject drugs, who are found to be HIV negative should be pro-
vided with risk-reduction information specific to their individual risks, given access to condoms and 
lubricant, needles and syringes, and counselled on strategies to negotiate safer sex. They should 
be counselled about the benefits of testing for their partners. 
• People who inject drugs who are found to be HIV positive should be offered immediate referral 
for long-term care and treatment, preferably at a clinic or hospital whose staff are respectful of 
people who inject drugs. Community-based case management or peer navigation could facili-
tate treatment initiation and adherence support for people who inject drugs. They should also 
receive counselling about how to avoid transmitting HIV to others, including being provided with 
condoms, and they should also be counselled about the benefits of testing for their partners and 
family members, and offered support in notifying partners.
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• It is important to assess for mental-health issues, such as anxiety and depression, and refer 
people to a specialist if needed. (See also Section 3.13.) 
Repeat testing
• People who inject drugs who test HIV negative should be advised about the importance of re-
testing every six months or annually, depending on their risk profile.
• Repeat HIV testing should also be offered whenever there is a new STI diagnosis.
• Individuals with potential exposure to HIV in the past three months should be advised to re-test. 
• An individual with a discrepant test result should be referred for re-testing in 14 days. 
• HIV positive individuals should be re-tested prior to initiating treatment. This can be done at 
community clinics that do clinical assessments, initiate and deliver ART and provide services to 
pregnant women or other populations that may initiate treatment immediately regardless of 
their CD4 count. 
• If people come for HTS within 72 hours of a potential exposure, provision of post-exposure 
prophylaxis (PEP) should be considered. For more information, see the WHO Guidelines on 
post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related 
infections among adults, adolescents and children (2014).
3.4.3 Pre-exposure prophylaxis (PrEP)
For all key populations, WHO recommends offering PrEP to people at substantial risk of HIV infec-
tion, as part of combination prevention approaches. For people who inject drugs, the priority inter-
ventions for HIV prevention remain covered by harm reduction, in particular NSP and OST for 
those who are opioid-dependent. These are the most effective interventions in preventing HIV and 
other bloodborne infections. Consideration should be given to providing PrEP to prevent sexual 
transmission of HIV, including to sexual partners of PWID living with HIV who are not virally sup-
pressed on ART. For more information, see the WHO Consolidated guidelines on HIV prevention, 
diagnosis, treatment and care for key populations–2016 update and the INPUD Background doc-
ument: an introduction to pre-exposure prophylaxis (PrEP) for people who inject drugs (2015).
3.4.4 Other approaches to testing
HIV self-testing
HIV self-testing is a process in which an individual who wants to know his or her HIV status collects 
a specimen, performs a test and interprets the result by him or herself, often in private. Self-testing 
does not provide a definitive diagnosis. A reactive (positive) self-test result always requires further 
testing by a health-care worker to confirm the result. For further information, see the WHO Guide-
lines on HIV self-testing and partner notification (2016).
HTS performed by peer outreach workers or lay providers
HTS are often more acceptable to people who inject drugs when performed by a trusted commu-
nity member, i.e. another person who injects drugs. Peer outreach workers can be an effective part 
of the voluntary HTS workforce. Adequate training, ongoing support and monitoring are essential 
for all personnel performing HIV testing at the community level, including health workers, pro-
gramme staff and peer outreach workers. (See also the WHO policy brief WHO recommends HIV 
testing by lay providers [2015].)
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Partners and family testing
When a person tests HIV positive, it is often helpful to offer voluntary testing of their sexual or 
injecting partners, spouses and family members. People who inject drugs living with HIV should be 
supported to disclose their results to their partners, trusted family members, and HTS should be 
available to their partners, children and other family members.
3.5 Antiretroviral therapy 
The increased availability of, and access to, ART has significantly decreased HIV-related illness 
and death. Recent advances in HIV treatment, coupled with advocacy for increased availability of 
affordable drugs, have resulted in substantial improvements in the quality of life of people living 
with HIV throughout the world. However, while global levels of treatment coverage have increased 
substantially over the last years, access among people who inject drugs is still very low, with a 
global average of less than 10%.
3.5.1 Treatment initiation
WHO guidelines recommend starting ART for all people with HIV, regardless of WHO clinical stage 
and at any CD4 cell count, including people who inject drugs with HIV. As a priority ART should be 
initiated in all individuals with severe or advanced HIV clinical disease (WHO clinical stage 3 or 4) 
and individuals with CD4 counts of ≤350 cells/mm3. Priority should be given to the following peo-
ple, regardless of WHO clinical stage or CD4 count:
• individuals with HIV and active TB disease 
• individuals co-infected with HIV and HBV or HVC with evidence of severe chronic liver disease 
• partners with HIV in serodiscordant couples, to reduce HIV transmission to uninfected partners 
• pregnant and breastfeeding women.
It is recommended that programme developers consult WHO for the most recent guidelines.
3.5.2 Adherence support
With adequate and sustained support, people who inject drugs have similar adherence results to 
other ART clients. OST is an enabling factor for ART adherence among people who are dependent 
on opioids, and WHO recommends provision of ART in OST clinics. There are several strategies for 
effective adherence support programmes:
• “Intensive” adherence support for the first six months of therapy, when maximum attention 
must be given to the client. 
• The community or peer counsellor can conduct an initial interview and risk assessment, offer 
adherence support during the intensive case management phase, and identify “dropouts” to 
offer them encouragement. Feedback from the community or peer counsellor to the multidis-
ciplinary team is a crucial part of case management.
• Like many people beginning ART, people who inject drugs may have fears and concerns about 
the treatment. Knowledge of current community understanding of ART is imperative to address 
concerns, fears or misconceptions with accurate and appropriate information. Counselling 
should include why it is beneficial to initiate ART before feeling unwell or having symptoms. 
Adherence, maintaining a suppressed viral load to support good health and prevent treatment 
76
➌ Health and Support Services
failure, as well as the benefit of ART in reducing risk of HIV transmission, should be fully dis-
cussed. This may happen over several sessions. The potential benefits of treatment preventing 
transmission of HIV to sex partners should be specifically discussed.
• Clients who drop out of treatment require priority attention with a detailed assessment of the 
factors that led to treatment termination and diligent attempts to re-engage them in treatment.
• Establish a system to ensure the continuity of treatment for people who are in detention or in 
prisons, including upon their release. 
3.5.3 Managing contraindications 
Interactions between ART, TB, HBV, HCV and OST medicines are addressed in HIV treatment 
guidelines (see Section 3.14). Ensuring effective collaboration and coordination between hepatitis, 
TB, ART and OST services will enable monitoring of possible withdrawal symptoms in clients who 
begin ART while on OST or TB treatment. If medications precipitate withdrawal, the dose adjust-
ments should follow WHO or national guidelines. (See also Section 3.3.)
3.5.4 Overcoming barriers to ART access for people who inject drugs 
Access to HIV screening with enrolment into care remains the weakest point in the continuum of 
services for people who inject drugs. Increasing the availability of HIV rapid testing performed by 
health-care workers and peer outreach workers should be a priority (Section 3.4.4). A case man-
agement approach to treating HIV positive people who inject drugs, and service integration, will 
also help (see Chapter 4, Section 4.2.2). 
Effective collaboration between the health-care system and outreach projects can help ensure 
services are as accessible as possible to clients, for example by:
• offering blood sampling for CD4-cells and viral load tests at outreach spots (mobile clinics), 
NSPs, or drop-in centres
• organizing clinical check-up days in mobile clinics, NSPs or drop-in centres.
3.6 Sexually transmitted infection services
Provision of basic HIV and STI clinical services is an essential component of a comprehensive pack-
age of services for people who inject drugs. Programmes should work to enhance STI care-seeking 
behaviour as a community norm: people who inject drugs and their sexual partners should know 
the symptoms of STIs and be encouraged to seek care promptly. Moreover, they should be aware 
that STIs are commonly asymptomatic and thus be encouraged to undergo regular STI screening. 
Linking STI services to other, community-led services, and involving people who inject drugs as 
service planners, implementers and providers, helps achieve this. 
People who inject drugs, particularly women, adolescents and young people,6 and men who have 
sex with men, may sell sex to support their drug use. This increases the risk of violence, including 
sexual violence, and their likelihood of acquiring STIs. 
6  Young people who use or inject drugs are those in the age range 10–24 years, in accordance with the Interagency Working Group on Key Populations 
HIV and young people who inject drugs: a technical brief (Geneva: World Health Organization; 2015).
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3.6.1 Designing STI services
STI services for people who inject drugs and their sexual partners should meet basic standards of 
quantity and quality. They should also address the sexual-health needs of people who sell sex or 
who have unprotected anal sex. Components of an STI service package are:
• Screen and treat for common STIs (e.g. syphilis, chlamydia, gonorrhea—for further information 
see the 2016 WHO clinical guidelines for these infections).
• Make a diagnosis of an STI (etiologic [lab] or syndromic).
• Provide treatment (etiologic or syndromic, as appropriate).
• Provide information.
• Enhance or ensure partner notification and management.
• Promote and provide condoms and lubricant.
• Assess client’s perceptions of risk and counsel on safer sex.
• Arrange follow-up.
• Provide confidential HTS. 
3.6.2 Organizing STI services
It is important that the STI service package be integrated with HIV, sexual and reproductive health 
(SRH) and primary care. Coordination and referral mechanisms between harm reduction and STI 
services should be identified. In the case of a positive rapid STI test, the individual is referred to 
a medical facility for diagnosis and treatment. Upon request, the individual may be accompanied 
to the service by a social worker or peer outreach worker. Mobile ambulatory staff may include a 
physician trained on STIs, nurse, social worker and driver.
Table 3.1 Provision of STI services through different delivery models
Community-based services via 
implementing organization7 
(at fixed NSP sites, drop-in centres)
● Counselling and rapid testing for HIV
● Counselling, risk assessment for STIs, syndromic STI management and rapid testing for syphilis
● Social worker counselling and support
● Provision of condoms and lubricant and advice on their use
● Community education to improve knowledge on STIs
Health-care facility ● Screening for STIs
● STI case management (etiologic or syndromic) 
 a) History, risk assessment and physical examination; b) Full laboratory diagnosis (if feasible)
 c) Diagnosis and treatment; d) Counselling; e) Condoms and lubricant; f) Partner management
 g) Follow-up; h) HTS
Mobile service (van or bus) ● Counselling and rapid testing for HIV
● Counselling, risk assessment for STIs and syndromic management and rapid testing for syphilis 
● Counselling and testing for hepatitis B and C
● Consultation with social worker issuing condoms and lubricant, syringes, alcohol wipes
7 An implementing organization is an organization delivering an intervention to people who inject drugs, with a client-centred approach. It may be 
a governmental, nongovernmental, community-based or community-led organization, and may work at a state, provincial, district or local level. 
Sometimes a nongovernmental organization provides services through subunits at multiple locations within an urban area, and in this case, each of 
those subunits may also be considered an implementing organization.
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3.7 Sexual and reproductive health and rights
People who inject drugs and their sexual partners have the same need for a full range of sexual and 
reproductive health (SRH) services as other people, extending beyond STIs and HIV, but these needs 
are often overlooked by harm reduction programmes. Staff of harm reduction services, as well as those 
of mainstream services, should be trained and supported to understand the SRH needs and rights of 
people who inject drugs so that appropriate and relevant services can be developed and delivered. 
3.7.1 Family planning and contraceptive counselling
The basic steps in ensuring contraceptive choices including family planning and contraceptive 
counselling for people who inject drugs and their partners are:
• Establish whether a client wants to have children, and how many children the client hopes to have.
• Discuss preventing and treating infertility as needed. 
• Discuss advantages and disadvantages of available contraceptive options, including condoms 
which provide protection against HIV, STIs and unintended pregnancies. Discuss dual protection—
use of condoms plus another contraceptive method to ensure more effective prevention of preg-
nancy—and discuss the side-effects of each contraceptive method. 
• Determine client preference and medical eligibility for the desired contraceptive method, pro-
vide counselling on its use, and supply the actual contraceptive, or a prescription if needed. 
• Discuss how to prevent sexual and drug-related transmission of HIV, including PrEP and PEP, 
and provide access to male and female condoms and lubricant, and education on their correct 
use and on condom negotiation skills.
Drug use can influence a woman’s menstrual cycle, causing menstruation to become irregular or 
to stop. Women should be informed that this does not prevent them from becoming pregnant (as 
the ovulation cycle can start at any time) and that if they do not wish to become pregnant they 
need contraception.
Emergency contraception may be provided to a woman who has had unprotected vaginal sex, is 
not currently using a contraceptive method and is not pregnant. It should be provided on request 
as soon as possible after unprotected sex, ideally within 72 hours, with a limit of 120 hours. (Effec-
tiveness is reduced beyond 72 hours.) 
Reproductive tract cancer screening
Cervical cancer screening promotes early detection of precancerous and cancerous cervical lesions 
and prevents serious morbidity and mortality. It is recommended that cervical screening be per-
formed for every woman aged 30–49 at least once in her lifetime. Screening may be done through 
visual inspection with conventional Pap smear or HPV (human papilloma virus) testing. Pre-cancer-
ous and cancerous lesions should be treated immediately.
Women who are living with HIV should be screened for cervical cancer regardless of age. Priority 
should be given to maximizing coverage of the risk age group and to ensuring complete follow-up 
of women with abnormal screening test results.
Screening for other cancers
Screening for breast cancer, ano-rectal and prostate cancer should be part of routine care, and 
links to treatment services should be provided.
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3.7.2 Pregnancy testing and pre- and postnatal care
If a woman who injects drugs believes she is pregnant, this should be confirmed with a pregnancy 
test. If confirmed, the woman should be referred for prenatal care—to manage her drug use during 
pregnancy, to monitor for any complications of pregnancy, to improve the pregnancy outcome and 
for the general health and well-being of both mother and infant. For further information, see the 
WHO Guidelines for identification and management of substance use and substance use disor-
ders in pregnancy (2014). Postnatal care continues after birth to ensure mother and baby continue 
to do well and receive routine follow-up services such as immunizations, and any further care and 
support as needed. Pre- and postnatal care are especially important for women who inject drugs 
to provide support and guidance on the best options in terms of continued drug use, substitution 
therapy or cessation of drug use during or after pregnancy. This guidance should be offered to sup-
port the woman in making her own voluntary and informed decision on the best course of action 
for herself and her infant. Pre- and postnatal care are also important for women living with HIV to 
prevent transmission of HIV and other STIs to infants during pregnancy, delivery or breastfeeding. 
 Considerations for prenatal care for women who inject drugs
• Service-providers, including outreach workers, harm reduction services, drug-treatment 
providers and antenatal care services must be adequately informed about drug use and 
pregnancy, in order to provide appropriate information to pregnant women who inject 
drugs. Harm reduction services should advocate with obstetric services to provide nonpu-
nitive, factual education and care to pregnant women and nursing mothers to protect their 
health and that of their infants.
• It is not uncommon for women who inject drugs to have irregular or absent periods, and 
they may not realize that they are pregnant until late into their second or even third trimes-
ter. It is therefore important that harm reduction service staff educate women who inject 
drugs on the potential benefits of prenatal care for pregnant women and their babies, and 
provide home pregnancy test kits. 
• Women may not be fully aware of the potential impact of drugs on the child during pregnancy 
and breastfeeding, and may have misconceptions about drug use and pregnancy. They should 
be provided with accurate and relevant information regarding the risks and harms to preg-
nancy associated with the continuing use of specific drugs, including tobacco and alcohol. 
• While the use of any drug while pregnant should be avoided, this may not be a realis-
tic option. Given that many women experience heightened stigma if pregnant and using 
drugs, which can discourage them from seeking services, it is essential that workers pro-
vide support in a nonjudgemental manner to pregnant women who continue to use drugs.
• Heroin users should be advised of the dangers of abrupt opioid withdrawal to the foetus, 
and referral to OST should be encouraged.
• Pregnant women living with HIV should receive ART and syphilis testing and treatment 
as needed, to maintain their own health and reduce mother-to-child transmission of HIV 
and syphilis.
Box 3.9
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Pregnant women who enter or are already on maintenance OST should be encouraged to con-
tinue in treatment while pregnant. Maternal and infant health services should include: 
• information on infant feeding options, nutritional counselling and support
• health information and education around HIV and HIV prevention, safer sex, PrEP, PEP, ART as 
prevention, and guidance on breastfeeding (see Box 3.9), as well as prevention of syphilis, viral 
hepatitis and TB
• For women living with HIV, provide ART (either on-site or by referral), HIV treatment, care and 
support for both mother, child, and partner, and on-site or by referral for prophylaxis and treat-
ment of HIV-related conditions, including TB. ART adherence and other types of counselling 
and support are also important. 
For guidelines on breastfeeding for women living with HIV, see the WHO guideline Updates on HIV 
and infant feeding (2016).
Case example: Care for pregnant women  
who use drugs in Canada
SHEWAY in Vancouver provides essential education and nutrition to pregnant women who use 
drugs, while adapting to whatever choice of drug or treatment the woman might decide on. 
For mothers who chose to continue using street drugs, the programme focuses on nutrition 
and on making better choices about the quality of street drugs they are using, while for others 
various substitution therapies are offered. By focusing on the best possible outcomes for 
mother and baby, SHEWAY delivers services that accommodate better birth outcomes and 
eliminate the experience of violence for women who use drugs who are giving birth. 
www.sheway.vcn.bc.ca
3.7.3 Abortion and post-abortion care
Where abortion is legal, links to safe abortion services should be established, but the decisions 
regarding abortion should always be voluntary on the part of the woman. Where abortion is ille-
gal, women who inject drugs should be informed about the risks of informal abortion methods. 
Women who inject drugs should have access to appropriate post-abortion care to reduce related 
morbidity and mortality, and care for post-abortion complications such as infection and excessive 
bleeding should be provided.
3.7.4 Clinical care for survivors of sexual assault 
Where possible, clinical care for survivors of sexual assault should be linked with community-based 
responses to violence. Full details of clinical care protocols can be found in the WHO clinical and 
policy guidelines on Responding to intimate partner violence and sexual violence against women 
(2013). First-line support to survivors of sexual assault includes:
• Provide practical care and respond to women’s emotional, physical, safety and support needs 
without intruding on privacy.
Box 3.10
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• Listen and enquire about needs and concerns, validate what women are feeling, enhance safety 
and support.
• Provide physical care:
– Treat physical injuries
– Take a complete history to determine what interventions are appropriate, and conduct a 
complete physical examination.
• Offer emergency contraception to women presenting within five days of sexual assault.
• Consider offering PEP for people who inject drugs presenting within 72 hours of a sexual assault. 
Use shared decision-making with the survivor to determine whether PEP is appropriate.
• Offer prophylaxis for chlamydia, gonorrhoea, trichomonas and syphilis (depending on the local 
prevalence). The choice of drug and regimens should follow national guidelines.
• Offer hepatitis B vaccination without hepatitis B immunoglobulin, as per national guidelines.
• Offer psychological support and care, including coping strategies for dealing with severe 
trauma, using evidence-based mental-health services that are accessible, available and follow 
the WHO mhGAP intervention guide–version 2.0 (2016). Assess the client’s needs for mental-
health services again at three months following the assault.
3.7.5 Services for sex workers who inject drugs
Harm reduction and sex worker services should be closely linked with SRH services. For more 
information, see Implementing comprehensive HIV/STI programmes with sex workers: practical 
approaches from collaborative interventions (2013—the SWIT) and the International Network of 
People Who Use Drugs (INPUD) and Global Network of Sex Work Projects (NSWP) publication 
Sex workers who use drugs: ensuring a joint approach (2015).
3.8 Condom and lubricant programmes for people who inject drugs and  
 their sexual partners
The effective supply, distribution and promotion of male and female condoms and condom-com-
patible lubricants is essential to successful HIV prevention interventions. Condoms have been rec-
ommended as an HIV prevention method since the mid-1980s and remain a very effective tool in 
preventing the sexual transmission of HIV. 
For detailed guidance, see the United Nations Population Fund’s (UNFPA) Comprehensive con-
dom programming: a guide for resource mobilization and country programming (2011) and Con-
dom programming for HIV prevention: a manual for service providers (2005) as well as relevant 
sections in Chapter 3 of Implementing comprehensive HIV/STI programmes with sex workers: 
practical approaches from collaborative interventions (2013—the SWIT).
Strategic partnerships are essential to improve access to, and use of, condoms and lubricant for tri-
ple protection against unintended pregnancies, STIs and HIV. Partners include organizations led by 
people who inject drugs, NGOs, the Ministry of Health or national AIDS programme, United Nations 
(UN) agencies, the private sector, social marketing organizations, donor agencies and law-enforce-
ment ministries.
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Effective, comprehensive condom and lubricant programming involves the following:
• The process is ideally led and owned by the government in partnership with implementing 
organizations and organizations of people who use drugs, and efforts are coordinated through 
sound leadership at the national level.
• Demand for condoms and lubricants is created and sustained.
• Adequate supplies of high-quality condoms and lubricants are available and distributed widely.
• An outreach approach is used for distribution to ensure access to condoms and lubricants at 
the community level. 
• Types and quantity of condoms and lubricants are provided in response to the stated needs and 
preferences of people who inject drugs. A wide range of male and female condoms is available. 
• Where people who inject drugs are engaging in sex work, it is important that law-enforcement 
officers do not use condoms as evidence of sex work. Stopping and searching sex workers for 
condoms makes them less likely to carry and use them. 
• Advocacy and capacity-building are carried out to ensure a supportive environment for the sus-
tainability of the programme over the long term. 
• A monitoring and evaluation system is established to ensure effectiveness of condom and 
lubricant distribution programmes.
Female condoms
The female condom is an important preventive commodity for women who inject drugs and should 
be promoted strongly. This requires the skills to demonstrate its correct use as well as an under-
standing of its advantages:
• It is useful during menstruation.
• It can be used when the male partner cannot maintain an erection.
• It requires less cooperation from the partner and therefore increases the woman’s control over 
the use of contraception.
Peer outreach workers should be trained to demonstrate correct use of the female condom and 
should be given female pelvic models to use in these demonstrations, as well as supporting infor-
mational materials. Note that female condoms are single-use commodities and should not be 
re-used.
3.9 Targeted information, education and communication 
Harm reduction programming involves efforts to change knowledge, attitudes, beliefs and behav-
iour, as well as build community solidarity. Information, education and communication (IEC) mate-
rials can complement and add value to these interventions. IEC materials, whether printed or elec-
tronic, can be shared from person to person without loss or misinterpretation of information. 
3.9.1 Creating effective IEC materials for people who inject drugs 
Involve the right people: A team approach is needed, including people with knowledge of evi-
dence-based medical and public-health practices, as well as people with skills in design, editing and 
proofreading. It is also essential to meaningfully involve people who inject drugs (specifically peo-
ple from the community targeted by the particular material) in the process of planning, developing, 
designing, testing and distributing the materials, and evaluating their effectiveness. 
83
➌ Health and Support Services
Take into account the knowledge, beliefs, attitudes, practices and needs among your target 
audience: Research the knowledge, attitudes and practices of the people who should benefit 
from the IEC materials planned. Focus group discussions are very useful to collect this information 
before developing the material. Written materials should use language that is easily understanda-
ble by the target community, including terminology common to the community (e.g. slang). 
Don’t reinvent the wheel: Examine materials that have been used by other programmes: they may 
require adaptation to the local context, but time and money can sometimes be saved by modelling 
materials on pre-existing ones. It is important to ask permission from the original creators and to 
acknowledge the source.
Take the sensitivities of the wider community into account: The materials may be seen by peo-
ple other than people who inject drugs, including family members, local authorities, religious lead-
ers and the police. When working on building consensus in the wider community about harm 
reduction services, it may be helpful to discuss the IEC materials that will be distributed, or to share 
drafts with partners before publication. 
Steps in creating IEC materials
1. Identify a clear purpose. Any material to be developed should have a specific learning 
or behaviour change objective. It is important to differentiate between the purpose of an 
overall informational campaign and the purpose of the specific IEC materials.
2. Identify a clear target audience. People using the materials may not be a homogenous 
group. Subgroups with differing knowledge, beliefs, practices and tastes should be 
taken into account. It may not be possible to use one version of a particular IEC material 
throughout a country or even throughout a single city. 
3. Organize focus group discussions with representatives of the targeted (sub)groups. 
4. Develop the key message in a short and clear form. 
5. Identify the best format for the message, bearing in mind the content, target audience 
and available resources for production and dissemination.
6. Develop a dissemination plan, which may include estimating the number of publications 
and how materials will be disseminated. 
7. Design the materials. Make sure that printed materials are in a convenient format, e.g. 
pocket-sized so that they can be carried discreetly.
8. Test the materials with a focus group of community members. Be prepared to change 
the text and design based on the feedback. 
9. Proofread the publication before and after it is laid out. 
10. Publish and disseminate!
11. Monitor and evaluate the materials. This can help you understand which items are 
popular and accepted, and why. 
Box 3.11
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3.9.2 IEC materials and community mobilization
Giving people who inject drugs the opportunity to lead in producing materials (websites, newslet-
ters, video documentaries, IEC etc.) can be very empowering. The production of periodic news-
letters or regular maintenance of websites and social media sites can bring people together and 
create a forum for creative expression, as well as be places where people can be informed about 
and discuss emerging health and rights issues. 
3.10 Prevention, vaccination, diagnosis and treatment of viral hepatitis
HBV and HCV disproportionately affect people who inject drugs, with a prevalence of HCV esti-
mated at 52% worldwide.8 Among people who inject drugs who are living with HIV, co-infection 
with HCV has been estimated globally to be 82% (55–89%), illustrating the risk of bloodborne virus 
transmission via sharing of injecting equipment.9 HIV–HCV co-infection alters the course of both 
diseases. HIV can accelerate HCV disease and increase HCV-related mortality.
HBV is preventable through vaccination, and treatment is effective in reversing liver disease and 
preventing liver cancer. There is currently no vaccination for HCV. Unlike HIV, HCV is curable with 
the appropriate medications.
3.10.1 Prevention 
Both HCV and HBV are preventable through combined harm reduction interventions. In the case 
of HCV in particular, high coverage levels and high-quality NSP and OST play an important role in 
reducing transmission. People who have been spontaneously or medically cured from hepatitis C 
are not completely protected against a new hepatitis infection. 
Since sharing drug use equipment such as cookers and filters may contribute strongly to HCV 
transmission, these items should be included in harm reduction sterile kits. Additionally, non- 
injecting drug users, such as crack smokers, may be at higher risk of HCV transmission through 
sharing smoking equipment (pipes). Noninjection equipment should be considered for distribu-
tion to this population. 
The WHO Guidance on the prevention of viral hepatitis B and C among people who inject drugs 
(2012) recommends:
• offering people who inject drugs the rapid hepatitis B vaccination regimen. Priority should be 
given to the first dose of the vaccination schedule.
• offering incentives to increase uptake and completion of the hepatitis B vaccine schedule by 
people who inject drugs
• that NSPs also provide low-dead-space syringes for distribution to people who inject drugs
• offering peer interventions to people who inject drugs to reduce the incidence of HBV and HBC; 
interventions to prevent HBV and HBC among people who inject drugs should be flexible and 
pragmatic, making use of opportunistic contact with the target population. 
8 World drug report 2016. Vienna: United Nations Office on Drugs and Crime; 2016.
9 Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-
analysis. Lancet Infectious Diseases. 2016;16(7):797–808. 
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3.10.2 HBV and HCV screening and testing 
As a population with a high risk of infection, people who inject drugs should be offered screening 
for HBV and HCV as an integral component of the comprehensive package of harm reduction 
interventions, in accordance with WHO and national guidance. Repeated testing may be required 
in people with ongoing risk.
In order to confirm HCV infection, an RNA test is required. Testing must be noncoercive and vol-
untary, and the client must understand the implications of the testing process. It is important to 
focus on what can be known, provided and offered. For example, in the case of a positive HCV 
antibody test, clients may be informed about the evolution of chronic hepatitis C, the main signs of 
advanced liver disease, the importance of confirming chronic HCV through RNA testing, the poten-
tial risk of transmission to others, the risks of alcohol use, and the effects/side-effects of OST and 
other treatment programmes, including curative antiviral therapy.
3.10.3 Treatment
HBV and HCV treatment are as effective among people who inject drugs as in other populations, 
especially if specific adherence and psychosocial support is provided. Therefore, people who inject 
drugs who have HBV or HBC should be offered treatment without any discrimination.
The treatment of HIV in people who inject drugs living with chronic HBV or HCV may reduce the 
progression of liver disease, so effective ART is recommended regardless of CD4 count. Coordi-
nation between hepatitis and HIV health-providers and OST clinics is crucial, and integrated care is 
ideal. Adequate training should be given to health-service providers to strengthen their knowledge 
and capacity to prevent, diagnose, educate and treat HBV and HCV in people who inject drugs, so 
that they can adequately support those with the disease. 
HBV and HCV treatment may interact with treatments for other bloodborne viruses as well as 
with OST. Treatment interactions are an important consideration in order to avoid side-effects and 
increase effectiveness. 
In order to potentially improve HBV and HCV treatment adherence and outcomes, people who 
inject drugs may be assessed for eligibility in OST and in other service settings. Additionally, adher-
ence may be increased through emotional, social and practical support by multidisciplinary teams, 
including peer workers. People who have been treated for HCV can play a valuable role in health-
care engagement and treatment support, and peer interventions have been an important source 
of support in HCV prevention, care and treatment.
For the treatment of HCV, WHO recommends new, combination direct acting antiviral (DAA) 
therapy with all oral medicines for at least 12 weeks. The effectiveness of new DAAs is less 
affected by genotype and HIV status, although DAAs are less effective in advanced liver disease 
such as cirrhosis.
For more guidance see WHO’s 2016 Guidelines for the screening, care and treatment of persons 
with chronic hepatitis C infection (2016) and the Guidelines for the prevention, care and treat-
ment of persons with chronic Hepatitis B infection (2015). 
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3.10.4 Implementation considerations
Outreach programmes, NSPs, drop-in centres and all service-providers should make sure that peo-
ple who inject drugs are properly informed about the different kinds of hepatitis, risks of transmis-
sion, and prevention and treatment. 
Hepatitis B vaccination
All people who inject drugs should be vaccinated against hepatitis B. Vaccination should be pro-
vided at drop-in centres or NSPs to optimize access for people who inject drugs. It should also be 
offered in drug-dependence centres, OST clinics, HIV clinics and other services attended by people 
who inject drugs.
Offering small financial or other incentives is associated with higher HBV vaccination completion 
rates among people who inject drugs. This recommendation applies to settings with lower vacci-
nation uptake rates among people who inject drugs, and where other efforts to increase vaccina-
tion uptake are already in place. For further information, see the WHO Guidance on prevention of 
viral hepatitis B and C among people who inject drugs (2012).
Women 
Women who use drugs are often affected even more negatively than men by viral hepatitis because 
of poor access to gender-sensitive harm reduction services. Prevention messages should be targeted 
to reflect the specific situations and contexts in which women use drugs. Women in general, includ-
ing those who use drugs, are an important priority for treating chronic hepatitis during pregnancy.
Young people
Young people are a high-risk group because of lack of information and the barriers they face to 
accessing health care. Harm reduction and HCV efforts should specifically target young people, and 
messages and programmes should be developed with their input in order to increase uptake. Ado-
lescents and youth are currently often excluded from treatment in many countries. This increases 
the risk of transmission. They should be a target population for treatment. For more information, 
see the technical brief on HIV and young people who inject drugs (2015).
3.11 Tuberculosis prevention, diagnosis and treatment 
Despite being preventable and curable, tuberculosis (TB) is the leading cause of HIV-related mor-
tality, accounting for almost a third of all HIV-related deaths. Evidence linking TB and drug use 
primarily relates to injecting drug use, but an increased risk of TB has also been linked to smoking 
crack cocaine and opium. 
There is a growing body of evidence that suggests an association between HIV, injecting drug use 
and multidrug resistant TB (MDR-TB), particularly in Eastern Europe. Clients with MDR-TB, and in 
particular HIV-associated MDR-TB, have poor treatment outcomes and high mortality rates. 
In countries with a high TB burden it has been estimated that two-thirds of people who inject 
drugs who have TB also have HCV. Detailed recommendations can be found in WHO’s consoli-
dated guidelines on Integrating collaborative TB and HIV services within a comprehensive pack-
age of care for people who inject drugs (2016).
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Case example: Integrating hepatitis care  
into harm reduction in Ukraine
The Alliance for Public Health’s strategy on hepatitis prevention and treatment for people 
who inject drugs includes collecting prevalence data via regular screenings, integrating a 
hepatitis component in harm reduction programmes, working with medical professionals 
(trainings, workshops on hepatitis testing, treatment and care), awareness and mobilization 
campaigns, and an advocacy campaign to expand access to treatment for vulnerable groups. 
The Alliance works with state and local hepatitis programmes, pharmaceutical companies 
(on price reduction for diagnostics and treatment), the general population and vulnerable 
groups (on hepatitis awareness and generating treatment demand). 
An integrated treatment model for HCV has been developed, with HIV centres that provide 
OST also carrying out diagnostics and treatment of HCV in collaboration with hepatological 
centres. NGO case managers ensure that clients are linked to services and to psychosocial 
support from community-based organizations, including peer consultations, counselling 
client’s relatives, and assistance in receiving ART and OST. The initial treatment programme 
began in late 2013 for 154 HIV/HCV co-infected OST clients in 10 regions of Ukraine. The 
programme was facilitated by considerable price reductions for diagnostics and treatment, 
and there are plans to expand the treatment programme to serve 1,500 clients.
As of June 2015, the Alliance implemented the first national-level DAA-based HCV treatment 
programme through a community-supported treatment model. Alliance is implementing the 
programme in 14 regions of Ukraine and across 19 health facilities, in cooperation with 14 
regional NGOs. The model of integrated medical and social support includes elements of 
case management and interventions to prevent reinfection. Of the 1,170 clients who have so 
far received treatment across the 14 regions, 96% were co-infected with HCV and HIV, and 
99% of these received ART. The Alliance has also been successful in influencing government 
policy. For instance, DAA-based treatment regimens are now included in the National Clinical 
Guidelines for Hepatitis C treatment.
3.11.1 Screening, diagnosis and treatment of latent TB infection
All people living with HIV should be screened regularly with the WHO-recommended four-symp-
tom TB screening algorithm (Figure 3.1). This screening helps to determine eligibility for treatment 
of latent TB infection—e.g. with isoniazid preventive therapy (IPT)—by ruling out the likelihood of 
active TB, and to identify those who need further evaluation, diagnosis and treatment for TB as 
necessary. WHO recommends using Xpert MTB/RIF as the first diagnostic test for active TB in all 
people living with HIV and for anyone suspected of MDR-TB. Programmes supporting people who 
inject drugs can offer gateways to early TB detection and timely prevention and treatment of both 
TB and HIV. It is crucial, therefore, that personnel are aware of the symptoms of TB. For more infor-
mation, see the WHO guidelines on Intensified tuberculosis case finding and isoniazid preventive 
therapy for people living with HIV in resource constrained settings (2011).
IPT can be tolerated by people who inject drugs who are living with HIV and are co-infected with 
HBV or HCV, without creating drug-induced hepatitis (DIH). However, excessive use of alcohol has 
been identified as a risk factor for DIH, so liver function needs assessment and monitoring. 
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Figure 3.1 TB symptom screening tool for people who inject drugs living with HIV
Are any of 
the following 
symptoms 
present? 
 
• Current cough 
• Fever 
• Night sweats 
• Weight loss
Yes Xpert MTB/RIF for first diagnostic test
TB diagnosis?
Yes
TB treatment, followed 
by ART 2–8 weeks after 
initiation of TB treatment
   
No
Offer IPT for latent TB 
infection (after assessing 
contraindications and 
eligibility)
No
Offer IPT for latent TB 
infection (after assessing 
contraindications and 
eligibility)
Systematic screening for TB using other methods such as X-ray, according to national guidelines, is 
also recommended among people who inject drugs not living with HIV, in countries where the TB 
prevalence is high (100 per 100,000 population or higher). Systematic TB screening in prisons and 
other closed settings should also be conducted where prevalence of TB, MDR-TB or HIV is high in 
the general or prison population. Algorithms for prisoners and people who inject drugs not living 
with HIV can be found in the WHO Systematic screening for active tuberculosis: principles and 
recommendations (2013).
Case example: Offering TB services  
as part of harm reduction in Afghanistan
A harm reduction implemented by Médecins du Monde (MdM) via professional and peer 
outreach workers built the capacity of people who inject drugs to reduce the risks related 
to their drug use through a range of services. OST was used as a starting point to engage, 
assess and stabilize clients. The seven-day-a-week methadone dispensing service provides 
a platform for delivering a range of other health-care interventions, including ART and TB 
treatment. This promoted high levels of treatment engagement and compliance despite the 
difficult service setting. Key features of MdM’s service in Kabul included:
• All people attending the service were offered TB screening and education about TB. 
• TB treatment was integrated alongside the daily dispensing of methadone and provision 
of ART for people also living with HIV.
• Routine monitoring of TB was included in the medical review of OST clients.
• MdM was able to access advanced analysis of TB tests in the mainstream health service.
• Clients requiring more advanced treatment were referred to general medical services 
(although stigma and discrimination against people who inject drugs posed barriers to a 
fully integrated service).
Although the MdM programme is no longer in operation, local harm reduction organizations 
continue to provide services to people who inject drugs, and one of the MdM’s main partners 
is scaling up methadone maintenance therapy. Numerous trained peer outreach workers still 
take part in advocacy initiatives, and with the support of Bridge Hope and Health Organization, 
a local NGO, one of the groups of people who use drugs has become an officially recognized 
organization that represents the community at the government level.
Box 3.13
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3.11.2 Treatment
Treatment of drug-sensitive TB consists of a standardized rifampicin- or rifabutin-based regimen 
for at least six months, irrespective of HIV status. It is crucial that the TB treatment is completed, 
both to reduce mortality and to avoid the development and spread of drug-resistant TB. For more 
information, see the WHO Guidelines for treatment of tuberculosis (2010). 
People who inject drugs who have a history of TB treatment interruption or of incarceration could 
be at higher risk of MDR-TB. Guidance on the management of MDR-TB and extensively drug-resist-
ant TB (XDR-TB) can be found in the Guidelines for the programmatic management of drug-re-
sistant tuberculosis. 
Case example: TB services in the context  
of HIV prevention and harm reduction in Belarus
TB, HIV and drug-dependence services in Belarus used to be delivered via separate 
programmes, each with its own administration, financing and staff. This was a barrier to 
people accessing ART after being diagnosed with TB, and many of these people injected 
drugs. Belarus responded by allowing ART to be initiated in TB clinics; however, people were 
still not able to start OST while in TB hospitals. This changed after a national consultation 
in early 2012 that recommended initiating OST in TB clinics, with financial support from the 
Global Fund and the Belarus Ministry of Health.
Some TB clinics have created positions for narcologists or made arrangements for 
consultancy services. One TB hospital plans to operate a permanent distribution site for 
OST, which would support stronger integration of services. The new approach is driving the 
expansion of the OST programmes in Belarus.
Source: WHO, UNICEF, UNAIDS. Global update on HIV treatment 2013: results, impact and 
opportunities
ART during TB treatment
Starting ART promptly significantly reduces the risk of mortality from TB associated with HIV. 
All people who inject drugs with suspected or diagnosed TB should be offered HTS as a priority 
so that those testing positive can start ART as soon as possible. ART should begin no later than 
eight weeks after the start of TB treatment, regardless of CD4 count. HIV positive people who 
inject drugs who have very compromised immune systems (CD4 <50 cells/mm3) should begin 
ART within two weeks of starting TB treatment. 
Drug interactions
Rifampicin can independently decrease methadone concentration levels in the blood, which, 
depending on the individual, may cause withdrawal and increase the risk of relapse to opioid use. 
Findings also indicate possible increased opiate withdrawal associated with interaction between 
rifampicin and buprenorphine. As an alternative to rifampicin, rifabutin may be used, as this is not 
Box 3.14
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documented to significantly affect buprenorphine or methadone levels. Clients receiving metha-
done or buprenorphine and rifampicin should be monitored closely, and those experiencing opioid 
withdrawal will need to have their OST doses adjusted according to the individual’s needs. In all 
cases, the client and the OST prescriber should be advised of potential interactions. Flexible dosing 
regulations and policies are particularly important for opioid-dependent people who inject drugs 
who are diagnosed with TB.
3.11.3 Encouraging adherence
People who inject drugs who are adequately supported can achieve adherence and clinical out-
comes comparable with people who do not use drugs. Adherence improves with directly observed 
therapy, adherence reminders, peer counselling, contingency management, monetary incentives, 
and through an integrated package of care that includes OST and attends to the psychosocial as 
well as health-care needs of people who inject drugs. 
The role of community-based support for  
TB treatment and adherence
Community organizations and networks play a key role in ensuring access to and engagement 
in TB services and supporting access to treatment and prevention services. Self-help groups 
and peer education can provide emotional support to deal with the additional complexities 
related to TB, including stigma and discrimination. They can also support treatment literacy 
and adherence, and advocate for those facing barriers to service access. Detailed guidance 
on developing advocacy can be found in the WHO, UNAIDS, HIT and INPUD TB advocacy 
guide for people who use drugs.
3.11.4 TB treatment in prisons
Continuity of TB treatment in prisons and other detention settings is essential to reduce mortal-
ity, the development of resistance or onward transmission. Treatment must follow the prisoner 
through all stages of detention, including pre-trial detention, during prison transfer and following 
release.
3.11.5 TB infection control
Places where people who inject drugs tend to congregate—e.g. safe spaces, drop-in centres, NSPs, 
drug-treatment centres, health facilities, shelters, sex-work venues and prisons—can expose them 
to increased risk of TB and MDR-TB if adequate TB infection control measures are not in place. 
These include early identification and respectful separation of individuals with TB symptoms, ade-
quate ventilation, respiratory hygiene and health education, alongside rapid diagnosis and prompt 
start of TB treatment. People who work in such facilities who live with HIV or use drugs are also at 
increased risk of TB and should have access to TB prevention measures and be given the option to 
transfer to other sites that put them at less risk. It is crucial that client confidentiality is respected 
to reduce double stigma and discrimination arising from using drugs and also having TB.
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3.12 Overdose prevention and management
Drug overdose is the leading cause of preventable drug-related deaths globally. In 2012 the UN 
General Assembly ratified a resolution of the Committee on Narcotic Drugs recommending that 
overdose prevention and treatment be included in every country’s drug strategy. 
Figure 3.2 Assessment and management guide for overdose emergencies
Adapted from: WHO. mhGAP intervention guide–version 2.0 (2016) 
3.12.1 Prevention
Several strategies for preventing opioid overdose exist. These include: 
• expansion of related harm reduction interventions, such as the establishment of safe injecting 
centres and expansion of access to OST, which has been shown to reduce the risk of overdose 
• education about the causes of opioid overdose and practical strategies for minimizing over-
dose risk 
Opioid overdose or other sedative 
overdose or mixed drug with or 
without alcohol overdose 
Unresponsive or minimally responsive 
Slow respiratory rate
Pinpoint pupils (opioid overdose)
Is the person suffering from a sedative 
overdose?
Dilated pupils
Excited, racing thoughts, disordered 
thinking, paranoia
Recent use of cocaine or other stimulants 
Raised pulse and blood pressure
Aggressive, erratic or violent behaviour
Is the person in a state of acute 
stimulant intoxication or overdose?
If unresponsive to naloxone provide airway and 
ventilatory support and TRANSFER TO HOSPITAL.
 Lay the person on their side to prevent aspiration. 
 Naloxone 0.4-2 mg subcutaneous, i.m. or i.v. OR intra-
nasal.
 Monitor vital signs. 
 Provide respiratory support (give oxygen if available).
 Consider intravenous (i.v.), rehydration but:
 • DO NOT give fluids orally while sedated. 
 • DO NOT INJECT WATER i.v.!
 Observe for 1–2 hours after naloxone administration. 
 For overdoses due to long-acting opioids, transport to 
hospital for naloxone infusion or ventilatory support.
 Urgently call the ambulance or take the person to an 
emergency clinic.
 Make the person drink a lot of fluid.
 Give diazepam 5-10 mg orally or i.v. in titrated doses 
until the person is calm and lightly sedated.
 During the post-intoxication phase, be alert for suicidal 
thoughts or actions.
If the person has chest pain, tachyarrythmias, or other 
neurological signs TRANSFER TO HOSPITAL.
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• training for responding to an overdose, including education on recognizing its symptoms, 
administering naloxone, and first aid and naloxone 
• provision and administration of naloxone to manage overdose
• strengthening community monitoring of the purity and quality of drugs.
See also the WHO guidance on Community management of opioid overdose (2014).
3.12.2 Interventions to expand access to naloxone
Naloxone should be available in conjunction with—not as a substitute for—comprehensive over-
dose prevention and management training in community settings. Based on the experience of 
harm reduction organizations, efforts to increase access to naloxone should focus on: 
• Training and providing naloxone directly to nonmedical people (lay people): This includes 
people at risk of an opioid overdose; friends and families of people who inject drugs; and peer 
outreach workers and others who might be present at an overdose.
• Ensuring professional responders are equipped with naloxone: This includes not just hospi-
tal, clinic and ambulance workers, but also emergency service workers/first responders such as 
law-enforcement and firefighters. 
• Expanding access through commercial points of sale: This includes encouraging physicians 
to prescribe naloxone and making the drug available over the counter in pharmacies without a 
prescription. 
Table 3.2 presents the features of the different approaches to distribution and their advantages 
and disadvantages.
Table 3.2 Approaches to naloxone provision
TYPE OF INTERVENTION DESCRIPTION ADVANTAGES DISADVANTAGES
Provision to professional 
responders
All first responders have access to and training in the 
administration of naloxone, e.g. ambulance, police, 
firefighters
First responders are 
often the first trained 
professionals on the 
scene of an overdose
Some first responders (e.g. law-
enforcement officers) may be 
unwelcome
Expanding points of sale Work to expand nonprescription access to naloxone 
through pharmacies and other points of distribution
Increases access to 
naloxone 
Lack of persons trained in 
administration
Direct distribution Harm reduction programme distributes naloxone and 
provides training to clients through existing NSP, drug 
treatment, prison or other services, as well as to peer 
outreach workers, family and friends of people who 
inject drugs
Targets those most 
likely to witness 
overdose 
Ease of integration
Relatively large quantities of 
overdose response kits/naloxone are 
needed
Political sensitivities may cause 
challenges to this approach
3.12.3 Steps to implement a naloxone distribution programme 
1. Raise awareness in the community: Where available, collect existing overdose data. Con-
duct stakeholder meetings with those familiar with the local overdose context, including 
drug-user organizations, medical- and social-service providers and, if applicable, law-enforce-
ment personnel. 
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2. Determine policy constraints, scope, and focus of the intervention: Because naloxone is a 
prescription medication in most countries, there may be a need for regulatory or legislative 
changes, or “trial” or other exemptions, in order for bystanders to administer naloxone. 
3. Select the formulation of naloxone for distribution: While intranasal administration is pref-
erable for laypersons (easy to administer and there are no needles) intramuscular injection 
may be the most readily available. Intramuscular is preferable to intravenous for laypersons 
as it is easier to administer, and the duration of action is longer. The minimum dose should be 
0.4–0.8 mg on the first dose. Further doses may be necessary.
4. Train trainers: Once the scope of the intervention is determined, the trainers should be cho-
sen. They may be people who inject drugs, medical staff, or social-service providers.
Case example: Peer-led naloxone provision in China
A harm reduction NGO in China distributed overdose hotline cards through an existing needle 
exchange. Bystanders witnessing overdoses contacted motorcycle-driving peer educators 
who administered naloxone. Six NGO peer workers successfully reversed 76 overdoses 
within 30 months with minimal extra programme costs. After gaining support from a local 
hospital, the programme began to distribute naloxone directly to clients and their family 
members. Community naloxone programmes are now operating in the provinces of Guangxi, 
Hubei, Sichuan, Xinjiang and Yunnan. 
3.13 Psychosocial services
HIV care and harm reduction settings can provide an opportunity for the detection and manage-
ment of mental-health issues among people who inject drugs. Studies suggest that mental-health 
problems in people living with HIV may interfere with treatment initiation and adherence and may 
lead to poor treatment outcomes. These issues can include depression and becoming suicidal, a 
range of anxiety-related issues as well as more severe mental illness, including affective disorders 
and psychosis, personality disorders and post-traumatic stress. 
It is important that providers be aware of internalized stigma—the self-acceptance of the preju-
dicial views or stereotypes of others—which can lead to social withdrawal, a poor sense of self-
worth and a subsequent reluctance to accept or adhere to treatment or other health and social 
services, as some individuals come to view themselves as undeserving of respectful treatment, or 
even of any treatment at all.
The WHO mhGAP intervention guide–version 2.0 (2016) makes recommendations related to 
general mental-health care that can be relevant to people living with HIV, including those from 
key populations. 
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3.14 Further resources 
NSP
1. Guide to starting and managing needle and syringe programmes. Geneva: World Health 
Organization; 2007. 
http://www.who.int/hiv/pub/idu/needleprogram/en
2. Strike C, et al. Needle exchange programmes: best practice recommendations. Toronto (ON): 
Ontario Needle Exchange Coordinating Committee; 2006. 
http://www.catie.ca/en/resources/ontario-needle-exchange-programs-best-practice-
recommendations
3. Burrows D. Starting and managing needle and syringe programs: a guide for Central and 
Eastern Europe/Newly Independent States. New York (NY): International Harm Reduction 
Development/ Open Society Institutes; 2000. 
https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact
=8&ved=0ahUKEwjBhP7bkoPQAhXJK8AKHbvsDnkQFggeMAA&url=http%3A%2F%2
Fharmreduction.org%2Fwp-content%2Fuploads%2F2012%2F01%2FStarting-and-managing-
NSP-programs.pdf&usg=AFQjCNEB9Gm30o_GgG5HErN58iKNBzBJSQ&sig2=mCr4Mbam
CY4NlC0wNTufsw
 
OST and other evidence-based drug-dependence services
4. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 
Geneva: World Health Organization; 2009.  
http://www.who.int/substance_abuse/publications/opioid_dependence_guidelines.pdf
5. Interventions to address HIV in prisons: HIV care, treatment and support. Evidence for action 
technical paper. Geneva: World Health Organization; 2007. 
http://www.who.int/hiv/pub/idu/idupolicybriefs/en
6. Principles of drug dependence treatment. Vienna: United Nations Office on Drugs and Crime; 
2009. 
https://www.unodc.org/docs/treatment/Principles_of_Drug_Dependence_Treatment_
and_Care.pdf
7. mhGAP intervention guide for mental, neurological and substance use disorders in 
nonspecialized health settings–version 2.0. Geneva: World Health Organization; 2016. 
http://www.who.int/mental_health/mhgap/mhGAP_intervention_guide_02/en
8. Technical briefs on amphetamine-type stimulants (ATS). Manila: World Health Organization 
Regional Office for the Western Pacific.  
http://www.who.int/hiv/pub/idu/ats_tech_brief/en
9. WHO/UNODC/UNAIDS position paper: substitution maintenance therapy in the management 
of opioid dependence and HIV/AIDS prevention. Geneva: World Health Organization, United 
Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS; 2004.  
http://www.unodc.org/documents/hiv-aids/Position%20Paper%20sub.%20maint.%20
therapy.pdf
10. UNODC Drug Dependence Treatment: Treatnet Training Package. Vienna: United Nations 
Office on Drugs and Crime; 2008. 
https://www.unodc.org/treatment/en/training-package.html
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HTS
11. Service delivery approaches to HIV testing and counselling (HTC): a strategic policy 
framework. Geneva: World Health Organization; 2012. 
http://apps.who.int/iris/bitstream/10665/75206/1/9789241593877_eng.pdf 
12. Delivering HIV test results and messages for re-testing and counselling in adults. Geneva: 
World Health Organization; 2010. 
http://www.who.int/hiv/pub/vct/hiv_re_testing/en
13. Guidelines on HIV self-testing and partner notification. Geneva: Joint United Nations 
Programme on HIV/AIDS; 2016. 
http://www.who.int/hiv/pub/vct/hiv-self-testing-guidelines/en
14. Consolidated guidelines on HIV testing services. Geneva: World Health Organization; 2015. 
http://www.who.int/hiv/pub/guidelines/hiv-testing-services/en
ART
15. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV 
infection. Second edition. Geneva: World Health Organization; 2016. 
http://www.who.int/hiv/pub/arv/arv-2016/en
Sexual and reproductive health
16. Guidelines for identification and management of substance use and substance use disorders 
in pregnancy. Geneva: World Health Organization; 2014. 
http://www.who.int/substance_abuse/publications/pregnancy_guidelines/en
17. Responding to intimate partner violence and sexual violence against women. WHO clinical 
and policy guidelines. Geneva: World Health Organization; 2013. 
http://www.who.int/reproductivehealth/publications/violence/9789241548595/en
18. Implementing comprehensive HIV/STI programmes with sex workers: practical approaches 
from collaborative interventions. [The SWIT]. Geneva: World Health Organization; 2013. 
http://www.unfpa.org/publications/implementing-comprehensive-hivsti-programmes-sex-
workers-practical-approaches
Condom programming
19. Condom programming for HIV prevention: a manual for service providers. Geneva: World 
Health Organization; 2005.  
http://www.unfpa.org/publications/condom-programming-hiv-prevention
20. Comprehensive condom programming: a guide for resource mobilization and country 
programming. New York (NY): United Nations Population Fund; 2011.  
http://www.unfpa.org/publications/comprehensive-condom-programming
Viral hepatitis B and C
21. Guidance on prevention of viral hepatitis B and C among people who inject drugs. Geneva, 
World Health Organization; 2012. 
http://www.who.int/hiv/pub/guidelines/hepatitis/en
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22. Guidelines for the screening, care and treatment of persons with chronic hepatitis C 
infection– updated version April 2016. Geneva: World Health Organization; 2016. 
http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en
23. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B 
infection. Geneva: World Health Organization; 2015. 
http://who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en
TB
24. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other 
stakeholders. Geneva: World Health Organization; 2012. 
http://www.who.int/tb/publications/2012/tb_hiv_policy_9789241503006/en/
25. Integrating collaborative TB and HIV services within a comprehensive package of care for 
people who inject drugs: consolidated guidelines. Geneva: World Health Organization; 2016. 
http://www.who.int/tb/publications/integrating-collaborative-tb-and-hiv_services_for_
pwid/en
26. TB advocacy guide for people who use drugs. Geneva: Joint United Nations Programme on 
HIV/AIDS, World Health Organization, HIT, International Network of People Who Use Drugs. 
http://www.stoptb.org/wg/tb_hiv/assets/documents/TBHIV_Advocacy_Guide.pdf
Overdose
27. Opioid overdose: preventing and reducing opioid overdose mortality. Vienna: United Nations 
Office on Drugs and Crime; 2013. 
https://www.unodc.org/treatment/en/discussion-paper.html
28. Community management of opioid overdose. Geneva: World Health Organization; 2014. 
http://www.who.int/substance_abuse/publications/management_opioid_overdose/en/
29. Stopping overdose: peer-based distribution of naloxone. New York (NY): Open Society 
Foundations; 2011.  
http://www.opensocietyfoundations.org/publications/stopping-overdose
30. Overdose prevention. [website.] Harm Reduction Coalition. Accessed 2016 December 5. 
http://harmreduction.org/issues/overdose-prevention
31. Naloxoneinfo.org [website.] Open Society Foundations. Accessed 2016 December 5. 
http://www.naloxoneinfo.org
Women and young people 
32. Women who inject drugs and HIV: addressing their specific needs. Vienna: United Nations 
Office on Drugs and Crime; 2014.  
http://www.unodc.org/documents/hiv-aids/publications/WOMEN_POLICY_BRIEF2014.pdf
33. Addressing the specific needs of women who inject drugs: practical guide for service 
providers on gender-responsive HIV services. Vienna: United Nations Office on Drugs and 
Crime; 2016. 
https://www.unodc.org/unodc/en/hiv-aids/new/publications_drugs.html
34. Responding to intimate partner violence and sexual violence against women. Geneva: World 
Health Organization; 2013. 
 http://www.who.int/reproductivehealth/publications/violence/9789241548595/en
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35. HIV and young people who inject drugs: a technical brief. Geneva: Joint United Nations 
Programme on HIV/AIDS; 2015. 
http://www.who.int/hiv/pub/toolkits/hiv-young-idu/en
Prisons
36. Interventions to address HIV in prisons: effectiveness of interventions to address HIV in 
prisons. Evidence for action technical paper. Geneva: World Health Organization; 2007.  
http://www.who.int/hiv/pub/idu/prisons_effective/en
37. A handbook for starting and managing needle and syringe programmes in prisons and other 
closed settings. Vienna: United Nations Office on Drugs and Crime; 2014.  
http://www.unodc.org/documents/hiv-aids/publications/Prisons_and_other_closed_
settings/ADV_COPY_NSP_PRISON_AUG_2014.pdf
38. HIV and AIDS in places of detention: a toolkit for policy makers, programme managers, prison 
managers and prison health staff. Vienna: United Nations Office on Drugs and Crime; 2008. 
https://www.unodc.org/documents/hiv-aids/HIV-toolkit-Dec08.pdf
39. Women and HIV in prison settings. Vienna: United Nations Office on Drugs and Crime; 2008. 
http://www.unodc.org/documents/hiv-aids/Women%20and%20HIV%20in%20prison%20
settings.pdf
40. Policy brief: HIV testing and counselling in prisons and other closed settings: a comprehensive 
package of interventions. Vienna: United Nations Office on Drugs and Crime; 2009.  
https://www.unodc.org/documents/hiv-aids/UNODC_WHO_UNAIDS_2009_Policy_brief_
HIV_TC_in_prisons_ebook_ENG.pdf
General 
41. Evidence for action: effectiveness of communitybased outreach in preventing HIV/AIDS 
among injecting drug users. Geneva: World Health Organization; 2004. 
http://www.who.int/hiv/pub/prev_care/en/evidenceforactionalcommunityfinal.pdf
42. Management of common health problems of drug users: guidelines for the primary health 
care of drug users. Delhi: World Health Organisation South East Asian Regional Office; 2009. 
http://www.searo.who.int/entity/hiv/documents/9789290222927/en
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What’s in this chapter?
This chapter offers practical advice on designing acceptable and accessible services for people 
who inject drugs, and on involving community members as programme staff. It also describes in 
detail two particular aspects of community-led services: peer-led outreach, and drop-in centres. 
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4.1 Introduction
This chapter describes strategies for designing and implementing effective services for people 
who inject drugs. The principles of community empowerment1 are particularly important: involv-
ing people who inject drugs in the design, planning, implementation and monitoring of services 
can have a positive impact on service uptake. The successful operation of community-led harm 
reduction programmes is constrained by the current environment of criminalization of drug use, 
stigma and discrimination. Harm reduction programmes have therefore been operated by nongov-
ernmental organizations (NGOs) and community-based organizations that in a few countries are 
supported and funded by governments. This chapter discusses some general principles of working 
with people who inject drugs as staff members, which will be of particular use where harm reduc-
tion services are provided by organizations that are not community-led.
People who inject drugs can take on many roles within a harm reduction programme, including in 
education, advocacy, clinical services, administration, programme management, monitoring and 
oversight. The chapter focuses on two specific categories: peer outreach workers, i.e. people who 
inject drugs who are trained to deliver or support access to harm reduction services, and peer 
navigators, who help people to navigate social services, legal bureaucracies, and health services 
for treatment and care for HIV and other conditions. Finally, the use of drop-in centres as delivery 
points for services is discussed.
4.2 Strategies for designing and starting effective services
• Planning and assessment: A careful assessment of the situation prior to starting services 
will improve the programme’s effectiveness and sustainability. The World Health Organization 
(WHO) Rapid assessment and response guide on injecting drug use (1998) provides tools 
that help in this process. Lack of data should not hold back development of services, but it is 
important to initiate and strengthen research and data collection to develop the evidence base 
and inform programming.
• Community mobilization: Effective programmes engage people who inject drugs in decision-
making from the earliest stages: in assessments, planning and decisions about sites, types of 
commodities and services to be provided. (For services in prisons, see the publication by the 
United Nations Office on Drugs and Crime and the European Monitoring Centre for Drugs and 
Drug Addiction, HIV in prisons: situation and needs assessment toolkit (2010).
• Community-led services: Meaningful involvement of the community can be enhanced by 
engaging and training community members to promote, coordinate, deliver and monitor ser-
vices, including outreach, running drop-in centres, navigating primary health care and other 
services, and for overdose prevention and treatment. For more details, see Section 4.3.
• Staff training: It is crucial to provide continual training for health-care workers and other staff 
who interact with people who inject drugs to improve their technical and communication skills.
1 In most contexts in this tool, “community” refers to populations of people who inject drugs rather than the broader geographic, social or 
cultural groupings of which they may be a part. Thus, “outreach to the community” means outreach to people who inject drugs, “community-led 
interventions” are interventions led by people who inject drugs or people with community connectedness, and “community members” are people 
who inject drugs or people with community connectedness. For a closer definition, see Chapter 1, Box 1.1.
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• Flexibility: Programmes must be flexible and be reorganized when necessary to stay effective 
in quickly changing local drug-using situations. 
• Monitoring: Monitoring and evaluation (M&E) is crucial to assess whether the intended objec-
tives of the programme are being accomplished, as well as to understand and respond to the 
changing needs of clients (see Section 4.2.4). People who inject drugs should play an important 
role in the M&E of programmes by giving feedback on the effectiveness, quality and accept-
ability of services. 
Client-focused services
Services that are carefully designed to meet the needs of people who inject drugs will be 
more effective. Equally important is a human-rights based approach. The United Nations 
Committee on Economic, Social and Cultural Rights (General Comment 14) recognizes that 
the right to health is fulfilled only if essential services are nondiscriminatory, scientifically 
sound, gender-sensitive, culturally appropriate, noncoercive, humane and respectful. The 
following characteristics apply to all services described in this chapter. Services should be:
• Appropriate: Effective, high-quality, and provided in a timely manner and addressing the 
needs of people who inject drugs. Health services should be in line with international 
standards, current best practices and guidelines. 
• Accessible: Offered at times and places convenient for people who inject drugs, includ-
ing outside normal working hours and at weekends. Where possible, services should be 
integrated (co-located) or closely linked so that a broader range of health services can 
be accessed in a single visit (see Section 4.2.2). Cross-training of providers is impor-
tant. Services should be low-threshold, available without appointment and with short 
waiting times.
• Acceptable: Health-service providers should be discreet and respectful, nonjudgemental 
and nonstigmatizing. They should be trained in duty of care and understand how to address 
the particular needs of people who inject drugs. Services for people who inject drugs are 
best delivered in community-based settings and with close collaboration with civil-soci-
ety organizations and government (or national) health services and authorities. Peer nav-
igators should be available where requested, to assist clients’ access to services and their 
understanding of proposed interventions (see Section 4.5.4). Programmes should take into 
account that women who inject drugs are often more marginalized and have extremely lim-
ited access to harm reduction services. The varying needs of young people and older people 
who inject drugs must also be considered when designing services.
• Confidential: There must be trust between clients and service-providers. Counselling and 
examinations should take place in private rooms. Confidentiality of personal information 
must be guaranteed according to medical standards. Whether the registration system is 
electronic or paper-based, access to it should be strictly limited and traceable. Client infor-
mation must never be given to nonmedical third parties without the client’s agreement. 
• Nondiscriminatory: All clients should be treated fairly regardless of age, sex, sexual ori-
entation, gender identity, ethnicity, religion, class, occupation and drug use status. There 
should be a clearly displayed “charter of service” for clients. In particular, there should be 
Box 4.1
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no legal impediments or barriers to young people accessing harm reduction services or to 
service-providers delivering such services to young people.
• Informed consent: Services must be voluntary. All clients must give consent for treatment, 
based on sufficient and accurate information to make an informed choice. The right of any 
client, including people who inject drugs, to refuse treatment must always be respected.
• Affordable: Services should be free or affordable, bearing in mind the cost of transport 
and lost income opportunities for people visiting a service-provider. Where possible, 
programmes should be easily accessible by public transport so that regular attendance 
is feasible. 
• Safe: Programmes must have policies to support client safety, particularly in settings 
where drug use is criminalized.
4.2.1 Considerations for providing services to specific groups
Reaching specific groups of people who inject drugs, such as women, young people, lesbian, gay, 
bisexual or transgender people, or sex workers can be challenging, and consideration should be 
given to how to make services flexible and accessible to these groups. Wherever possible, it is 
advisable to recruit drug-injecting individuals from these groups to reach out to their peers, and 
adapt the services to meet their expressed needs. 
All staff should be trained on the differences between the ways in which specific groups procure, 
use and respond to different drugs. Training should be provided by representatives from all specific 
groups who inject drugs and health specialists. Evidence-based information can ensure that ser-
vices are appropriate and incorporate the community’s knowledge and experience. 
Harm reduction interventions, including needle and syringe programmes (NSPs) and opioid substi-
tution therapy (OST), and like treatment for HIV, tuberculosis (TB) and hepatitis, should be available 
without interruption within all parts of the criminal justice system. Prisoners enrolled in NSP or OST 
prior to imprisonment should be able to continue these programmes while on remand, in prison and 
after being released. A seamless continuum of care requires close collaboration between prison 
health services, police and court services, health-care providers and community-led organizations. 
Liaison with community services provides an important point of connection for people leaving 
prison that can support prompt engagement with health-care services and treatment adherence. 
Bringing community services into prisons can reduce the risk of disengagement from health-care 
services upon release and strengthen the care pathway. See also Chapter 2, Section 2.3.5. 
4.2.2 Service delivery models
People who inject drugs can have multiple health, economic and psychosocial needs which pose 
significant challenges to service-providers. Detention, chronic unemployment, homelessness, 
stigma and discrimination have severe negative impacts on their experience and uptake of health 
care, including treatment adherence. Systems of service delivery must be based on a solid under-
standing of these complexities and provide an enabling environment for treatment success. The 
quality and effectiveness of service provision should be defined by the client and monitored by the 
service-provider and the government. 
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Box 4.2
Case example: Providing services  
to women who inject drugs in Ukraine
The Women for Women (W4W) initiative was developed to provide gender-sensitive HIV 
and harm reduction services, especially for women who inject drugs, female partners of 
people who inject drugs and female ex-prisoners. The programme, initially piloted with the 
support of UNODC, was handed over to municipal services in Ukraine in November 2013. 
Six existing harm reduction NGOs were awarded grants to incorporate gender sensitivity into 
their services, including support for interventions of particular importance to women such as 
prevention of gender-based violence (including counselling for male sexual partners), legal 
assistance, child care, hygiene and food supplies, shelter, self-esteem skills-building and job 
placement. Links were also established with local government clinics and social services. 
Training for the NGO staff as well as some government representatives included a study tour 
to Vienna to familiarize participants with the day-to-day running of HIV and harm reduction 
services for women, and workshops on how to develop these services. Participants also 
received capacity-building in outreach techniques, leadership and empowerment, advocacy 
and fundraising. Women who inject drugs are involved in many aspects of service delivery.
Over the project period (2011–2013), just over 2,000 women received services through the 
programme. Involving municipal service-providers in harm reduction services for vulnerable 
women in their own communities has helped to reduce stigmatization and discrimination. 
The challenge of financial sustainability is addressed by incorporating programme activities 
in local service-delivery structures. Intensive training ensures that NGO and government 
providers have the advocacy, management and fundraising skills needed for long-term 
sustainability of the services. Equally important has been maintaining a dialogue between 
the civil-society organizations and local administrative structures.
Although separate sections of this chapter address distinct health services, the goal of effective 
programme planning should be to create closely linked or integrated service-delivery models with 
the fewest barriers for people to access services. High-quality services are ideally based where 
people who inject drugs live or congregate, so that they are easy to access and use. Various models 
can be considered, depending on the available infrastructure, as shown in Table 4.1. Some services 
may be delivered from a fixed site, usually a drop-in centre (see Section 4.6) or clinic. Some ser-
vices may be wholly outreach-based, i.e. delivered either from a mobile unit or by peer outreach 
workers2 visiting people in the community. Ideally, programmes should combine both fixed-site and 
outreach models. 
2 A peer outreach worker is a person who injects drugs who conducts outreach to other people who inject drugs, and who is not generally full-time 
staff of an HIV prevention intervention (full-time staff might be called “staff outreach workers” or simply “outreach workers”). Peer outreach workers 
may also be known by other terms, such as “peer educators” or “community outreach workers”. However, the terms “peer” or “community” should not 
be understood or used to imply that they are less qualified or less capable than staff outreach workers.
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Table 4.1 Models and locations of primary clinical care for people who inject drugs
DELIVERY LOCATION BENEFITS CHALLENGES
Drop-in centre ● Comprehensive services may be provided; mix 
of clinical interventions and prevention and 
information is possible 
● Flexible to address needs of men and women who 
inject drugs 
● Involvement of people who inject drugs is possible
● May not have clinical services
● Quality of service provision can vary
● Can be difficult to form formal links with 
mainstream health services
Mobile outreach
Van or bus, or on foot
● May reach hard-to-reach people who inject drugs
● Acceptable and accessible 
● Cost-effective if accessing significant numbers of 
hard-to-reach people who inject drugs 
● Flexible response where there is a hostile 
environment for fixed sites
● Hours of service delivery and range of services 
provided may be more limited than at a drop-in 
centre
Clinic
Government, NGO, or 
private
● Better clinical services
● Quality assurance standards are monitored
● Linked directly to other mainstream health 
services
● Stigma and discrimination may be an issue
● Limited hours of access
The services provided to people who inject drugs, and the means by which they are delivered, will 
depend on a variety of factors, including the legal status of drug use and of harm reduction services 
and materials. As harm reduction becomes more widely accepted, it is important that services be 
made available not just in urban areas but in rural ones or small communities where drug use is 
common. In such settings, formal committees of people who inject drugs may not be established, 
but a village committee may work to ensure that people who inject drugs in their villages have 
access to sterile needles and syringes, for example via pharmacies or shops. 
Organizations planning programmes should take into account that law-enforcement practices in 
specific localities may not reflect what is prescribed in national law. This presents an opportunity 
for engagement with law enforcement at certain sites. Where possible, and if safe to do so, organ-
izations can work with law enforcement by initiating dialogue and negotiating agreements to pre-
vent the harassment of community members at service sites. (See Chapter 2, Boxes 2.11 and 2.12 
for further information.) Further factors to be considered are the local types and patterns of drug 
use, the level of empowerment of the community, and the human and financial resources available 
for implementation activities. 
Case management
Case management is an effective model for maintaining long-term compliance with health care for 
people who inject drugs, particularly when receiving services at a health-care facility (rather than a 
community-based one). Case management is based on the following approach:
• Initial on-site interview as part of disease screening and diagnosis
• Intensive case management phase to support clients through challenges when entering the 
health-care system. Here, the case manager and client address issues such as:
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– transport problems (financial and logistical)
– the optimal time for the client to attend clinical services
– fears or negative prior experience with medical staff
– scheduling all upcoming exams and clinical check-ups.
During this phase the case manager has regular meetings with the client, accompanies them to 
the health-care clinic, introduces them to staff and adjusts the schedule for future visits.
• Maintenance phase: the case manager makes regular calls to the client and checks with health-
care personnel about any problems. During this phase it is recommended to invite the client to 
prevention and treatment literacy sessions, to ensure that they fully understand the purpose of 
medical procedures and future steps, i.e. antiretroviral therapy (ART). Case management during 
the maintenance phase addresses broader issues of health, social and psychological well-being, 
including clinical decisions regarding takeaway doses of methadone, and addressing the sup-
port needs of the client’s family, especially the health and well-being of any children. 
Service integration
Integrated services provide the opportunity for client-centred prevention, diagnosis, treatment and 
care for the multitude of issues adversely affecting people who inject drugs. This “one-stop shop” 
approach can include any of the comprehensive package of harm reduction services. The key fac-
tor in effective integration is not only co-location of services, but also collaboration between ser-
vice-providers, e.g. to enable ARV dispensing and condom and lubricant distribution at OST clinics. 
Where integrated service provision is not possible, it is important to establish and maintain strong 
links among health services working with people who inject drugs. This can be facilitated through 
interagency cross-training, staff secondment and by strengthening quality across referral networks. 
4.2.3 Making harm reduction programmes acceptable to the local community
The stigma that attaches to people who inject drugs affects where services can be located, includ-
ing fixed-site NSPs and OST clinics. In some cities and municipalities, laws and ordinances stipulate 
that a drug-treatment clinic may not be located close to schools, churches, playgrounds and similar 
public spaces. Local authorities and politicians respond to the real or perceived concerns of the 
wider community and often fail to support the establishment of harm reduction services in the 
places where they are needed. As a result, there are often too few clinics, and ones that are set up 
may be difficult to reach, with limited public transport options. This increases the daily hardship for 
people who inject drugs and reduces access to and uptake of services, including treatment. 
Careful and ongoing advocacy is needed in the local wider community to prepare for the estab-
lishment of any service for people who inject drugs, and in particular for low-threshold services 
such as NSP or OST. Implementation and delivery of essential services may be hampered not only 
by laws but by negative (and frequently inaccurate) media coverage. Frequent harm reduction 
trainings for media and police personnel, timely meetings with law enforcement and sensitization 
programmes for members of the wider community and policy-makers may help to create a more 
supportive environment for programmes. In addition, programme managers and service-provid-
ers can work with people who inject drugs to address concerns presented by members of the 
wider community. In many cases, behaviours that raise objections are easily addressed by people 
who inject drugs themselves; for example, peer outreach workers may collect used syringes from 
locales frequented by members of the wider community, or may persuade people who inject drugs 
not to do so in locations such as children’s playgrounds. For more information, see Section 4.6.2.
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4.2.4 Monitoring and evaluation
Several frameworks exist for monitoring the response to HIV among people who inject drugs: 
• WHO, UNAIDS, UNODC technical guide for countries to set targets for universal access to 
HIV prevention, treatment and care for injecting drug users–2012 revision. Geneva: World 
Health Organization; 2013. 
• Tool to set and monitor targets for HIV prevention, diagnosis, treatment and care for key 
populations. Geneva: World Health Organization; 2015. 
• Consolidated strategic information guidelines for HIV in the health sector. Geneva: World 
Health Organization; 2015.
• Operational guidelines for monitoring and evaluation of HIV programmes for people who 
inject drugs. Geneva: Joint United Nations Programme on HIV/AIDS; 2011. 
Each of these frameworks recommends a set of national-level indicators. These indicators assess 
key factors related to the enabling environment; measure the availability, coverage and quality of 
specific interventions; and examine their outcome and impact. 
4.3 Planning community-led harm reduction services
Community-led harm reduction services are interventions designed and delivered by people who 
inject drugs to help others in their community access the health care and support they need, espe-
cially for HIV and hepatitis C (HCV) prevention. It is an approach that worldwide has been under-
employed and would benefit from scale-up. If a harm reduction programme is not run by a com-
munity-led organization, employing staff who are people who inject drugs, or former injecting drug 
users who maintain community connectedness (i.e. who continue to maintain association, shared 
values and understandings with others who inject drugs), will make it easier to connect and estab-
lish relationships with other people who inject drugs in their location. 
People who inject drugs can create an enabling environment that encourages other people who 
inject drugs to access health care and social support, even where the national policy and legislative 
framework is hostile, or injecting drug use is criminalized or discriminated against. With sustained 
support, community-led harm reduction services can also provide the basis for a strong advocacy 
movement that challenges structural barriers and the stigma and discrimination that underpin many 
institutional responses. Whenever possible, therefore, community members should be recruited to 
the programme team. These should be current or former people who inject drugs who live in the 
service area and know it well, and who also know and are respected and trusted by their peers. The 
steps outlined in Chapter 1 to build trust and rapport with the community should be followed.
In some contexts, community-led harm reduction programming may not be feasible, either because 
there is no organized community of people who inject drugs, or because punitive laws and prac-
tices make it unsafe for people who inject drugs to provide visible outreach. In these cases, an 
NGO may organize initial outreach. If the programme team consists primarily of noncommunity 
members, they should ideally be people with local knowledge who are connected to and trusted by 
people who inject drugs. Where feasible, the implementing organization should establish a steer-
ing committee of community members to help monitor and oversee the outreach work done by 
noncommunity members (see also Section 4.4.3). 
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Box 4.4
Box 4.3
Case example: Comprehensive outreach in Indonesia
PEKA, a civil-society organization based in Indonesia’s West Java province, provides a 
continuum of care for people who inject drugs in Jakarta, and the cities and districts of 
Bogor. The majority of workers also have experience using drugs. PEKA offers an education 
programme on life skills, HIV prevention and care, and addressing stigma. The peer outreach 
programme distributes sterile injecting equipment and offers referrals for HIV counselling 
and testing, antiretroviral treatment and other medical consultations, and referrals for 
general health as well as for HIV. A peer support group disseminates up-to-date information 
on HIV and drug use. The programme also offers counselling and paralegal assistance to 
advocate for the legal and other needs of clients in detention. All the services provided are 
documented and managed under the programme division of PEKA Halfway House. 
   Fundamentals for community-led harm reduction services
While there are various approaches and models for delivering community-led harm reduction 
services, certain organizational practices will help ensure that the services effectively address 
the needs of people who inject drugs within their own context and community:
• The organization has a values statement supportive of people who inject drugs, and devel-
oped with their close participation. 
• People who inject drugs hold decision-making positions in the management structure.
• The policies of the organization take into consideration staff who inject drugs and protect 
their safety and their human rights.
• The organizational strategy is responsive and adaptable to accommodate needs and 
changes in the community. 
• An independent body, composed of community members (e.g. drug user unions), is set up 
to deal with concerns from the community.
• There is good documentation of both the lived experience of people who inject drugs 
and the services that have a positive impact on their lives, to ensure that learning can be 
shared and built upon.
4.4 Recruiting and managing community staff in programmes
4.4.1 Recruiting community members
In the initial stages of a programme, selecting community staff (including, but not limited to, peer 
outreach workers) may be an informal process: the implementing organization may invite people 
who inject drugs to become involved in the programme as peer outreach workers or in other 
capacities, and to help identify and recruit others. As the programme grows, it is likely that more 
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people who inject drugs will come to know of it and may want to be involved. An optimal process 
for recruiting and training community staff can be developed over time, and the following steps 
should be considered:
• Form a steering committee comprising community members, the funding body, members of 
the wider community and other stakeholders.
• The steering committee drafts a Terms of Reference for staff positions, outlining the selection 
and recruitment criteria as well as the roles and responsibilities and reporting lines of the staff. 
This includes policies on salaries and allowances as well as career progression opportunities. 
• Develop a strategy to disseminate the Terms of Reference so that the greatest possible num-
ber of people who inject drugs know about the opportunity to be part of the programme as 
staff and have time to apply. 
• Develop or choose a training curriculum: many are now available for a range of settings, espe-
cially for peer outreach workers, so one can be chosen that best fits the environment and 
available resources. (See also the examples of training topics for peer outreach workers later 
in this chapter.)
• Articulate the options for staff to develop their role within the organization over time and to 
take on greater responsibilities for outreach, programme management or other services and 
activities.
4.4.2 Managing and supporting community members
In certain settings, community members joining a harm reduction programme as staff may have 
little or no prior work experience. The programme must commit to working patiently with them 
and making allowances that might not be given to noncommunity staff (e.g. regarding punctuality, 
frequency of breaks). Organizations should not replicate prohibitive antidrug strategies such as 
urine analysis or threats of dismissal for using drugs. Flexibility for delivery should be built in and 
should reflect the often-changing environments in which staff who inject drugs live. This means 
accepting that their health, legal or family commitments may have to take precedence over their 
work at times.
Nevertheless, there should be clear communication between pre-existing programme staff (both 
community and noncommunity) and community members who work for the programme, covering 
expectations for their work and for interactions with programme staff and clients. All staff need a 
clear line management structure and job descriptions that explicitly state the boundaries of their 
role and the tasks for which they are responsible. 
Working in the harm reduction field can be stressful in and of itself, and “burnout” is an occupa-
tional hazard. This is damaging not only to the staff but to the programme as well, since valuable 
experience and knowledge may be lost if a staff member leaves. It is therefore crucial to ensure 
that staff have access to and take advantage of regular supervision to enable them to process 
some of their experiences, learn from them where possible, and receive support and assurance 
that they are not working in isolation. Supervision should be compulsory and weekly, and should 
address not just the functions of the job but also its impact upon the worker, including how to 
maintain good boundaries. Some organizations offer training on any relevant topic requested by 
staff and pay them for attending training sessions. 
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Box 4.5
The fair and equal remuneration of staff who are community members is essential and should be 
considered from the beginning of the programme planning process. Even if there is a lack of for-
mal qualifications, community members possess crucial and practical knowledge based on lived 
experience. These contributions, over time, can mean that community members often become the 
backbone of an organization as peer outreach workers, as well as in other positions.
4.4.3 Independent oversight
In addition to the programme steering committee, it is important to create an independent body 
comprised of community members to oversee the management of the programme, advise on pol-
icy and act as arbitrator in the event of disputes or complaints from service users. This ensures that 
community interests remain paramount.
Case example: Community-led  
monitoring of access to health and rights in Pakistan
From 2013 to 2015 the Association of People Living with HIV in Pakistan (APLHIV), in 
partnership with Mainline, a Netherlands-based organization, established a network of 
people who inject drugs in Pakistan, and a tool with which this network could monitor their 
community’s access to health and rights and the quality of services.
APLHIV and Mainline first led a community assessment of access to health facilities, harm 
reduction services and rights for people who use drugs in Pakistan. Based on the assessment, 
the Drug User Network Pakistan (DUNE) was established under the umbrella of APLHIV and 
equipped with a project officer. With APLHIV support, DUNE developed a tool for community-
led monitoring, and members of the network were trained to use it. The tool contains questions 
for service-providers and service beneficiaries on health services and rights issues.
Once the tool had been reviewed by Mainline and finalized, Nai Zindagi, the Global Fund’s 
Principal Recipient organization for HIV projects in Pakistan, agreed to have its services 
monitored. Community members implemented the questionnaire, taking care to ensure 
regional coverage, representation of females, and age diversity. After the questionnaires 
were completed, a technical consultant helped analyse the data, and DUNE reported the 
results to Nai Zindagi, which responded and discussed how it could improve its projects to 
better serve people who inject drugs. 
www.theaplhiv.org.pk/index.php/our-networks/dune
4.5 Peer-led outreach 
4.5.1 How peer outreach workers promote access to services
Employing and training members of the community, i.e. people who inject drugs, can be the most 
effective way for a programme to reach people who inject drugs, because:
• They have a personal investment in providing services to other members of the drug-using 
community.
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• They often live in communities, or visit locations, that are inaccessible to outsiders, including 
workers from traditional service-providing organizations.
• They have firsthand knowledge of how to inject drugs safely, and are familiar with drug trends 
and changing patterns of use.
• They are more likely to be trusted by the community to give appropriate, high-quality referrals 
to services, being consumers of those services themselves.
• By instilling trust, they increase the likelihood that people who inject drugs will follow up on 
referrals, adhere to treatments and engage in health-seeking and health-protective behaviours.
• People who inject drugs are likely to be more comfortable discussing personal details of their 
lives with someone who has similar experience.
• The common experience may help decrease internalized stigma and increase self-worth and 
collective solidarity.
• They are well placed to provide support to the family and friends of people who inject drugs, if 
requested to do so.
A person who injects drugs may move in and out of injecting or using other drugs, either by their own 
choice or in response to life events or treatment programmes. Peer outreach workers can act as a 
mentor and catalyst for positive change, by helping persons who inject drugs to identify elements 
of their lives that they want to change, putting them in contact with available relevant services, and 
supporting their decisions. They can also help them evaluate the impact of such decisions as changes 
occur. Peer outreach workers may also be able to help mitigate the damage from life events caused 
by circumstances outside the control of the person who injects drugs.
With appropriate training opportunities, peer outreach workers can become powerful advocates, 
by articulating changes needed in services, and in society as a whole, and by challenging the stere-
otypes often held by the wider community that people who inject drugs are unreliable, dishonest 
or victims of circumstance. 
4.5.2 Recruiting and training peer outreach workers 
As with other positions occupied by community members, the selection criteria for peer outreach 
workers should be clearly articulated and written down. A peer outreach worker should be:
• someone who currently injects drugs, or a person who has previously injected drugs who main-
tains community connectedness3 
• in places where harm reduction services for people who inject drugs are already established, 
a peer outreach worker should have been receiving services from the programme for people 
who inject drugs for at least six months 
• committed to the goals and objectives of the programme
• knowledgeable about the local area
• accepted, respected and trusted by the community
• accountable to the community as well as the programme
3 In some contexts there can be challenges in employing former injecting drug users who do not maintain community connectedness. They may 
express a feeling of superiority towards current injecting drug users, and there may be a risk that former users become active users again, which could 
present an increased risk of overdose for them. 
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• able to maintain confidentiality
• good at listening and communicating, and nonjudgemental
• tolerant and respectful of others and of diverse communities of people who inject drugs, where 
these exist
• self-confident, with leadership potential
• potentially a strong role model for the behaviour they want to promote
• willing to learn and experiment in the field
• committed to being with other people who inject drugs through crises that may occur 
• potentially able to negotiate with police and government officials, when needed.
 Services commonly offered by peer outreach workers
• Deliver harm reduction commodities to ensure safer injection and use, as well as helping 
to safely dispose of used equipment (see Chapter 3, Section 3.2 for details).
• Provide condoms and lubricants, along with information on safer sex and sexual and repro-
ductive health (SRH) and rights.
• Provide information on request on:
– overdose prevention (including naloxone distribution), safe injection, wound manage-
ment and other harm reduction principles
– specific drugs, routes of administration and drug trends identified within the commu-
nity and more generally
– prevention, testing, care and support for HIV, hepatitis, other sexually-transmitted 
infections (STIs) and TB
– options to manage drug use (including distributing prescriptions or take-home doses of 
methadone or buprenorphine, where possible, and other therapeutic alternatives)
– legal aid, health care or social support services. 
• Promote the services available at the drop-in centre, where this exists (see Section 4.6).
• Help to facilitate continuity of care for people who inject drugs who transition into or out 
of incarceration.
• Encourage people who inject drugs to articulate and demand services they need for 
themselves and for their families.
• Encourage people to test their drugs in order to identify adulterants or substituted chem-
icals/pharmaceuticals/drugs.
• Help in managing crises—whether personal, family or community.
• Providing differentiated information for the specific needs of women, men, young people 
and transgender persons or other groups with distinct needs.
• Accompany people who inject drugs to health clinics, courts or other official meetings for 
support, if requested (see Section 4.5.4).
• Deliver peer-provided HIV testing services, and case management services (see Chapter 
3, Section 3.4.4). 
• Help people who inject drugs living with HIV to acquire sustained access to ART (see 
Section 4.5.4).
Box 4.6
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Box 4.7
Case example: Peer-led outreach in Thailand
CHAMPION-IDU began in 2009 as a peer-led HIV prevention project that sought to improve 
the quality of life of people who inject drugs in Thailand. Around 80% of the 250 CHAMPION-
IDU workers hired have been people who inject drugs (currently or formerly), giving them an 
opportunity for meaningful employment and building their capacity to become productive 
members of society. 
Peer outreach workers operate via drop-in centres and mobile outreach, offering behaviour 
change communication to reduce risks, education about sterile injecting equipment, 
condoms, overdose prevention with naloxone, and referrals for HIV testing and counselling, 
methadone maintenance treatment, ART and diagnosis and treatment of STIs. Peer outreach 
workers are provided extensive support, especially in the context of frequent, negative law-
enforcement encounters, to empower them, promote their professional development and 
safeguard their health and safety. 
CHAMPION-IDU’s strategy has been successful in engaging people who inject drugs and 
facilitating their access to health services because of the innate trust that exists between 
peers. Government drug-treatment centres have seen up to a fourfold increase in in-patient 
and out-patient admissions since the project began.
CHAMPION-IDU was implemented by the Global Fund until the end of 2014. Since 2015, it 
has continued in a scaled-down version called the STAR project, currently implemented by 
the Ozone Foundation, a locally registered peer-driven organization. For more information, 
see CHAMPION-IDU: Innovations, best practices and lessons learned. Washington (DC): 
Population Services International; 2015.
Basic training should be given before peer outreach workers begin. Further specific training should 
then be offered regularly to enable peer outreach workers to develop their skills and learn new 
ones, as well as keep up to date with current thinking on the issues with which they are working 
(see Box 4.8). This may include acquiring formal qualifications that will equip them to work in other 
facilities or contexts if they wish.
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Box 4.8
Training topics for peer outreach workers and staff
Basic training Advanced training
• An overview of the programme 
• Harm reduction
• Basic knowledge of drugs and drug-
injecting equipment, safe injecting 
practices, local trends in drug use and 
novel psychoactive substances (NPS) 
• Safe distribution and collection of injecting 
equipment, as well as sharps disposal
• Overdose prevention and treatment 
(including how to administer naloxone 
and how to identify stimulant and 
depressant overdoses) 
• Prevention, diagnosis and treatment of 
HIV, HCV and TB 
• Condom and lubricant distribution 
• Health services and referral systems 
• Gender issues, including differences in 
how males and females use drugs 
• Developmental, welfare and special 
needs of young people who inject drugs 
• Violence and crisis intervention, including 
de-escalation skills
• Identifying and addressing stigma and 
discrimination and recording human-
rights violations
• Interpersonal communication skills
• Mapping, planning and monitoring 
outreach routes 
• Data collection
• Leadership skills
• Community mobilization
• Providing counselling and 
support
• Challenging prejudice
• Legal literacy, negotiating with 
police 
• Using the media to advantage
• Income generation skills, e.g. 
training to advise and set up 
loans and savings groups and 
income-generating activities
• M&E
• First aid
• Drug policies
4.5.3 Implementing outreach 
Programmes should recognize peer outreach workers for the special expertise and experience 
they bring, also being sensitive towards and accommodating the challenges faced by people who 
inject drugs. Flexibility and support are key to the successful integration of people who inject drugs 
as peer outreach workers, both in terms of the outreach worker’s work plan, and in terms of how 
the programme as a whole interacts with the outreach worker. 
• Working hours may be unconventional, since it is often more convenient to meet and work 
with people who inject drugs in the evening or at night. 
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Box 4.9
Case example: Peer-led outreach in Pakistan
The Nai Zindagi Trust has been providing comprehensive and evidence-based services to 
street-based people who inject drugs, their families and sexual partners in selected districts 
of Pakistan for 25 years. The trust works in cooperation and collaboration with the public 
health-care system to avoid creating parallel services, and 60% of services are provided by 
Nai Zindagi partner organizations.
A core principle of Nai Zindagi’s work is the involvement of people who inject drugs in 
programme design, implementation and evaluation: 30% to 40% of peer outreach workers 
and field supervisors are former injectors. The programme prioritizes outreach over facility-
based service-delivery approaches. Harm reduction (including NSP but not OST), HIV and 
STI prevention, diagnosis, treatment, care and support services are offered, as well as a two-
month residential ART adherence programme for people living with HIV. Access to skills 
training and employment for clients is also available.
Over 600 individuals have been trained to provide a range of comprehensive services 
since the inception of current programme activities (funded by the Global Fund) in 2012. 
Consistent and expanded outreach has supported services for approximately 13,000 
street-based people who inject drugs. Inclusion of sexual partners and children has been 
a significant intervention for prevention of secondary infections. District AIDS Councils 
have been established in selected districts to reduce stigma, engage government and the 
public sector in order to facilitate access to health, social welfare and HIV-related services 
for Nai Zindagi clients. Nai Zindagi has shared experiences and technical information with 
programmes in Nepal, Indonesia and Kenya.
www.naizindagi.org
Source: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key 
populations–2016 update. Geneva: World Health Organization; 2016.
• Levels of contact with clients may vary: Although each peer outreach worker may be assigned 
a specific set of individuals to contact on a monthly basis (usually in a specific area), the needs 
and circumstances of those individuals will play a significant role in determining the level of 
contact. When life is fairly stable, a service-user may only want to see the staff for resources 
such as injecting equipment or condoms and lubricant. In times of crisis such as arrest or deten-
tion, or the illness or death of a partner or family member, the service-user may seek out the 
peer outreach worker and need more time and attention.
• Regular supervision is essential, particularly when peer outreach workers are beginning their 
work, so that they do not feel overwhelmed by the responsibility of working within programme 
parameters that are still new to them. Starting a peer outreach worker off with a few hours a 
week and gradually building their time may be an effective approach.
• Listen to the peer outreach worker when they advise of changes in the number of contacts 
or commodities supplied. Reasons for increases may include greater use of drugs by clients at 
weekends or at holidays or around paydays; reasons for decreases may include clients going 
into treatment, or being incarcerated. These changes are important to document in order to 
share learning and inform programming decisions. 
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• For administration and record-keeping, meet the peer outreach worker where they are: 
be clear about the importance of tracking data that the programme needs, and offer repeated 
training as needed. Find ways to simplify forms to make them as easy as possible to use, or 
offer to have an outreach supervisor help the peer outreach worker complete forms until they 
are used to doing so themselves.
• Allow for time off because of sickness, medical or legal appointments. Be considerate with 
breaks (e.g. smoking breaks) during meetings and trainings. If a peer outreach worker is arrested 
or incarcerated, offer support—and reassure them that their position will be open to them 
upon their release, if they wish to continue. 
• Ensure that support is available to help peer outreach workers deal with stress, burnout 
and grief, and that these support structures are incorporated into human-resources policies. 
As frontline workers, peer outreach workers may have to deal with very difficult situations with 
their clients as well as in their own lives. Proper support will enable them to remain engaged in 
their work.
Confidentiality
Privacy and confidentiality are essential when working with people who inject drugs, as with other 
criminalized and stigmatized communities. The risk is that their status as drug users will be exposed 
to law enforcement or the wider community when accessing services. 
Respect for privacy, confidentiality and the principle of “do no harm” must guide the programming 
cycle. Maintaining these principles and values is not only crucial for the protection of people who 
inject drugs, but has positive implications for the programme. People who inject drugs are much 
more likely to enrol in and continue to access services where they know that their rights to safety 
and confidentiality are respected. 
All staff must be trained to ensure that confidential consultations are not held in places where they 
can be overheard, and to not speak openly about the HIV status, drug-use status and personal life 
of community members. During the delivery of HIV prevention services, outreach workers must be 
careful not to draw attention to people who inject drugs or to drug use. 
Managing information in such a way as to protect confidentiality is essential. Any written documen-
tation regarding the identity and location of people who inject drugs must be kept confidential and 
in a secure location. If there is any possibility that it could be confiscated by authorities and used 
to arrest or harass people who inject drugs, it should be coded in a way that keeps key information 
about them safe from such misuse. One approach is to have a unique identifier code (UIC) or an 
alias for each client, so that there is a clear and easy way to record and follow up the interaction 
with that person, but at the same time, the identity, location or residence of the client cannot be 
determined by information contained in the file. 
Using ID
It is helpful to have identification cards made for peer outreach workers and endorsed by a senior 
public-health official (or law-enforcement official, where possible) that they can carry while work-
ing, to help them confirm their positions if stopped by the police or when advocating on behalf of 
a client for services. 
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Safety
The safety and well-being of service-users and staff should always come first. The arrest, harass-
ment or even kidnapping of people involved in outreach, especially needle and syringe distribution, 
is not unknown. Outreach workers should always carry at least one phone and leave a record of 
their approximate schedule or itinerary so that the programme knows where they plan to go. Pro-
grammes should consider sending outreach workers out in pairs, particularly in hostile or danger-
ous environments. 
4.5.4 Peer navigation
Staff who use drugs can be ideal navigators to help their peers deal with health, social-service and 
legal systems that are often discriminatory, stigmatizing or simply confusing. Many people who 
inject drugs have negative experiences of these systems, and their distrust often leads them to 
avoid seeking services. 
Trained peer navigators—peer outreach workers or other community members with experience of 
these systems—can encourage other people who inject drugs to access the services they need and 
can support them by accompanying them when requested (Box 4.10). Similarly, if a person who 
injects drugs tests positive for HIV, a peer navigator living with HIV can be particularly effective in link-
ing them to ART services, answering their questions and encouraging them to adhere to treatment. 
4.6 Drop-in centres
Where possible, a drop-in centre to access harm reduction and basic support services should be 
created in the location where people who inject drugs live. Such centres should always be hosted 
by staff members who inject drugs who are already known to the community. 
4.6.1 Planning a drop-in centre
Consulting with community members is important to help decide where to locate a drop-in centre, 
the services to be provided, staffing and service hours. Services should be available when people 
who use drugs most need them. The choice of location should take into consideration not only its 
accessibility but also its visibility to the public. Care should be taken to ensure that the centre is 
safe from intrusion by outsiders and the police.
Before opening a drop-in centre, it is important to engage with the neighbours and the wider 
community, to explain the centre’s purpose, the operational plan and to address any questions or 
concerns. Unless they have experience living with or working with people who inject drugs, local 
residents may be anxious and prone to prejudice and stereotyping about people who inject drugs. 
Often service-providers face opposition because of fears over increased crime, improper needle 
and syringe disposal, and public-order disturbances. 
Programme managers can prevent and deal with opposition through sustained advocacy and 
through health promotion and education efforts within the general community. This involves 
coordinating and cooperating with local law-enforcement and government officials, health- and 
social-service providers, community leaders, and other members of the wider community. Patience, 
careful planning and the ability to show that the facility will be properly run and managed are 
essential at this stage. 
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Box 4.10
Case example: Peer navigation in Canada
The COUNTERfit programme in Toronto observed that people who inject drugs were 
most likely to seek services from a doctor, nurse or social worker if they had established a 
positive, trusting relationship with them. However, it was observed that service users were 
reluctant to keep appointments with housing workers, lawyers, parole officers and specialist 
doctors because they frequently experienced disrespect, discrimination and violation of 
their confidentiality. COUNTERfit found that even at its own clinic, service users who were 
accompanied by drug-using staff members received better care than those who went to 
their initial appointments alone. 
These observations led COUNTERfit to offer accompaniment by peer navigators to service 
users who needed to attend court proceedings, parole hearings, bail reviews, HIV or HCV 
testing (or receiving test results), social work appointments, landlords and tenant boards, 
and specialist physician appointments. Peer navigation offers several advantages:
• Many service users forget their appointments, often because they are not regularly 
employed and have a problem maintaining a schedule. Peer navigators remind the service 
user of their appointment and go to their home in good time in case they have forgotten 
or are asleep. 
• Service users have already established relationships with the peer navigators, who are 
community members who understand discrimination and the effects of stigmatization. 
The service user trusts completely that the peer navigator is on their side and will do their 
best to get the best service available for the client.
• Service-providers treat service users much more professionally when they are accompa-
nied by a peer navigator—both outside and within COUNTERfit’s services.
• Peer navigation is a cost-efficient and effective way of disease prevention for people who 
inject drugs. COUNTERfit’s peer navigators are paid $15.75 Canadian dollars per hour, 
which is very little compared with the savings gained by keeping a person who injects 
drugs healthy and reducing the likelihood of their being admitted to an emergency room 
or sent to prison. 
A challenge to making peer navigation work is the length of some appointments, especially 
court cases or specialist medical appointments, where there may be long delays or waiting 
times. This can increase costs for the peer navigation service, although delays can sometimes 
be mitigated with some advance preparation (e.g. calling a court clerk or doctor’s secretary 
to explain and ask for an expedited appointment). Some peer navigation work can be 
stressful for the navigator, who is contending with stigma and discrimination directed both 
at the client and at themselves. It is important that programmes offer proper support (e.g. 
debriefing) and financial compensation. It is also very important to have back-up navigators 
available in case the peer navigator is unable to make the appointment as planned. 
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People who inject drugs can play a crucial role in helping to show neighbours that they are respon-
sible and committed to maintaining the security and stability of the community and that this facility 
will benefit all. In some instances, hostility and suspicion may not abate until after the centre has 
opened and the feared disadvantages fail to materialize. Continuous and open communication is 
needed to avoid confrontational situations.
Plans to address potential opposition to a drop-in centre should be integrated into the programme 
design and planning stages. A first step would be to map and identify potential allies, with the aim 
of reaching out and engaging them to build relationships of trust, communication and cooperation. 
Sensitization workshops and discussions can take place on the needs and rights of people who inject 
drugs to health and social support services. Running public information campaigns is also useful in 
improving the knowledge and changing the attitudes of the wider community. Finally, being able 
to provide and share locally generated evidence of the success and efficacy of the programme is a 
key factor to its ongoing success. The time invested in building and fostering community relations 
improves the acceptability of the programme and creates a strong enabling environment.
4.6.2 Setting up the centre
Lease agreements and landlords: Maintaining a fixed location for the drop-in centre is important 
to prevent disruption of services. The lease drawn up with the landlord should clearly state the 
duration of the agreement and clarify the hours and nature of use. 
Infrastructure and safety: The drop-in centre should ideally have at least two rooms: one that 
can be used for one-on-one meetings or counselling, and one for community activities. If possible, 
there should be a private bathroom with a sink and shower. The centre should be equipped with 
basic equipment to handle fires and other emergencies. Since it is likely to have numerous visitors 
in close proximity to one another, measures should be taken to reduce the risk of transmission of 
TB through adequate ventilation and awareness of symptoms (see Chapter 3, Section 3.11).
Designing the space: The drop-in centre should be both functional and inviting. Meeting tables 
and chairs may be kept to one side unless in use; couches or mattresses can make the room com-
fortable. Walls may be decorated by community members. 
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Figure 4.1 Example of a drop-in centre floor plan
Mats and pillows 
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grooming area
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small-group
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Cabinets, sink, refrigerator
4.6.3 Providing services
Harm reduction services that can be offered in a drop-in centre include:
• harm reduction resources and commodities, especially sterile needles and syringes
• primary health care (abscess/wound management, other health issues) 
• peer education
• user-friendly information, education and communication materials
• information on safer injecting and safer sex 
• condoms and lubricant 
• drug analysis 
• counselling and referral to other services
• OST
• counselling and testing for HIV, hepatitis, STIs, TB—or referrals for these services if they are not 
available at the drop-in centre 
• safer consumption facilities.
Where possible, qualified staff might provide:
• mental-health services
• housing or shelter services
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Box 4.11
• emotional support with family crises
• alternatives for well-being and healthier lifestyles
• legal advice, both criminal and civil
• support in getting papers in order after release from prison
• overdose support.
Providing services for the whole person
A drop-in centre provides the programme with the opportunity to offer services that 
address the wider physical and social needs of its clients, beyond harm reduction. This is 
important because these needs often go unaddressed when people who inject drugs suffer 
stigmatization and isolation. The following support services can be considered: 
Food: People who inject drugs who face housing insecurity and lack social support are 
often undernourished, and this can seriously exacerbate any health conditions they may 
have. Where possible, food should be made available and offered free of charge or at a 
nominal cost. Some people who inject drugs like to volunteer to work in the kitchen, either 
to alleviate boredom, or to have company or physical warmth. This should be encouraged to 
create a sense of ownership in the centre.
Laundry facilities
Showers/baths where homeless people who inject drugs can maintain personal hygiene
Comfortable seating area where people can meet, talk and relax in a safe environment
Sleeping space: If homeless or ill, people who inject drugs frequently have nowhere to 
safely rest. Where possible, a place with camp-beds for short naps or longer periods of sleep 
should be made available.
Computer/Internet facilities 
Crèche facilities or play area for the children of people who inject drugs
Careful consideration should be given as to how the drop-in centre can be used by the wide diver-
sity of people who might require a service. The possibility of opening the centre exclusively for 
particular groups at some points during the week should be considered, such as:
• women
• young people 
• migrants and ethnic minorities (who may need language support)
• lesbian, gay, bisexual and transgender people 
• sex workers.
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Case example: Providing services  
to women via a drop-in centre in Tanzania
In 2010, when Médecins du Monde opened the first drop-in centre for people who use drugs 
in Tanzania, most of the attendees were male drug users. Staff recognized that women 
who inject drugs had different needs and access barriers than men, and identified additional 
interventions to enhance access to harm reduction for women.
A weekly “women only” evening commenced for women who inject drugs to access services 
in a woman-focused environment. Services include gender-based violence support and STI 
and sexual health care services by a gynaecologist. There is a women’s room and bathroom 
at the centre. Various commodities are provided in addition to new injecting equipment and 
condoms. Women can participate in peer education activity. A women’s outreach service has 
also been established.
The women’s night is well attended, with an increasing uptake of HIV testing, sexual and 
reproductive health, referrals to prevention of mother-to-child transmission and other 
harm reduction services. Women use the space to share ideas concerning drug use, health, 
pregnancy, child care, gender issues and family issues. For some, the service has been an 
entry point to become peer outreach workers. Women report that ancillary services (e.g. 
showers, provision of hygiene materials, nutritional support, hair, make-up and washing 
facilities) are crucial and improve their access to health services and NSP. A self-support 
group is engaged in income-generating activities.
The benefits of a gender-sensitive service model relevant to women who inject drugs 
have drawn the attention of stakeholders interested in expanding the model to other harm 
reduction services in Tanzania.
4.6.4 Operating the centre 
Management: The programme should provide resources for the drop-in centre. To ensure that the 
community feels ownership, people who use drugs should have the lead role in decisions about the 
centre and its management. 
Service promotion: To ensure people who use drugs are aware of the drop-in centre and its 
services, it should be promoted through flyers, text messages and community networking. 
House rules: These should be formulated by those using the centre so that they understand what 
behaviour is acceptable, e.g. with regard to noise levels. 
Relationships with neighbours: The managers, including the community, should make plans to 
manage relationships with neighbours and those outside the community. Some communities have 
performed neighbourhood clean-ups to establish a good relationship with their neighbours. 
Scheduling: If the programme needs to use the drop-in centre for programme activities that 
involve a limited number of participants (e.g. outreach planning, training, or interpersonal and 
group communication activities), these should be scheduled during off-peak hours so that they do 
not infringe upon access for the broader community. 
Box 4.12
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Box 4.13
Programme use: Growing implementing organizations may want to use the drop-in centre for 
other programme activities. However, efforts should be made to ensure that this does not happen 
or that such activities are kept to a minimum. The centre should remain open to members of the 
community. 
Sustainability: Drop-in centres can be made financially sustainable when managed by the com-
munity. For example, the community might rent out space to the programme on a limited basis, or 
develop catering services for events at drop-in centres as a form of income generation. 
Case example: A community-led drop-in centre in the USA
The San Francisco Drug Users Union runs a drop-in centre offering low-threshold services 
for drug users, provided by drug users. The centre operates in the Tenderloin District, the 
lowest-income neighbourhood in the city and the one with the highest concentration of 
people who inject drugs. 
The drop-in centre offers services including needle distribution (in conjunction with the state 
department of public health), naloxone for overdose, rapid testing for HIV and HCV, wound 
care, and education. It also provides bathroom access and Internet access, both important 
amenities for people who inject drugs, many of whom live on the streets. It is the largest fixed-
site NSP in San Francisco, serving over 350 people each week and exchanging an average of 
30,000 syringes monthly. Volunteers and staff are all people who use drugs. Some do street 
outreach, and a volunteer crew cleans up discarded injection equipment in the neighbourhood. 
This service has helped build and maintain support for the centre in the wider local community. 
The drop-in centre is a base for activism too, such as organizing marches for drug-users’ rights. 
Because the community in San Francisco is quite transient, there is some turnover of staff and 
volunteers, but this has not affected the centre’s ability to provide consistent services. The 
centre is funded by the state, nonprofit donors and private donations. It is currently open five 
days a week but is seeking funding to open on additional days.
www.sfdrugusersunion.com
4.7 Further resources
1. WHO, UNODC and UNAIDS technical guide for countries to set targets for universal access 
to HIV prevention, treatment and care for injecting drug users–2012 revision. Geneva: World 
Health Organization; 2013. 
http://www.who.int/hiv/pub/idu/targets_universal_access/en
2. Policy and programming guide for HIV/AIDS prevention and care among injecting drug users. 
Geneva: World Health Organization; 2005. 
http://www.who.int/hiv/pub/idu/iduguide/en
3. WHO rapid assessment and response guide on injecting drug use. Geneva: World Health 
Organization; 1998. 
http://www.who.int/hiv/pub/idu/rar/en
126
➍ Service Delivery Approaches
4. Tool to set and monitor targets for HIV prevention, diagnosis, treatment and care for key 
populations. Geneva: World Health Organization; 2015. 
http://www.who.int/hiv/pub/toolkits/kpp-monitoring-tools/en
5. Good practice guide for employing people who use drugs. Hove (UK): International HIV/AIDS 
Alliance; 2015. 
http://www.aidsalliance.org/resources/631-good-practice-guide-for-employing-people-
who-use-drugs
6. Good practice guide: HIV and drug use: community responses to injecting drug use and HIV. 
Hove (UK): International HIV/AIDS Alliance; 2010. 
www.aidsalliance.org/assets/000/000/383/454-Good-practice-guide-HIV-and-drug-use_
original.pdf?1405520726 
7. Developing HIV/AIDS work with drug users: a guide to participatory assessment and response. 
Brighton (UK): International HIV/AIDS Alliance; 2003. 
http://www.aidsalliance.org/resources/311-developing-hivaids-work-with-drug-users
8. Programme monitoring and evaluation: practical manual for organizations coordinating and 
implementing prevention projects among injecting drug users, commercial sex workers, men 
who have sex with men, prisoners and care and support projects for people living with HIV/
AIDS. Kiev: International HIV/AIDS Alliance Ukraine; 2008. 
aph.org.ua/wp-content/uploads/2016/08/ProgramMEManualeng.pdf
9. “Nothing about us without us”– greater meaningful involvement of people who use illegal 
drugs: a public health, ethical, and human rights imperative. Canadian HIV/AIDS Legal 
Network, International HIV/AIDS Alliance, Open Society Institute; 2008. 
http://www.aidsalliance.org/resources/310-nothing-about-us-without-us 
10. Reaching drug users: a toolkit for outreach services. Hove (UK) International HIV/AIDS 
Alliance; 2013. 
http://www.aidsalliance.org/resources/314-reaching-drug-users-a-toolkit-for-outreach-
workers
11. Standard operating procedures to reduce and manage relapse and burnout. Bangkok: 
Population Services International; 2014.  
http://www.cahrproject.org/resource/standard-operating-procedures-to-reduce-and-
manage-relapse-and-burnout
12. Harm reduction at work: a guide for organizations employing people who use drugs. New 
York (NY): Open Society Foundations; 2010. 
www.opensocietyfoundations.org/reports/harm-reduction-work
13. Evidence for action: effectiveness of community-based outreach in preventing HIV/AIDS 
among injecting drug users. Geneva: World Health Organization; 2004.  
http://www.who.int/hiv/pub/prev_care/en/evidenceforactionalcommunityfinal.pdf
14. Peer-driven intervention. Storrs (CT): University of Connecticut, Institute for Collaboration on 
Health, Intervention, and Policy.  
http://chip.uconn.edu/research/intervention-resources/peer-driven-intervention
15. Broadhead RS, Heckathorn DD, Weakliem DL, Anthony DL, Madray H, Mills RJ, et al. 
Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven 
intervention. Public Health Rep. 1998; 113(Suppl 1):42–57. 
https://www.ncbi.nlm.nih.gov/pubmed/9722809
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16. Information guide for peer workers and agencies. Toronto: Toronto Harm Reduction Task 
Force; 2013.  
http://canadianharmreduction.com/node/2208
17. Peerology: a guide by and for people who use drugs on how to get involved. Ottawa: Canadian 
AIDS Society; 2015.  
http://www.catie.ca/en/resources/peerology-guide-and-people-who-use-drugs-how-get-
involved
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What’s in this chapter?
This chapter presents principles and approaches for programme management, divided accord-
ing to a sequence of assessment, planning, implementation, and monitoring and evaluation. This 
sequence is appropriate for developing a programme from scratch, or where existing programmes 
are to be added to or scaled up.
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Box 5.1
5.1 Introduction
This chapter explains how to establish a management system for an HIV and hepatitis C (HCV) pro-
gramme for people who inject drugs, serving multiple locations within a country, and multiple sites 
within urban locations. Such a programme will use various service-delivery approaches (see Chap-
ter 4) to cover a high proportion of people who inject drugs with a minimum package of services. 
Principles for programme management
• Programme managers should always be focused on the programme’s purpose—to opti-
mize the health and well-being of people who inject drugs—and base decisions and 
approaches on it. 
• Services for people who inject drugs should be comprehensive, evidence-informed and 
human-rights based and include a variety of types of service delivery, including peer-led 
outreach.
• As a general principle, all data collected for planning, for monitoring and for evaluation 
should be disaggregated by gender and age group.
• While it is ideal for programmes to be initiated and led by community members,1 this will 
not always be possible. Nevertheless, governmental and nongovernmental organizations 
planning programmes for people who inject drugs must remember that it is crucial to 
involve community members in the design, implementation, monitoring and evaluation of 
programmes to ensure their success and sustainability. Regular and meaningful engage-
ment with service recipients should be institutionalized, with mechanisms provided for 
input and feedback on a regular and as-needed basis.
Effective management systems enable managers and teams to:
• plan and administer the activities of multiple interventions at various levels within the programme
• define roles and responsibilities, provide oversight and manage relationships with external partners
• ensure all levels of the organization are trained appropriately with regular training updates, 
performance measures, and staff planning and development
• take into account the range of individuals involved, the networks and organizations within which 
they operate, and the social systems and structures that surround them
• coordinate the operational activities that support the work, including data reporting systems, 
commodity procurement, quality monitoring and improvement, support and supervision, training 
etc.
1 In most contexts in this tool, “community” refers to populations of people who inject drugs, rather than the 
broader geographic, social or cultural groupings of which they may be a part. People may move into or out of 
injecting drug use at various times in their lives but may maintain community connectedness. Thus, “community 
members” are people who inject drugs or people with community connectedness, “outreach to the community” 
means outreach to people who inject drugs, and “community-led interventions” are interventions led by people 
who inject drugs or people with community connectedness. For a closer definition, see Chapter 1, Box 1.1.
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• implement financial procedures and controls
• adopt best practices, i.e. policies, programmes and initiatives that are:
– evidence-informed 
– human-rights based 
– sensitive to the subgroups of people who inject drugs (e.g. women, young people)2
– sustainable
– regularly evaluated
– participatory, involving all partners, especially community members.
5.2 Assessment
5.2.1 Define the scope of the response—population size estimates and mapping
Key steps in starting a programme include knowing where to establish services and contracting 
with implementing organizations.3 
• At the central planning level, reliable information about the size of the community of people who 
inject drugs within a given geographic area forms the basis for locating services, funding, setting 
performance targets, allocating programme resources and assessing coverage. Data disaggre-
gated by age and gender are a critical component of effective planning and programming.   
• At the implementation level, programmers can use mapping and size estimates to: 
– estimate the size of the community in a given area to determine personnel needs
– identify locations of people who inject drugs for locating interventions
– understand the demographics of the community (e.g. age, gender, ethnicity, family context, 
type of drugs used) to ensure that outreach and services are appropriately tailored to local 
settings and to individual and community needs
– identify which services are needed and where
– obtain information on risk behaviours, risk perceptions, barriers and structural issues to 
inform initial design of the intervention. 
Engaging local people who inject drugs is particularly important when mapping community mem-
bers and services because it helps ensure that the information collected is complete and not based 
on inaccurate or discriminatory assumptions. Knowledgeable members of the community can val-
idate the information and help ensure that the programme provides acceptable and accessible 
services to the greatest possible number of community members. 
Mapping should aim to gather information on the numbers of people who inject drugs, their age 
group and gender, locations and times where they congregate, and the types of drugs used. In 
addition, already existing services for harm reduction should be mapped to avoid duplication. 
Information can be gained through informal conversations with community members or through 
2 Young people who use or inject drugs are those in the age range 10–24 years, in accordance with the Interagency Working Group on Key Populations 
HIV and young people who inject drugs: a technical brief (Geneva: World Health Organization; 2015).
3 An implementing organization is an organization delivering an intervention to people who inject drugs, with a client-centred approach. It may be 
a governmental, nongovernmental, community-based or community-led organization, and may work at a state, provincial, district or local level. 
Sometimes a nongovernmental organization provides services through subunits at multiple locations within an urban area, and in this case, each of 
those subunits may also be considered an implementing organization.
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a series of discussions or workshops held in a safe environment, where community members can 
talk about their needs and priorities.
Mapping and size estimation is a multistage process, focusing on increasingly local levels to refine 
the information and make it more accurate. Mathematical size estimate exercises may be used to 
validate these programme estimates. The size estimates are updated periodically, and remapping 
may be done if social, political or economic forces lead to significant changes in the population of 
people who inject drugs.  
First stage: “Where in the country are significant numbers of people who inject drugs?” 
To determine where services should be established, a central-level planner must first understand 
where people who inject drugs are located. This information may be obtained by interviewing key 
informants, such as health-care providers and people who inject drugs who are already known to 
the programme. An approximate number of people who inject drugs should be obtained for each 
identified area in order to focus interventions initially on the locations with the largest number. 
Second stage: “How many people who inject drugs are found in this municipality/area, and 
where? What is their risk and vulnerability, and what are their service needs and preferences?” 
Once the general geographic area is known, more detailed mapping and size estimation may be 
done. This exercise can be an adaptation of the PLACE method (Priorities for Local AIDS Control 
Efforts) or a participatory site assessment, depending on the level of involvement of people who 
inject drugs in the mapping and size estimation process. 
Participatory site assessments can be conducted with trained community members, researchers 
and local community organizations. These help establish initial population size estimates and map 
subgroups (e.g. young people, women, sex workers, men who have sex with men), as well as hot-
spots where community members gather, and existing services for people who inject drugs. By 
ensuring the involvement of community members, the participatory mapping process can help 
increase their self-esteem, empowerment and identification with the programme and ensure that 
programmes are implemented with maximum safety in mind.
Locations identified by multiple informants or described as having large numbers of people who 
inject drugs are investigated further to ascertain whether these are people at high risk of HIV and 
HVC. Detailed information is sought from, discussed with and validated by people who inject drugs 
on the number of people who inject drugs in their social circle, specific places where people who 
inject drugs gather and any additional areas near the location where other people who inject drugs 
may be found.  
The programme uses this information in close consultation with the community to decide where 
service points such as drop-in centres4 and clinics should be located. Other clinics may be listed and 
mapped to establish referral relationships. The programme design is further refined and informed 
4 A drop-in centre is a place where people who inject drugs may gather to relax, meet other community members, and hold social events, meetings or 
training. See Chapter 4, Section 4.6, for details.
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Box 5.2
by people who inject drugs who describe the locations, hours, habits and other information that 
will determine when, where and how services are set up.
Third stage: “How can people who inject drugs be reached?” 
In this stage, social network maps are typically used to identify precisely who may be reached by 
individual peer outreach workers5 and to further inform local planning, taking into account the val-
ues and preferences of people who inject drugs. 
Mapping and the confidentiality and safety  
of community members
Mapping should always be done discreetly and with the active involvement of the community 
of people who inject drugs. Maps and other data containing information about people who 
inject drugs (e.g. location) should be considered confidential and stored securely at a central 
location, such as a drop-in centre. Programme planners and implementing organizations 
should guard against the possibility of maps being obtained by law-enforcement authorities 
or other groups that might use them to locate sites or otherwise cause harm to people who 
inject drugs. If these confidential materials are disclosed, it is likely that the programme will 
lose the trust of the community.
It is important to note that lack of data cannot be an excuse for inaction. Interventions should be 
implemented while investing in the necessary research and data collection initiatives required to 
further develop the evidence base.
5.2.2 Develop national and local responses—needs assessment
A needs assessment provides the opportunity to focus on the specific needs of the communities 
of people who inject drugs nationally or in a more local area. It provides essential input to supple-
ment information gathered during the process of population size estimation and mapping. For 
organizations already involved in harm reduction or HIV prevention programming, it can confirm—
or revise—existing understandings of communities of people who inject drugs.
A needs assessment can help identify a new initiative or demonstrate the validity of existing pro-
grammes. It can also provide valuable evidence to create a persuasive argument for why a specific 
service or programme is needed, and support funding applications and discussions with donors 
and partners. It is important that as many stakeholders as possible be involved in a needs assess-
ment: community members, including women and young people, their families, key service-provid-
ers, other civil-society partners, policy-makers, funders and donors. 
5  A peer outreach worker is a person who injects drugs, or a person with community connectedness, who conducts outreach to other people who 
inject drugs, and who is not generally full-time staff of an HIV prevention intervention (full-time staff might be called “staff outreach workers” or 
simply “outreach workers”). Peer outreach workers may also be known by other terms, including “peer educators”, “community outreach workers” or 
“outreach workers”. However, the terms “peer” or “community” should not be understood or used to imply that they are less qualified or less capable 
than staff outreach workers.
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Box 5.3
Four steps in conducting a needs assessment
Step 1: Perform a “gap” analysis
A gap analysis identifies the gaps that exist in programming to prove there is a need for a 
further intervention. This can be done by conducting a written survey or interviews with key 
informants; running a consultation, focus group or meeting with them to identify gaps and 
discuss solutions; or, at the local level, giving a feedback form to current programme clients 
that can be completed anonymously.
Step 2: Identify priorities
The gap analysis will generate a list of ideas for potential new initiatives or ways to develop 
an existing programme. All organizations must prioritize and decide what they can and 
cannot provide or achieve. This means reviewing the list of gaps and deciding which ones 
are most important to the organization’s goals, capacities and constraints, and the needs of 
the community.
Step 3: Identify problems and opportunities
A needs assessment will also raise potential problems and opportunities. It is useful to think 
about how the organization can respond by listing data and ideas that fall into these two 
categories. This is a level of detail that donors and funders will be interested in; it shows 
that the organization is taking into account all the issues that may arise, both negative and 
positive, and how the organization will manage them. 
Step 4: Identify possible solutions and planning
Using the information from Step 3, solutions and potential plans can be mapped to show 
how to manage each of the problems and opportunities identified.
5.2.3 Understand the environment
The community’s on-the-ground knowledge should be supplemented by research to gain a clear 
picture of factors that might affect the way services can be delivered and where service points may 
be located. These factors include:
• national and local laws and policies regarding drug use6 and harm reduction services
• the attitudes and behaviour of police and other law-enforcement authorities
• the attitudes of health- and social-services providers 
• the attitudes and behaviour of the general community towards drug use, including people in 
neighbourhoods where service points (such as a drop-in centre or an opioid substitution ther-
apy [OST] clinic) might be located
• attitudes of families of people using drugs, especially in communities where drug use is common
• the attitudes towards drug use of local politicians and local media
• the role of organized crime in drug provision (and whether a harm reduction programme might 
be seen as a threat to the business of selling drugs).
6 Drug use refers to the nonmedically sanctioned use of psychoactive drugs, including drugs that are illegal, controlled, or prescription.
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Consulting with the community
Outreach to the wider community, programme partners and service-providers is important 
for the security and protection of people who inject drugs and those who will provide 
services to them. The following steps will help ensure successful rollout of the programme:
• Consult with the community at large to explain the project and address possible concerns 
from the beginning.
• Consult with local police to explain the project and ensure the protection of people 
involved (service-providers and clients).
• Obtain authorizations from relevant authorities.
For more details, see Chapter 4, Section 4.6.2.
Local authorities can become allies following dialogue and negotiation to clarify the benefits they 
may see from harm reduction services (such as reduced expenditures on policing). Some of this 
information can be gathered through desk research, but most will require informal conversations 
with residents and local communities, partners and interested groups, and possibly more formal 
meetings with local authorities. In more open contexts, it may be possible to use established forums 
such as meetings of community councils to have a structured dialogue. Steps towards establishing 
productive relationships can include:
• Visit the relevant authorities during the programme-planning stage and identify a contact per-
son within them for future communications.
• Develop joint multidisciplinary training sessions on working with people who inject drugs.
• Establish “rules” and agreements on how the outreach programme will work in conjunction 
with the higher-threshold services without breaching the trust or confidentiality of the drug-
using community.
When working with these authorities, and especially with the police, who may be liable to harass 
and arrest people who inject drugs, every care must be taken to ensure confidentiality and pro-
tection for the community. This is a priority that cannot be compromised for any reason. For more 
information, see the Practical guide for civil society HIV providers among people who use drugs: 
improving cooperation and interaction with law enforcement officials (published by the United 
Nations Office on Drugs and Crime [UNODC], the International Network of People Who use Drugs 
[INPUD], and the Law Enforcement and HIV Network [LEAHN]).
Age barriers and underage drug use
While some countries may have restrictions and age barriers for accessing specific services, the 
programme’s should aim to be as inclusive as possible and not to deny services to anyone who 
needs them, recognizing that children may start injecting well before the legal age of majority.
In some places parental consent is required in order to provide services, and this can prevent young 
people from getting tested for HIV. Again, programmes should strive to be as open as legally possi-
ble and to exercise flexibility to meet the needs of those seeking services. Service-providers should 
be enabled and formally approved to use discretion regarding managing younger clients. 
Box 5.4
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5.2.4 Prioritize geographically
Financial resources are usually insufficient to cover all people who inject drugs in the entire coun-
try with the same package of services; as a result, programmes must prioritize both interventions 
and locations and match them according to local need, evident through the mapping and demo-
graphic analysis. This may be accomplished by varying the way in which technical components are 
delivered and by prioritizing those areas where the largest number of people who inject drugs and 
those at highest risk may be reached (see Section 5.2.2). 
5.3 Planning
5.3.1 Develop the programme plan 
The programme plan provides the direction for the programme. It can be developed at both a 
large-scale (e.g. national or state/provincial level) or at a smaller, simpler local scale (district or 
municipality level). Where local programmes are a part of a national programme, local plans will be 
coordinated with the national one. In general terms, the programme plan:
• gives clarity on the intervention elements and programme package
• establishes a logic model as a basis for monitoring the programme7 
• makes it possible to assess programme quality. 
The plan should be reviewed and revised as necessary over the life of the programme to reflect 
any changes in the population(s) being served or in the external political or funding environment. 
Components of the programme plan include:
Scope statement: Describes the need that the programme is aiming to meet and the rationale for 
the planned interventions. It outlines the parameters and restrictions (e.g. legal, funding) within which 
the programme will operate. It presents the interventions that will be delivered (i.e. the elements of 
the comprehensive package outlined in Chapter 3),8 the approaches that will be used, and measur-
able objectives and deliverables. The scope statement is a communications document that can be 
used to gain agreement with key governmental or sponsor organizations. The programme plan is 
closely linked to the logic model, which represents much of the same information in an abbreviated, 
graphic form and emphasizes the process of the programme (inputs, outputs and outcomes).
Baselines: These are initial measures of the elements that the programme intends to have an 
impact on, e.g. number of people who inject drugs, number of drop-in centres and attendees, 
number of needles and syringes distributed monthly, HIV or HCV infection rates etc. Progress of 
the programme is measured against these baselines indicators.
Task list: The task list includes a hierarchy of tasks for the whole life cycle of the programme 
(based on which tasks are dependent on other tasks being completed first), and a schedule that 
places all the tasks into a calendar. It identifies resources for each task, how long each task will take, 
how much it will cost and any constraints.
7 A logic model defines the programme’s inputs, activities, outputs, outcome(s) and impact, plus associated indicators.
8 See also WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug 
users–2012 revision.
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Roles and responsibilities: It is important for the programme management to get clarity and 
agreement on what tasks and actions need to be done by whom, as well as which decisions and 
inputs each partner will make.
Reporting plan: This document specifies reporting processes, i.e. what reports are to be sent to 
whom, how often, when, in what format and using which media. It is important that the reporting 
plan specifies where programme information will be stored and who can access it.
 
Once the planning process is complete, its contents must be delivered to key partners. This com-
munication should include: 
• review and approval of the programme plan 
• process for changing the contents of the programme 
• next steps: executing and controlling the programme and key roles and responsibilities in the 
upcoming phases.
5.3.2 Establish management structures
A clear structure for implementation is essential for smooth programme management. This 
includes the roles and responsibilities at each level of implementation, both in the programme and 
outside (e.g. government, community, medical services, social services). 
At the national/central level, the government or central management agency:
• sets programming standards
• monitors dashboard indicators9 from all implementing organizations in the country
• ensures that programmes are implemented in prioritized areas and subpopulations of people 
who inject drugs
• has a centralized view of the monitoring data
• ensures a countrywide evaluation plan.  
If government or a designated central management agency is not setting standards or requiring 
centralized indicator reporting, implementing organizations should work together to implement 
the service package and centralize indicator collection in consultation with the government.
Figure 5.1 illustrates a management structure for a national programme, showing the oversight and 
reporting relationships with the programme as well as the external relationships managed at the 
various levels. Key management roles are:
• setting milestones coupled with field oversight for both quality and progress; it involves regu-
lar review of progress against targets to adjust strategies and tactics; and use of programme 
experience and data to make mid-course corrections as needed
• establishing an organizational culture that aims to:
– empower people who inject drugs to manage the programme
– empower staff at all levels to use local monitoring data to improve the programme
– foster the professional development of all staff and promote cross-learning.
9 Dashboard indicators are the most important programme monitoring indicators, aggregated to a national level. They provide an overview of how well 
the programme is functioning (rather like the way gauges on the dashboard of a car inform the driver how well the engine is running).
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Figure 5.1 Illustrative management structure for a national HIV prevention and care programme 
with people who inject drugs 
Note: programme roles are not exhaustive.
5.4 Hiring and training staff
HIV programmes for people who inject drugs require team members with a variety of skills. The 
composition of a team depends on the services provided, how the services are delivered, the size 
of the community, and the geographic area being covered. 
Several good practices have been articulated to ensure that staffing is optimal and that staff are 
motivated and satisfied by their work: 
National
State/Province
District/County
Municipality/
Submunicipality
Frontline worker/ 
Community
Programme level Programme role Other possible relationships
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• clear job descriptions and roles and responsibilities for all positions in the programme, including 
positions held by community members 
• clear reporting lines showing to whom each person is accountable  
• team-building and a culture of mentoring  
• clear criteria for performance reviews  
• clear policies on leave, travel reimbursement and remuneration for work, including equitable 
policies for people who use drugs; ideally, these should be uniform across a country  
• opportunities for training for different positions in the organization, such as outreach supervi-
sor, clinic assistant, nurse, counsellor, social worker, office manager.  
The relationships in a staff team that include both noncommunity staff (i.e. staff who do not use 
drugs) and community members need to be well managed. Noncommunity staff should be sen-
sitive to the context of drug use, and to the stigma, discrimination, violence, and other problems 
people who use drugs face. They should also be able to discuss such topics as sex, drugs and ser-
vice delivery needs in a nonjudgemental manner. A flexible approach and mindset amongst all staff 
members is crucial to respond to the needs and changing situation on the ground. Noncommunity 
staff should be prepared to learn from people who use drugs as well as serve as mentors. 
Capacity-building of human resources is particularly important in programmes where the intent is 
to progressively empower people who use drugs to be meaningfully involved in programming. The 
capacity of noncommunity staff and community members can be built through classroom training, 
exposure, supervision and mentoring, and interactive problem-solving sessions. Training materials 
should be adapted or developed centrally to maintain quality of training and consistency with the 
minimum standards specified by the programme and be based on an assessment of the capaci-
ty-building needs. Pre- and post-assessments are useful to monitor the quality of the trainings.
Training goals for general staff include: 
• acquainting the staff with the specifics of the project (e.g. intervention, reporting forms)  
• building technical skills in new areas (e.g. examining for abscesses, counselling issues related to 
drug use)  
• orienting staff to the issues of drug use and the important goal of imparting skills and respon-
sibilities to the community. This may require a change in staff members’ attitudes toward drug 
use (morality of drug use etc.).  
Some approaches to capture programme lessons include: 
• routine visits for programme managers to learn about local innovations and transfer lessons to 
other sites  
• regularly scheduled programme reviews with several implementing organizations together; 
they may also be used for cross-sharing  
• cross-site meetings of technical officers to share approaches  
• formal revision of programme approaches, minimum standards, standard operating procedures 
and reporting forms.  
For staff who are community members, the programme goal is to increasingly involve people who 
use drugs in the management of the programme and to capacitate them to address some of the 
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environmental and structural constraints that inhibit preventive behaviour. Training objectives are 
to strengthen the capacity of the people who use drugs to do peer outreach, increasingly manage 
all aspects of outreach and to move into other staff positions in the programme, including manage-
ment. This can be phased as basic and advanced training. 
Although staff may differ in their types and levels of experience, wherever possible training should 
take place jointly so that all participants can learn from one another and bridge the gaps in their 
knowledge and skills in a collaborative manner. 
5.5 Programme implementation
Implementing and executing the programme in clear stages helps achieve wide geographic cov-
erage (Figure 5.2). First, the programme is rolled out nearly simultaneously across the target geo-
graphic areas (as opposed to a pilot-and-replicate approach) by creating a physical infrastructure 
in these areas. 
This is followed by a focus on implementing services and constant quality improvement. During 
implementation, the focus is on ensuring coverage of the community with services and on improving 
quality. The implementation phase is a continuous process in which management reviews progress 
against targets and adjusts strategies and tactics, as necessary. Mid-course corrections are made 
based on new data, new approaches or environmental or structural changes that affect programming. 
The intensity and the quality of coverage increases as staff become more skilled in their positions. It is 
during this phase that flexibility and continuous programme learning are extremely valuable. A strong 
monitoring system with regular reviews is essential to the successful rollout of services. It also signals 
to funders and the government whether programming is being implemented successfully.
Finally, as the interventions mature, the focus of implementation shifts to making interventions and 
services more sustainable. Additional services may be layered on over time. 
5.6 Community-led quality improvement 
Improving the quality, accessibility and acceptability of programme services requires collecting rou-
tine feedback on the community’s experience of services. There are several ways to do this. 
5.6.1 Community committees  
A community committee is a forum for members of the community to bring important issues, 
problems and solutions to the attention of the programme on a routine basis. Committees may 
review clinical services, commodity distribution, and initiatives to address structural barriers. They 
can also be a communication channel for the programme to discuss any changes that are being 
considered and to share monitoring data with the community. 
Community committees are comprised of people from the drug-using community, as well as from 
the wider community. They should meet monthly. Regular (e.g. annual) elections for committee 
representatives should be held. Staff from the relevant implementing organization may be invited 
to the meetings to discuss issues that arise. 
144
➎ Programme Management
Figure 5.2 Stages of implementing a multicomponent programme with people who inject drugs
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Community committees operate primarily at the frontline level, although they may also contribute 
to the oversight of the programme at the municipality/submunicipality level. A meeting report like 
the one shown in Figure 5.3 may be used to systematically consider issues and report to the com-
munity and programme. 
Figure 5.3 Sample community committee report
COMMUNITY COMMITTEE REPORT  [LOCATION]                             DATE: 
Area Issue Proposed Resolution
Issues with supply, quality or 
quantity (e.g. needles and syringes, 
medications) at individual site or 
across sites
Community reports that some peer workers 
who do outreach in the train station do not 
provide enough sterile needles.
1. Outreach coordinator to work with peer outreach 
workers to provide the number of needles and syringes 
required by each community member.
2. Follow up at train station to ensure change.
Closure or lack of service availability 
at referral facilities or through 
outreach
Government Clinic on Central Road often will 
not accept people after 15:00. 
1. Write letter to health officer documenting problem. 
Ask NGO director to sign along with community 
representative.
2. NGO health officer and community representative 
should visit Chief Medical Officer to advocate for 
compliance with agreement on later opening hours 
signed in May.
Service quality problems, e.g. 
poor treatment at facilities, 
discrimination in referral services, 
unresolved problems at safe spaces
Nurses at Central Road doing initial 
questioning of patients in a public area, not 
a private room.
1. NGO health officer and community representative 
should bring this up during visit with Chief Medical 
Officer to ensure compliance with STI treatment 
protocol.
2. Follow up with community to determine if clinic is 
compliant with policy.
Service overlap by other providers 
that may be causing confusion
No problems. N/A
Violence response activities, 
perpetrators of violence and trends 
in violence.
Report on number of incidents was not 
given at last community meeting at drop-in 
centre.
Response team members taking survivors 
to hospital have not been reimbursed for 
transport costs.
Ensure that community leaders get information from crisis 
response team members and double-check it with NGO 
data officer before monthly community meetings.
Outreach supervisor to check and ensure that 
reimbursements are made within one week.
Any other issues...
Actions taken by programme staff or peer outreach workers themselves, and the results, should 
be shared at subsequent meetings to ensure good communication with the community. A record 
of these discussions and actions should be maintained. 
Because the community committee may at times raise quality issues that programme staff are 
reluctant to address, it is essential to involve programme management staff from a higher level 
than those immediately responsible for the components of the intervention locally. Confidentiality 
should be respected at all times, and senior management should monitor the committee to ensure 
that the community has the freedom to be critical. A trusted advocate should act as the pro-
gramme intermediary; ideally this person should be a community member, although they may be 
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paired with a staff member from the implementing organization who can advocate for changes. A 
mechanism for communicating problems, beyond that of the local manager, should be established 
in case they are perceived to be obstacles to change. 
Other community-led approaches to reinforce quality of clinical services 
• Obtain agreement with referral clinics to display patients’ rights charters, which are a state-
ment of government policy for all who enter a medical facility.  
• Obtain agreement with senior medical personal to post information in clinics on the right to 
confidentiality.  
• Design ways to share information about reliable services in the community. This information 
may be posted on a notice board or on a protected Facebook page.  
• Schedule regular contact (via visits or letters) with the chief medical officer of a facility to for-
mally report issues and give positive feedback.  
• Educate the community on patients’ rights and community-based monitoring of services.  
• Formally introduce committee members to health-service providers. 
For ways in which community members can contribute to quality assurance in programme moni-
toring and evaluation, see Section 5.7.3.
5.7 Monitoring and evaluation 
5.7.1 Monitoring
A routine data collection system is needed that aggregates and consolidates information so that 
dashboard indicators may be monitored. Monitoring data is used to: 
• encourage ongoing improvement
• identify trends and emerging issues
• provide evidence of the impact of activities and outputs 
• provide an informed basis for decision-making, review and future planning of services
• enable communities to shape service provision and engage in decision-making processes.   
 
There are several data sources necessary to design, monitor and manage a programme: 
Programme baseline data: These include mapping and age- and gender-disaggregated popula-
tion size estimates, and baseline data from enrolment of people who inject drugs as they enter the 
programme. These data are useful to estimate the expected needle and syringe needs of people 
who inject drugs (as well as other commodities like condoms and lubricant) and give some gauge 
of risk in the population for prioritization of services.
Infrastructure and personnel: This includes the number of drop-in centres and clinics, and the 
number of people hired and trained, by position. These data are important to monitor service pro-
vision over the predetermined geographic area, and human resources. 
Routine programme data: These include contacts between programme clients and outreach 
workers, outreach services and clinical services. Data should be disaggregated by gender and by 
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Box 5.5
age group and can include number of new and repeat contacts, number of needles, syringes and 
associated injection equipment distributed, number of referrals, number enrolled in OST, num-
ber of requests for information, types of education requested, education supplied, publications 
produced, aggregate distribution of publications. Referral outcomes (i.e. whether an individual 
referred to a service attended the service, not the clinical outcome) should be assessed through 
an established communication channel with the referral service. Referral outcomes can be a meas-
urement of programme effectiveness.
Tracking clients across services
The mobility of some people who inject drugs makes it difficult to monitor the total 
number receiving services, because as they move into areas serviced by a different team 
or implementing organization they may be counted as a “new” to the programme. One way 
to address this is to ask people receiving services whether they have done so before and 
where; another is to provide an anonymous ID card that indicates that the individual receives 
services from the programme. The card should use a unique identifier code (UIC) generated 
by the local programme rather than the individual’s name, and it should not identify the 
programme by name nor identify the holder as a person who injects drugs. In some contexts 
it may be feasible to coordinate the UIC between service-providers within a country so 
that all use the same format. A local nongovernmental organization or service unit might 
record new contacts, new-to-area contacts and previous contacts as a way to distinguish 
this while capturing the degree of mobility. Whatever avenue is pursued by the programme, 
the tracking mechanisms need to be consistent across time to be effective. 
Administrative data: Drugs and consumable supplies are managed with appropriate stock man-
agement policies and procedures. Accurate data are important to ensure consistent, uninterrupted 
supply of needles, syringes, condoms and lubricant and other harm-reduction commodities. The 
monitoring of consumption and distribution of these commodities is a marker of coverage (e.g. the 
number of needles and syringes distributed compared to the estimated gaps) and can corroborate 
clinic reporting.
Referral outcomes (i.e. whether a community member attended the service, not the clinical out-
come) should be assessed through an established communication channel with the referral service. 
Expenditure data: These are important to monitor the project’s financial status and ensure that 
payments to implementing organizations and vendors are punctual, to keep the programme running.
Surveys and qualitative assessments: These include quantitative surveys of reported condom 
use, needle sharing, or access to HIV and HCV services. They may be used for setting baselines or 
for monitoring progress. Regular qualitative assessments with programme clients can determine 
whether communication is being understood and whether there are unaddressed needs that could 
be met by the programme. 
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Quality monitoring: Clear standards are the foundation of quality monitoring, as services are 
assessed against specified standards (quality assurance). Assessments may be done externally 
through quality audits or using participatory approaches such as “mystery client” interviews.
Outside data: Data from sources outside the programme, such as government HIV surveillance, 
academic research, or surveys conducted by other institutions, may be useful to inform progress, 
highlight environmental issues or make necessary adjustments in the programme. 
5.7.2 Evaluation
Broadly speaking, a programme evaluation assesses first how well the implementation matched 
the original programme design (e.g. in terms of programme content and coverage), and second 
the ultimate impact of the programme, i.e. its end results. Did it prevent and manage HIV and HCV 
within communities of people who inject drugs? Did it build capacity of the implementing organi-
zations? An illustrative, national-programme-level evaluation framework is depicted in Figure 5.4. 
See Section 5.8 for guidance documents on designing evaluation programmes with people who 
inject drugs.
Figure 5.4 Evaluation framework for a multicomponent programme with people who inject drugs
Did the programme 
achieve scale/coverage—
geographic area and 
population covered with 
high-quality services?
What impact has the 
programme had on: 
 HIV transmission? 
 Lives saved?
 Agency of trans people?
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5.7.3 Community quality assurance in monitoring and evaluation 
Programmes are more effective when routine monitoring is designed with local input, and there 
are systems for using data at the community level. The programme at the central level should 
engage those managing multiple sites to determine what information is useful to them to monitor 
their programmes. (A simple approach is to brainstorm the aspects of the programme that they 
typically examine during site visits.)
Where interventions are not already community-led, community leaders should be consulted on 
the kinds of measures that are important to improve the quality of services and outreach. All pro-
grammes need to collect and report data to monitor progress, which can be used to hold the 
programme accountable to its objectives. It is important to develop a clear understanding in the 
community on what data will be collected, how this will happen, and how the data are to be used 
locally. Data should not simply be “reported up” to a higher level; an approach should be designed 
that also integrates monitoring for use at the local level. This is important because targets that are 
set at high levels are easily misinterpreted as being the primary goal of the programme, leading, 
for example, to focus on the number of people accessing services rather than the quality of those 
services or community engagement in the programme.
5.8 Further resources
1. Planning guide for the health sector response to HIV/AIDS. Geneva: World Health 
Organization; 2011. 
http://whqlibdoc.who.int/publications/2011/9789241502535_eng.pdf 
2. Planning and managing for HIV/AIDS results: a handbook. Washington (DC): Global AIDS 
Monitoring and Evaluation Team, World Bank Global HIV/AIDS Program; 2007. 
http://siteresources.worldbank.org/INTHIVAIDS/Resources/375798-1103037153392/
Results_Handbook_31Oct2007.pdf 
3. Guide to the strategic planning process for a national response to HIV/AIDS. Geneva: Joint 
United Nations Programme on HIV/AIDS; 1998. 
http://data.unaids.org/publications/IRC-pub05/jc441-stratplan-intro_en.pdf 
4. Practical guidance for scaling up health service innovations. Geneva: World Health 
Organization and ExpandNet; 2009. 
http://www.expandnet.net/PDFs/WHO_ExpandNet_Practical_Guide_published.pdf 
5. Nine steps for developing a scaling-up strategy. Geneva: World Health Organization and 
ExpandNet; 2010. 
http://whqlibdoc.who.int/publications/2010/9789241500319_eng.pdf 
6. A commodity management planning guide for the scale-up of HIV counseling and testing 
services. Arlington (VA): Management Sciences for Health; 2008. 
http://www.msh.org/sites/msh.org/files/HIV-Testing-Commodity-Guide-VCT_final.pdf
7. Management and Organizational Sustainability Tool (MOST): a guide for users and 
facilitators–second edition. Cambridge (MA): Management Sciences for Health; 2004. 
http://www.msh.org/resources/management-and-organizational-sustainability-tool-most
8. Guidelines on estimating the size of populations most at risk to HIV. Geneva: World Health 
Organization and Joint United Nations Programme on HIV/AIDS; 2010. 
http://www.who.int/hiv/pub/surveillance/estimating_populations_HIV_risk/en
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9. Estimating prevalence: indirect methods for estimating the size of the drug problem. Global 
assessment programme on drug abuse: toolkit module 2. Vienna: United Nations Office on 
Drugs and Crime; 2003.  
http://www.unodc.org/documents/data-and-analysis/statistics/Drugs/GAP_module_2.pdf
10. Priorities for local AIDS control efforts: a manual for implementing the PLACE method. 
Chapel Hill (NC): MEASURE Evaluation; 2005. 
http://www.cpc.unc.edu/measure/publications/ms-05-13
11. Using logic models to bring together planning, evaluation, and action: logic model 
development guide. Battle Creek (MI): W.K. Kellogg Foundation; 2004. 
http://www.wkkf.org/knowledge-center/resources/2006/02/wk-kellogg-foundation-logic-
model-development-guide.aspx
12. Tool to set and monitor targets for HIV prevention, diagnosis, treatment and care for key 
populations. Geneva: World Health Organization; 2015. 
http://www.who.int/hiv/pub/toolkits/kpp-monitoring-tools/en
13. Monitoring and evaluation systems strengthening tool. Developed by the Global Fund, 
PEPFAR, USAID, and others. Chapel Hill (NC): USAID Measure Evaluation Project, Carolina 
Population Center, University of North Carolina-Chapel Hill; 2007. 
http://www.cpc.unc.edu/measure/publications/ms-07-18
For more information, contact:
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United Nations Office on Drugs and Crime
PO Box 500
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